Alcohol Use Disorder

Psychiatric MONDO:0007079 Pathograph 69 Show in embeddings browser Substance Use Disorder Mental Health Disorder

Alcohol use disorder (AUD) is a heterogeneous pattern of alcohol use causing clinically significant impairment or distress. DSM-5-TR diagnosis requires at least two of eleven criteria within a year and grades severity by criterion count; tolerance and withdrawal are possible criteria rather than requirements. Genetic liability, environment, reinforcement, learning and exposure-related adaptations contribute probabilistically. The three-stage addiction framework organizes relevant mechanisms but is not a necessary linear course for every patient. Remission, recurrence and sustained recovery all occur.

Ask OpenScientist

Ask a research question about Alcohol Use Disorder. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

👪

Inheritance

Polygenic (multifactorial) liability HP:0010982

Liability is polygenic and depends on environmental exposure. Protective ADH1B and ALDH2 alleles affect ethanol metabolism; their effects do not make this a Mendelian disorder. Twin and adoption meta-analysis estimates roughly 50% heritability in the studied populations, with a modest shared-environment component. Heritability is a population variance estimate, not the fraction of an individual case caused by genes.

polygenic inheritance

Show evidence (3 references)

PMID:25171596 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"AUD is approximately 50% heritable."

Meta-analysis of 12 twin and 5 adoption studies gives the reference heritability estimate for AUD liability.

PMID:25171596 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"We also found evidence for modest shared environmental effects suggesting that environmental factors also contribute to the familial aggregation of AUDs."

Supports the multifactorial framing: familial aggregation is not purely genetic.

PMID:38062264 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"We observed a high degree of cross-ancestral similarity in the genetic architecture of PAU and identified 110 independent risk variants in within- and cross-ancestry analyses."

The largest multi-ancestry GWAS of problematic alcohol use demonstrates the highly polygenic architecture expected under multifactorial inheritance.

Discussions and Knowledge Gaps

Which experimental receptor and stress-system adaptations causally contribute to clinically defined AUD in humans?

HUMAN MODEL MISMATCH aud_model_translation

Attached to

pathophysiology#GABA-A Receptor Redistribution pathophysiology#CRF-Associated Stress Signaling pathophysiology#Dynorphin–Kappa-Opioid Signaling pathophysiology#TLR4-Dependent Inflammatory Signaling

Rodent exposure, preference and drinking-in-the-dark paradigms interrogate distinct endpoints. They do not reproduce every diagnostic feature, and region-, time- and genotype-dependent effects limit a universal mechanistic chain. Human imaging, genetic associations and treatment efficacy cannot by themselves prove mediation through these specific experimental processes.

Does devaluation-insensitive alcohol seeking causally mediate persistent harmful drinking in humans?

HUMAN MODEL MISMATCH aud_habit_system_human_fidelity

Attached to

pathophysiology#Habitual Alcohol Seeking

The curated rat study relates behavioral habit measures to later punishment resistance. Its abstract does not itself measure the proposed dorsal-striatal dopamine mechanism, and the correspondence to human diagnostic loss of control requires direct testing.

Which clinical trajectories reflect exposure effects, pre-existing liability or bidirectional comorbidity?

KNOWLEDGE GAP aud_heterogeneity_and_comorbidity

Attached to

phenotypes#Depression pathophysiology#Impaired Executive Control pathophysiology#Polygenic Liability

Cross-sectional psychiatric associations and MRI differences do not isolate causal direction. The depression study selected people with major depressive disorder, not an unselected AUD population. Genetic PAU combines heterogeneous diagnoses and questionnaire measures; current polygenic scores are not sufficient for individual clinical risk prediction.

Show evidence (1 reference)

PMID:38062264 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"We note that the current findings are not sufficient for clinical risk prediction at the individual level, given the limited SNP-based heritability and small proportion of variance explained by PRS."

The authors explicitly reject individual clinical risk prediction from the current results, limiting use of the PAU polygenic score.

⚙

Pathophysiology

Polygenic Liability

Common-variant associations contribute to liability rather than determining disease. The 2023 meta-analysis combines 165,952 AUD or dependence cases, controls and AUDIT problems scores in 1,079,947 participants; it is not a cohort of one million diagnosed cases. The 110 variants are the union of within- and cross-ancestry results, and most data are European ancestry. Specific nonmetabolic variant-to-neural causal routes remain unresolved.

Downstream

Impaired Control over Alcohol Use Association establishes probabilistic liability; the intervening molecular and behavioral mechanisms are incompletely resolved.

Show evidence (2 references)

PMID:38062264 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"In total, 110 unique variants were associated with PAU in either the within-ancestry or cross-ancestry analyses (Fig. 1b and Supplementary Table 1)."

The union of within- and cross-ancestry signals supports distributed susceptibility; it does not identify a single necessary mechanism of impaired control.

PMID:38062264 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Despite the high genetic correlation between AUD and AUDIT–P, they are not identical traits, which introduces heterogeneity."

The authors explicitly distinguish diagnosed AUD from AUDIT-P, limiting disease-specific interpretation of the combined PAU analysis.

Repeated Ethanol Exposure

Repeated alcohol intake supplies the exposure for intoxication, neuroadaptation and medical complications. Dose, timing, host susceptibility and environment influence outcomes; exposure alone does not establish AUD. This exposure node is separate from enzymatic metabolism and from the impaired-control phenotype.

Animal models

Alcohol-preferring P rats Rattus norvegicus measures Voluntary intake and binge-access endpoints model high alcohol exposure.

High-alcohol-drinking HAD rat lines Rattus norvegicus measures Selected high-drinking lines model voluntary exposure.

HAP/LAP preference QTL mouse cross Mus musculus measures Alcohol preference varied in a segregating HAP1 × LAP1 F2 cross and was linked to a chromosome 9 QTL; no single increase relative to a control is asserted.

HDID selected-line aversion and reward assays Mus musculus measures Blood ethanol concentrations after a four-hour drinking-in-the-dark test increased in both selected replicate lines relative to the founding generation; aversion and reward were assessed in separate experiments.

Downstream

Acute GABA-A Signaling Modulation Ethanol acutely modulates inhibitory GABA-A signaling in neuronal preparations. This pharmacological effect is distinct from chronic receptor redistribution and does not imply identical effects at every receptor subtype.

Acute NMDA Receptor Inhibition Ethanol inhibits NMDA-receptor-mediated calcium influx in the reviewed neuronal experiments; the acute receptor action is separate from chronic glutamate adaptation.

Alcohol-Evoked Endogenous Opioid Signaling Drinking produces an opioid-sensitive PET ligand-displacement response in human accumbens and orbitofrontal cortex; the intervening release machinery is not resolved by this experiment.

Mesolimbic Dopamine Reinforcement Alcohol engages mesolimbic reinforcement circuitry through several neuronal and receptor routes; the dopamine synthesis does not establish one exclusive upstream relay.

GABA-A Receptor Redistribution Single and repeated ethanol regimens alter receptor trafficking and surface composition in rodents. The exact signaling route and persistence depend on the regimen and neuronal compartment.

Altered Glutamate Homeostasis Exposure and withdrawal are associated with altered glutamate regulation. Human regional measurements and repeated-vapor rodent experiments do not imply a single uniform trajectory.

CRF-Associated Stress Signaling The withdrawal framework recruits extended-amygdala CRF systems after repeated drug exposure; complete mediation of the human stress response remains unresolved.

Dynorphin–Kappa-Opioid Signaling Dependent-animal and neurocircuitry evidence implicates dynorphin signaling in withdrawal-related stress, without establishing its recruitment as universal in AUD.

Withdrawal-Associated Reward Deficit Withdrawal from chronic exposure lowers dopamine activity in reviewed rodent experiments; the transition to a human subjective reward deficit requires additional interpretation.

Habitual Alcohol Seeking Repeated seeking and reinforcement permit habitual control to develop in the rat paradigm; the predictor relationship does not prove that exposure alone determines later compulsivity.

Thiamine Deficiency Heavy drinking can reduce nutritional intake and impair thiamine availability. These known nutritional intermediates are not expanded into separate nodes here.

TLR4-Dependent Inflammatory Signaling Chronic ethanol exposure produces TLR4-dependent inflammatory responses in mouse and astrocyte models; the experiments do not establish ethanol as a direct TLR4 ligand.

Alcohol Cue Responsivity Repeated pairing and learning offer an interpretation of cue-associated responses; the imaging synthesis alone does not prove longitudinal sensitization.

Impaired Executive Control The framework describes an exposure-associated contribution to executive dysfunction; pre-existing liability and other factors cannot be excluded by cross-sectional imaging.

Withdrawal-Associated Autonomic Activation Withdrawal after sustained heavy exposure can activate autonomic responses in physiologically dependent individuals.

Hepatic Steatosis Alcohol metabolism and disturbed lipid handling connect sustained exposure to hepatic fat accumulation; those known liver-specific intermediates are curated in Alcoholic_Liver_Disease.

Cirrhosis Alcohol-associated liver disease can progress from steatosis through hepatitis to cirrhosis in a subset of patients; the liver-specific intermediate processes are not expanded in this AUD graph.

Dilated Cardiomyopathy Chronic alcohol toxicity can produce myocardial injury and adverse remodeling before ventricular dilation; the organ-specific intermediates are not expanded here.

Pancreatitis Alcohol-related pancreatic injury and inflammation can lead to acute or chronic pancreatitis through organ-specific pathways omitted from this graph.

Peripheral Neuropathy Direct neurotoxicity and nutritional injury are recognized routes from chronic alcohol use to peripheral neuropathy; the nerve-specific intermediates are not expanded here.

Acetaldehyde Accumulation Ethanol is converted by ADH enzymes to acetaldehyde; accumulation depends on the balance between this known formation step and ALDH-mediated clearance.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK436003/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"The fact that not every person who drinks alcohol will necessarily experience a loss of control and progression to addiction indicates that AUD is not solely driven by exposure to alcohol."

The clinical synthesis distinguishes alcohol exposure from the additional susceptibility required for impaired control and addiction.

Increased ADH1B-Mediated Ethanol Oxidation

In carriers of protective high-activity ADH1B alleles, faster enzyme-catalyzed conversion of ethanol to acetaldehyde is proposed to contribute to aversive effects and reduced dependence risk. Purified-enzyme kinetics do not imply the same fold change in whole-body clearance or a universal flushing response.

ADH1B hgnc:250

alcohol metabolic process GO:0006066

alcohol dehydrogenase (NAD+) activity GO:0004022 ↑ INCREASED

liver UBERON:0002107

Downstream

Acetaldehyde Accumulation Faster formation may increase local or transient acetaldehyde exposure; systemic accumulation and symptom severity also depend on clearance.

Show evidence (1 reference)

PMID:17718394 SUPPORT DIRECT REVIEW SYNTHESIS In Vitro

"certain ADH1B and ADH1C alleles encode particularly active ADH enzymes, resulting in more rapid conversion of alcohol (i.e., ethanol) to acetaldehyde"

High-activity ADH alleles accelerate the enzymatic ethanol-to-acetaldehyde step; net systemic accumulation still depends on concurrent aldehyde clearance.

Reduced ALDH2-Mediated Acetaldehyde Clearance

The ALDH2*2 variant markedly reduces conversion of acetaldehyde to acetate. Under alcohol exposure this favors acetaldehyde accumulation; the allele is protective against dependence rather than a monogenic cause of AUD.

ALDH2 hgnc:404

aldehyde dehydrogenase (NAD+) activity GO:0004029 ↓ DECREASED

liver UBERON:0002107

Downstream

Acetaldehyde Accumulation Reduced aldehyde oxidation impairs acetaldehyde clearance during alcohol exposure.

Show evidence (1 reference)

PMID:17718394 SUPPORT DIRECT REVIEW SYNTHESIS In Vitro

"A variant of the ALDH2 gene encodes an essentially inactive ALDH enzyme, resulting in acetaldehyde accumulation"

Reduced ALDH2 function decreases aldehyde clearance and favors acetaldehyde accumulation during drinking; its association with lower dependence risk is protective.

Acetaldehyde Accumulation

Reduced clearance, or an imbalance between formation and clearance, increases exposure to the toxic ethanol metabolite acetaldehyde. This conditional metabolic branch is especially well supported for reduced ALDH2 activity.

Downstream

Acetaldehyde-Associated Aversion Acetaldehyde accumulation elicits downstream vasoactive and autonomic responses that contribute to aversion; these physiological intermediates are not expanded in this graph.

Show evidence (1 reference)

PMID:17718394 SUPPORT DIRECT REVIEW SYNTHESIS In Vitro

"A variant of the ALDH2 gene encodes an essentially inactive ALDH enzyme, resulting in acetaldehyde accumulation"

Reduced ALDH2 function decreases aldehyde clearance and favors acetaldehyde accumulation during drinking; its association with lower dependence risk is protective.

Acetaldehyde-Associated Aversion

Flushing, nausea and tachycardia after acetaldehyde accumulation can discourage drinking. This is a protective modifier pathway, not an obligatory step in the progression of AUD. Disulfiram deliberately engages an aversive response by inhibiting aldehyde clearance.

Downstream

Facial Flushing After Alcohol Intake Flushing is one component of the exposure-dependent aversive reaction.

Show evidence (1 reference)

PMID:17718394 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"Acetaldehyde is a toxic substance whose accumulation leads to a highly aversive reaction that includes facial flushing, nausea, and rapid heart beat (i.e., tachycardia)."

The review explicitly connects accumulated acetaldehyde with flushing, nausea and tachycardia, supporting an aversive modifier rather than a required AUD pathway.

Acute GABA-A Signaling Modulation

Acute ethanol can enhance GABAergic inhibition through effects that depend on receptor composition, synaptic compartment, dose and brain region. The review evidence includes rodent and cellular work; it does not establish uniform potentiation at every receptor or a single necessary route to human intoxication. GABAergic neurons supply the inhibitory transmitter; receptor-bearing target neurons need not themselves be GABAergic.

GABAergic neuron CL:0000617

synaptic transmission, GABAergic GO:0051932 ↑ INCREASED

GABA-A receptor activity GO:0004890

Show evidence (1 reference)

PMID:25954150 SUPPORT DIRECT REVIEW SYNTHESIS In Vitro

"the acute actions of ethanol are to inhibit glutamatergic activity and potentiate GABAergic activity."

The review describes acute enhancement of inhibitory GABA signaling; receptor subtype, cellular compartment and experimental preparation determine the response.

Acute NMDA Receptor Inhibition

Experimental literature describes inhibition of NMDA-receptor-mediated calcium influx by ethanol. This acute receptor effect is distinct from chronic changes in receptor trafficking, glutamate release and uptake.

synaptic transmission, glutamatergic GO:0035249 ↓ DECREASED

NMDA glutamate receptor activity GO:0004972 ↓ DECREASED

nucleus accumbens UBERON:0001882 ventral tegmental area UBERON:0002691 cerebral cortex UBERON:0000956 hippocampal formation UBERON:0002421

Show evidence (1 reference)

PMID:25954150 SUPPORT DIRECT REVIEW SYNTHESIS In Vitro

"Intracellularly, ethanol inhibits, non-competitively, the NMDAR-mediated calcium influx in the cortex, Acb, amygdala, hippocampus, and VTA (Nie et al., 1994; Wirkner et al., 2000; Roberto et al., 2004; Stobbs et al., 2004; Zhu et al., 2007)."

The reviewed neuronal experiments identify inhibition of NMDA-mediated calcium influx, supporting the acute receptor effect rather than chronic glutamate depletion.

Alcohol-Evoked Endogenous Opioid Signaling

Human positron-emission tomography after drinking showed displacement of a mu-opioid radioligand in nucleus accumbens and orbitofrontal cortex, interpreted as endogenous opioid release. This is an indirect release measure; the study did not identify the peptide, resolve a dopamine relay, or test naltrexone efficacy.

G protein-coupled opioid receptor signaling pathway GO:0038003

nucleus accumbens UBERON:0001882 orbitofrontal cortex UBERON:0004167

Downstream

Impaired Control over Alcohol Use Alcohol-evoked opioid signaling provides a reward-related input that may promote continued use; this PET experiment does not demonstrate the intervening steps to loss of control.

Show evidence (1 reference)

PMID:22238334 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Drinking alcohol induced opioid release in the nucleus accumbens and orbitofrontal cortex, areas of the brain implicated in reward valuation."

Human ligand-displacement PET supports alcohol-evoked endogenous opioid release in accumbens and orbitofrontal cortex, without resolving a peptide or downstream dopamine relay.

Mesolimbic Dopamine Reinforcement

Mesolimbic dopamine signaling contributes to alcohol reinforcement in the reviewed experimental framework. Dopamine is one contributor among several; the cited human opioid PET result alone does not prove an opioid-to-dopamine causal sequence.

dopaminergic neuron CL:0000700

ventral tegmental area UBERON:0002691 nucleus accumbens UBERON:0001882

Downstream

Impaired Control over Alcohol Use Dopamine-dependent reinforcement can strengthen alcohol-directed behavior, while the transition to impaired control involves additional learning and executive processes.

Show evidence (1 reference)

PMID:25307573 SUPPORT DIRECT REVIEW SYNTHESIS Model Organism

"Dopamine, through its actions via mesolimbic and mesocortical pathways, has long been viewed as playing a central role in mediating alcohol reward (Gonzales et al., 2004; Spanagel, 2009)."

The experimental synthesis assigns mesolimbic and mesocortical dopamine a reinforcement role; extension to loss of control requires additional circuit and behavioral steps.

Alcohol Cue Responsivity

Alcohol-associated cues evoke brain responses that can correlate with craving. The meta-analysis included 28 studies of heavy-drinking/AUD samples; within-case ventral-striatal activation was not equivalent to a significant case-versus-control difference. Region-of-interest selection, heterogeneous ascertainment and mainly male samples limit generalization. This is an associative circuit finding, not a validated clinical biomarker.

ventral striatum UBERON:0005403 prefrontal cortex UBERON:0000451

Downstream

Impaired Control over Alcohol Use Cue-related circuit responses correlate with behavior, but the imaging synthesis does not prove that those responses cause later loss of control.

Craving Brain cue responses can correlate with reported craving, but association does not establish a necessary causal circuit.

Show evidence (2 references)

PMID:22574861 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Among cases, alcohol cues elicited robust activation of limbic and prefrontal regions, including ventral striatum, anterior cingulate and ventromedial prefrontal cortex."

The human imaging meta-analysis localizes within-case cue responses to ventral striatal and prefrontal circuitry, without equating activation with a causal deficit.

PMID:22574861 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Cue-elicited activation of ventral striatum was most frequently correlated with behavioral measures and most frequently reduced by treatment, but these results were often derived from region-of-interest analyses that interrogated only limbic regions."

Behavioral correlations and treatment-related changes support cue responsivity as an associative mechanism candidate, while region-of-interest selection limits generalization.

GABA-A Receptor Redistribution

Rodent chronic-intermittent-ethanol studies and cell/slice assays describe time- and compartment-dependent changes in GABA-A receptor surface composition. Reduced tonic ethanol sensitivity can coexist with increased sensitivity of some synaptic currents. Single-dose changes can reverse, while repeated regimens produce longer persistence; endpoint-specific tolerance is not universal receptor loss or proven lifelong human dysfunction. Hippocampal and cortical pyramidal-neuron recordings are among the preparations supporting these changes.

pyramidal neuron CL:0000598

GABA-A receptor activity GO:0004890

hippocampal formation UBERON:0002421 cerebral cortex UBERON:0000956

Animal models

Chronic intermittent ethanol rodent paradigms Rattus norvegicus measures Repeated exposure changes receptor composition and localization over measured follow-up.

Downstream

Withdrawal-Associated CNS Hyperexcitability Changes in inhibitory or excitatory synaptic signaling alter neuronal excitability when ethanol is reduced. These known physiological intermediates are summarized here; their relative contribution differs across models and patients.

Show evidence (3 references)

PMID:28931433 SUPPORT DIRECT REVIEW SYNTHESIS Model Organism

"One-dose ethanol exposure induces transient plastic changes in GABAA receptor subunit levels, composition, and regional and subcellular localization."

Rodent exposure experiments summarized here show receptor redistribution after one dose, supporting plasticity without implying permanent or uniform receptor loss.

PMID:25307573 SUPPORT DIRECT REVIEW SYNTHESIS In Vitro

"For example, studies in hippocampal and cortical pyramidal neurons have shown that chronic alcohol exposure reduces the frequency, amplitude, and decay time of mini inhibitory postsynaptic currents, effects that all contribute to increased neural excitability during withdrawal (Fleming et al., 2009)."

The review explicitly identifies hippocampal and cortical pyramidal-neuron recordings as evidence for altered inhibitory currents after chronic exposure.

PMID:28931433 SUPPORT INDIRECT REVIEW SYNTHESIS Model Organism

"One-dose ethanol exposure induces transient plastic changes in GABA A receptor subunit levels, composition, and regional and subcellular localization. ... After chronic intermittent ethanol (CIE) treatment the same changes are observed but they become persistent after 30 or more doses, lasting..."

The review distinguishes persistent receptor remodeling after repeated exposure from the reversible single-dose changes; this is a rat result, not a human threshold.

Altered Glutamate Homeostasis

Repeated ethanol exposure and withdrawal can alter glutamate release, uptake and receptor regulation. Elevated extracellular glutamate is supported in particular rodent dependence models, while human spectroscopy results vary by region and timing and do not all show elevation. The whole process should not be reduced to universal NMDA-receptor upregulation.

synaptic transmission, glutamatergic GO:0035249 ⚠ ABNORMAL

nucleus accumbens UBERON:0001882 cerebral cortex UBERON:0000956

Downstream

Show evidence (2 references)

PMID:25307573 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"Some studies have reported reduced cortical glutamate levels associated with dependence and acute withdrawal (Mon et al., 2012; Ende et al., 2013), while other studies have shown elevated glutamate activity in anterior cingulate and striatum in alcohol-dependent subjects (Hermann et al., 2012;..."

Human measurements differ by brain region and withdrawal timing, supporting altered glutamate regulation rather than a universal increase or decrease.

PMID:25307573 SUPPORT DIRECT REVIEW SYNTHESIS Model Organism

"Repeated cycles of chronic intermittent exposure to alcohol vapor were shown to increase basal levels of glutamate in the nucleus accumbens (NAc) at time points beyond acute withdrawal."

Repeated vapor exposure increases accumbal glutamate in the reviewed rodent experiments beyond the acute withdrawal period.

Withdrawal-Associated CNS Hyperexcitability

Reduction or cessation after sustained heavy exposure in a physiologically dependent person can uncover altered inhibitory/excitatory regulation. This contributes to tremor, insomnia, hallucinations and, in severe cases, seizures or delirium. Withdrawal is neither universal in AUD nor a requirement for diagnosis.

Downstream

Tremor Withdrawal-related neural hyperexcitability can manifest as tremor through motor-system output.

Alcohol Withdrawal Seizures Excessive synchronized neuronal activity can produce a generalized withdrawal seizure in susceptible patients.

Alcohol Withdrawal Delirium Severe withdrawal can impair attention and awareness through distributed brain dysfunction; hyperexcitability is contributory rather than a complete explanation of delirium.

Withdrawal Hallucinations Withdrawal-associated circuit dysfunction can produce hallucinations; the precise sensory-network mediation is incompletely resolved.

Insomnia Withdrawal-related arousal can disrupt sleep through central sleep-wake regulation.

Nausea and Vomiting Withdrawal can produce nausea and vomiting through central and autonomic responses; the cited clinical account does not resolve their exact mediation.

Show evidence (1 reference)

PMID:25307573 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"Clinical features of alcohol withdrawal include signs of central nervous system hyperexcitability, heightened autonomic nervous system activation, and a constellation of symptoms contributing to psychologic discomfort and negative affect."

The human withdrawal syndrome includes both central hyperexcitability and autonomic activation; this clinical description alone does not identify a particular receptor mediator.

Withdrawal-Associated Autonomic Activation

Autonomic activation during withdrawal can produce tachycardia, sweating and elevated blood pressure. This component is separated from cortical excitability because controlling heart rate or blood pressure does not prevent withdrawal seizures or delirium.

Downstream

Withdrawal Tachycardia Sympathetic efferent signaling increases cardiac rate during withdrawal.

Withdrawal Hyperhidrosis Autonomic sudomotor output increases sweating during withdrawal.

Withdrawal Hypertension Autonomic cardiovascular output can raise blood pressure during withdrawal.

Show evidence (1 reference)

url:https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"Clinical signs include sweating, elevated blood pressure, tachycardia, hyperthermia, and hyperactive reflexes."

The guideline explicitly lists sweating, tachycardia and elevated blood pressure among withdrawal signs, supporting the autonomic branch.

CRF-Associated Stress Signaling

The addiction framework implicates CRF signaling in dependence-related stress and negative affect, with much of the causal evidence from rodent regional pharmacology. This is distinct from the nondependent VTA CRF-binding-protein/CRF2 drinking-in-the-dark experiment; that result is not evidence of central-amygdala CRF1 mediation.

response to stress GO:0006950 ↑ INCREASED

central amygdaloid nucleus UBERON:0002883 bed nucleus of stria terminalis UBERON:0001880

Downstream

Withdrawal-Associated Negative Affect The review framework proposes a contribution to aversive withdrawal states; human mediation and treatment response are not established by the cited model evidence.

Show evidence (1 reference)

PMID:27475769 SUPPORT DIRECT REVIEW SYNTHESIS Model Organism

"The increases in negative emotional states and dysphoric and stress-like responses in the withdrawal/negative affect stage involve decreases in the function of the dopamine component of the reward system and recruitment of brain stress neurotransmitters, such as corticotropin-releasing factor..."

The review places CRF, dynorphin and reduced reward signaling within the extended-amygdala withdrawal framework; their contributions are not an obligatory sequence in every patient.

Dynorphin–Kappa-Opioid Signaling

Dynorphin and kappa-opioid signaling are implicated in aversion and dependence-related drinking in experimental literature. Effects depend on timing, region, sex and model; knockout findings are not uniform. The conference review contains preliminary reports, and human postmortem expression associations do not prove that blocking this pathway treats AUD.

central amygdaloid nucleus UBERON:0002883 bed nucleus of stria terminalis UBERON:0001880

Downstream

Show evidence (1 reference)

PMID:22459870 SUPPORT DIRECT REVIEW SYNTHESIS Model Organism

"Dr. Brendan Walker presented data characterizing the effects of KOR antagonism within the extended amygdala on withdrawal-induced escalation of alcohol self-administration in dependent animals."

Kappa-opioid antagonist effects in dependent animals support an extended-amygdala dynorphin hypothesis, not established efficacy of such treatment in humans.

Withdrawal-Associated Reward Deficit

Reviewed dependence models show reduced dopamine neuronal activity or basal striatal dopamine during withdrawal. These observations support a reward-deficit hypothesis but should not be generalized to every brain region, exposure phase or individual with AUD.

dopamine secretion GO:0014046 ↓ DECREASED

ventral tegmental area UBERON:0002691 ventral striatum UBERON:0005403 dorsal striatum UBERON:0005382

Downstream

Show evidence (1 reference)

PMID:25307573 SUPPORT DIRECT REVIEW SYNTHESIS Model Organism

"By contrast, withdrawal from chronic alcohol exposure has been reported to result in decreased VTA dopamine neuronal activity (Diana et al., 1996; Bailey et al., 2001), and reduced basal levels of dopamine in ventral and dorsal subregions of the striatum, possibly due to enhanced dopamine uptake..."

The reviewed rodent measurements link withdrawal to reduced VTA firing and striatal dopamine, supporting a reward-deficit model with incompletely resolved behavioral mediation.

Withdrawal-Associated Negative Affect

Anxiety, dysphoria and other aversive states can motivate renewed drinking for relief. Hyperkatifeia is a cross-drug heuristic framework integrating reward deficits and stress signaling, not a biomarker or a required stage in every patient. Persistent symptoms also require assessment for independent psychiatric illness.

Downstream

Impaired Control over Alcohol Use Relief of aversive withdrawal states can motivate renewed use through negative reinforcement; this does not account for all patterns of impaired control.

Anxiety Anxiety can be part of an aversive withdrawal state, without implying all independent anxiety disorders arise through this route.

Show evidence (1 reference)

PMID:33318153 SUPPORT REVIEW SYNTHESIS Other

"This review focuses on neurochemical/neurocircuitry dysregulations that contribute to hyperkatifeia, defined as a greater intensity of negative emotional/motivational signs and symptoms during withdrawal from drugs of abuse in the withdrawal/negative affect stage of the addiction cycle."

The review defines heightened negative affect during withdrawal and proposes its motivational role; it does not establish a single causal neurochemical route.

Habitual Alcohol Seeking

In alcohol-preferring male rats, devaluation-insensitive seeking predicted subsequent punishment-resistant seeking and quinine-resistant drinking. The cited abstract supplies behavioral evidence; its background anatomical account is not a new direct assay of dorsal-striatal dopamine or proof of the same causal sequence in humans.

Animal models

P-rat seeking-taking and outcome-devaluation paradigm Rattus norvegicus measures Behavioral devaluation sensitivity and punishment resistance are related.

Downstream

Impaired Control over Alcohol Use In the rat paradigm, stronger habitual control predicted punishment-resistant seeking; extrapolation to human impaired control remains indirect.

Show evidence (1 reference)

PMID:33955649 SUPPORT DIRECT PRIMARY RESULT Model Organism

"After seeking behaviour was well established, subjects that had developed greater resistance to outcome devaluation (were more habitual) were more likely to show punishment-resistant (compulsive) alcohol seeking."

Outcome-devaluation resistance predicted punishment-resistant seeking in selected rats; the association does not prove that habitual control alone causes human compulsive drinking.

Impaired Executive Control

Reduced inhibitory control and altered decision-making can contribute to difficulty limiting alcohol use in the addiction framework. Cross-sectional MRI differences in AUD provide anatomical associations, not proof that alcohol caused progressive atrophy or that a measured structural difference mediated an executive deficit.

prefrontal cortex UBERON:0000451

Downstream

Impaired Control over Alcohol Use Reduced executive regulation can make limiting use more difficult, but imaging and review evidence do not establish one necessary causal pathway.

Impaired Executive Functioning This clinical domain is represented in the review framework; severity and cause vary among individuals.

Show evidence (2 references)

PMID:27475769 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"The craving and deficits in executive function in the so-called preoccupation/anticipation stage involve the dysregulation of key afferent projections from the prefrontal cortex and insula, including glutamate, to the basal ganglia and extended amygdala."

The synthesis links executive-control problems to prefrontal projections, providing circuit context without proving a single lesion causes impaired control.

PMID:32643841 SUPPORT INDIRECT PRIMARY RESULT Human Clinical

"On measures of cortical thickness, AUD was associated with significant differences bilaterally in the fusiform gyrus, inferior temporal gyrus, temporal pole, superior frontal gyrus, and rostral and caudal anterior cingulate gyri."

Cross-sectional anatomical associations support context for the framework, without directly measuring a causal effect on executive performance.

Impaired Control over Alcohol Use

Impaired control and persistent use despite harm are clinical manifestations to which reinforcement, learned cue responses, aversive-state relief and executive-control problems may contribute. These routes can coexist but are not a mandatory ordered sequence, and DSM criteria allow heterogeneous presentations.

Downstream

Addictive Alcohol Use The node describes the impaired-control component of the clinical phenotype, while individual DSM criterion combinations vary.

Problematic Alcohol Consumption Persistent impaired control can produce problematic consumption and related impairment.

Repeated Ethanol Exposure Difficulty limiting use can perpetuate exposure, creating a feedback relationship rather than a necessary one-way progression.

Show evidence (1 reference)

PMID:37844924 SUPPORT REVIEW SYNTHESIS Other

"The diagnosis of AUD can be made when a patient has a problematic pattern of alcohol use over a year that leads to clinically significant impairment or distress, involving at least 2 of the 11 DSM-5-TR criteria."

The guideline states the DSM-5-TR clinical threshold, supporting the diagnostic construct rather than a molecular cause of addiction.

Thiamine Deficiency

Poor intake and alcohol-related interference with thiamine handling can produce deficiency and neurologic complications. Nutritional deficiency is an exposure-associated pathway distinct from reinforcement and receptor adaptation; not everyone with AUD develops it.

Downstream

Memory Impairment Thiamine deficiency can cause metabolic brain injury and region-specific neurologic dysfunction, leading to this manifestation in affected patients.

Ataxia Thiamine deficiency can cause metabolic brain injury and region-specific neurologic dysfunction, leading to this manifestation in affected patients.

Show evidence (1 reference)

url:https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"Patients consuming large volumes of alcohol are at an increased risk of developing Wernicke encephalopathy due to inadequate nutrition as well as biological interactions between cellular functioning and alcohol."

The guideline connects heavy drinking with nutritional and biological risks for thiamine-related disease, supporting a conditional deficiency pathway.

TLR4-Dependent Inflammatory Signaling

In female mice exposed to ethanol for five months and in neonatal rodent astrocyte preparations, Tlr4 deletion or knockdown attenuated inflammatory responses. Direct ethanol binding to TLR4 was not established. The constitutive whole-body knockout does not isolate an astrocyte- or microglia-autonomous mechanism in vivo or prove this pathway causes human AUD.

TLR4 hgnc:11850

Downstream

Astrocytic NF-kappa-B Activation TLR4 signals through intracellular adaptor and kinase pathways to NF-kappa-B. Astrocyte knockdown supports this route, while the intervening canonical signaling steps are not separate graph nodes.

Cortical Inflammatory Mediator Induction Constitutive Tlr4 deletion prevents the measured cortical cytokine induction in this mouse regimen; cell-specific production and all intervening routes remain unresolved.

Cortical Glial Reactivity Tlr4 deletion attenuates cortical GFAP reactivity but leaves a residual response; the experiment does not isolate every intervening glial signal.

Cortical Caspase-3 Activation The mouse comparison associates TLR4 function with ethanol-induced cortical caspase-3 cleavage; the responsible cell type and intervening death pathway remain unresolved.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6634595/ SUPPORT DIRECT PRIMARY RESULT Model Organism

"Our findings support the critical role of the TLR4 response in the neuroinflammation, brain injury, and possibly in the neurodegeneration induced by chronic ethanol intake."

The mouse study supports receptor dependence of measured inflammatory and injury markers; neurodegeneration was proposed rather than a measured clinical outcome.

Astrocytic NF-kappa-B Activation

In neonatal rodent astrocyte cultures, ethanol increased nuclear NF-kappa-B p65 signaling, and TLR4 knockdown or deficiency attenuated it. These cell-culture findings are separate from whole-cortex measurements and do not establish a universal patient biomarker.

astrocyte CL:0000127

Experimental models

Neonatal rodent astrocyte TLR4 perturbations PRIMARY CELL CULTURE TLR4 knockdown attenuates ethanol-associated nuclear p65 signaling.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6634595/ SUPPORT DIRECT PRIMARY RESULT In Vitro

"Gene silencing of TLR4 downregulates the TLR4 expression and reduces NFκB activation induced by ethanol in astrocytes in culture."

TLR4 knockdown reduces ethanol-induced NF-kappa-B activation in cultured astrocytes, establishing a perturbation result within that cell preparation.

Cortical Inflammatory Mediator Induction

Chronic ethanol-exposed wild-type mouse cortex showed increased TNF-alpha and IL-1beta protein and IL-6 transcript, with attenuated responses in Tlr4-knockout mice. Whole-tissue measurements do not identify the producing cell type, and transcript and protein readouts are not interchangeable.

cerebral cortex UBERON:0000956

Animal models

Chronic ethanol exposure in constitutive Tlr4-knockout mice Mus musculus measures Chronic ethanol increases the measured endpoint in wild-type mice, with attenuation in Tlr4-deficient mice.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6634595/ SUPPORT DIRECT PRIMARY RESULT Model Organism

"chronic ethanol treatment upregulated the levels of TNF-α, IL-1β, and mRNA IL-6 in the cortex homogenates of the WT mice, whereas no changes were observed in the levels of these cytokines in the cerebral cortices of the TLR4-KO mice."

The wild-type versus knockout comparison shows TLR4-dependent cortical cytokine changes in mice; homogenate measurements do not identify every producing cell.

Cortical Glial Reactivity

GFAP and CD11b immunoreactivity increased in the cortex of ethanol-exposed wild-type mice. Tlr4 deficiency attenuated these changes, but the residual approximately threefold GFAP increase shows that not all astroglial response was abolished. Immunoreactivity is a marker readout rather than a direct count of newly generated glia.

cerebral cortex UBERON:0000956

Animal models

Chronic ethanol exposure in constitutive Tlr4-knockout mice Mus musculus measures Chronic ethanol increases the measured endpoint in wild-type mice, with attenuation in Tlr4-deficient mice.

Show evidence (2 references)

url:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6634595/ SUPPORT DIRECT PRIMARY RESULT Model Organism

"although GFAP immunoreactivity markedly increased (∼16-fold) in the medial frontal cortex of the WT ethanol-treated mice, the levels of this protein only increased ∼3-fold in the TLR4-KO ethanol-treated animals"

The GFAP increase is attenuated but persists in knockout mice, supporting a partial TLR4 contribution rather than complete prevention of glial reactivity.

url:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6634595/ SUPPORT DIRECT PRIMARY RESULT Model Organism

"A significant upregulation of GFAP ... and CD11b ... immunoreactivity was observed in the ethanol-treated WT mice versus the WT nontreated controls"

The figure legend reports increases in both glial markers, complementing the separate quantitative GFAP comparison.

Cortical Caspase-3 Activation

Cleaved caspase-3 and immunoreactivity increased in ethanol-exposed wild-type mouse cortex and were attenuated by Tlr4 deficiency. This supports an injury/apoptosis-associated signal, without directly identifying dying neurons, quantifying cognitive impairment, or proving an inflammatory mediator was the necessary intermediate.

cerebral cortex UBERON:0000956

Animal models

Chronic ethanol exposure in constitutive Tlr4-knockout mice Mus musculus measures Chronic ethanol increases the measured endpoint in wild-type mice, with attenuation in Tlr4-deficient mice.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6634595/ SUPPORT DIRECT PRIMARY RESULT Model Organism

"the Western blot analysis shows caspase-3 activation as the appearance of the ∼17 kDa caspase-3 cleavage fragment in cerebral cortices of the ethanol-treated WT animals. Conversely, chronic ethanol treatment did not induce caspase-3 activation in the TLR4-KO animals"

The passage compares ethanol-exposed wild-type and Tlr4-knockout cortices, supporting genotype-dependent caspase-3 activation without identifying a dying cell type.

VTA CRF2-Associated Drinking Modulation

In male mice, local VTA CRF2 antagonism reduced nondependent drinking-in-the-dark intake; CRF-binding-protein interference added to the effect under tested conditions. The study did not assay dopamine, NMDA currents or physical receptor interactions. CRF-binding-protein blockade was ineffective in central amygdala and in the dependent intermittent-access VTA condition.

ventral tegmental area UBERON:0002691

Animal models

Regional CRF pharmacology in DID and intermittent-access mice Mus musculus measures VTA antagonism reduces intake in the tested DID context.

Downstream

Repeated Ethanol Exposure Regional pharmacological perturbation altered intake in nondependent DID mice; the intervening neuronal mechanism and human relevance are unresolved.

Show evidence (2 references)

PMID:26247973 SUPPORT DIRECT PRIMARY RESULT Model Organism

"These results indicate that VTA CRF2 receptors modulate ethanol binge drinking, and CRFBP may add to the anti-alcohol effect of A2B."

Local VTA pharmacology modifies drinking in the nondependent binge paradigm; the result does not establish the same effect in dependence or in all brain regions.

PMID:26247973 SUPPORT DIRECT PRIMARY RESULT Model Organism

"Intra-CeA CRF6–33 neither affected ethanol binge drinking nor escalated ethanol consumption in mice given IAA."

The central-amygdala null result limits regional generalization of the VTA CRF-binding-protein finding.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

Cardiovascular 3

Withdrawal Tachycardia HP:0001649

Temporal: ACUTE

Show evidence (1 reference)

url:https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"Clinical signs include sweating, elevated blood pressure, tachycardia, hyperthermia, and hyperactive reflexes."

The guideline explicitly lists sweating, tachycardia and elevated blood pressure among withdrawal signs, supporting the autonomic branch.

Dilated Cardiomyopathy HP:0001644

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK436003/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"Chronic alcohol use can accelerate coronary artery disease and cause dilated cardiomyopathy."

The source recognizes dilated cardiomyopathy as a possible consequence of chronic alcohol use, rather than a defining AUD phenotype.

Withdrawal Hypertension HP:0000822

Show evidence (1 reference)

url:https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"Clinical signs include sweating, elevated blood pressure, tachycardia, hyperthermia, and hyperactive reflexes."

The guideline explicitly lists sweating, tachycardia and elevated blood pressure among withdrawal signs, supporting the autonomic branch.

Digestive 4

Nausea and Vomiting HP:0002017

Temporal: ACUTE

Show evidence (1 reference)

url:https://www.aafp.org/pubs/afp/issues/2021/0900/p253.pdf SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"leading to tremors, insomnia, nausea and vomiting, hallucinations, anxiety, and agitation."

Lists nausea and vomiting among withdrawal manifestations.

Hepatic Steatosis HP:0001397

Show evidence (1 reference)

PMID:31536239 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"Alcoholic Fatty Liver or Steatosis - At this stage, fat accumulates in the liver parenchyma."

The clinical review describes hepatic fat accumulation as alcohol-associated steatosis; the detailed metabolic pathway is curated separately.

Cirrhosis HP:0001394

Show evidence (1 reference)

PMID:31536239 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"The alcoholic liver disease covers a spectrum of disorders beginning from the fatty liver, progressing at times to alcoholic hepatitis and culminating in alcoholic cirrhosis"

The clinical synthesis describes progression to cirrhosis within alcohol-associated liver disease; progression is conditional, not inevitable.

Pancreatitis HP:0001733

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK436003/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"In addition to liver disease, alcohol can cause both acute and chronic pancreatitis as well as exocrine insufficiency."

The clinical synthesis supports both acute and chronic pancreatitis as alcohol-related complications; it does not assign a population frequency.

Integument 2

Facial Flushing After Alcohol Intake HP:0001033

Show evidence (1 reference)

PMID:17718394 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"Acetaldehyde is a toxic substance whose accumulation leads to a highly aversive reaction that includes facial flushing, nausea, and rapid heart beat (i.e., tachycardia)."

Ties the flushing phenotype to acetaldehyde accumulation.

Withdrawal Hyperhidrosis HP:0000975

Show evidence (1 reference)

url:https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"Clinical signs include sweating, elevated blood pressure, tachycardia, hyperthermia, and hyperactive reflexes."

The guideline explicitly lists sweating, tachycardia and elevated blood pressure among withdrawal signs, supporting the autonomic branch.

Nervous System 14

Addictive Alcohol Use HP:0030955

Show evidence (1 reference)

PMID:37844924 SUPPORT REVIEW SYNTHESIS Other

The guideline states the DSM-5-TR clinical threshold, supporting the diagnostic construct rather than a molecular cause of addiction.

Problematic Alcohol Consumption HP:5200329

Show evidence (2 references)

PMID:31194891 SUPPORT REVIEW SYNTHESIS Other

"This review describes and discusses the alcohol diagnoses within this section of ICD-11, including Alcohol Dependence, Harmful Pattern of Use of Alcohol, and entities such as Alcohol Intoxication, Alcohol Withdrawal, and several alcohol-induced mental disorders, and briefly covers Hazardous..."

Documents the ICD-11 diagnostic structure that grades problematic drinking into harmful use and dependence.

PMID:37844924 SUPPORT REVIEW SYNTHESIS Other

The guideline states the DSM-5-TR clinical threshold, supporting the diagnostic construct rather than a molecular cause of addiction.

Hazardous Alcohol Use HP:6000028

Show evidence (1 reference)

PMID:37844924 SUPPORT REVIEW SYNTHESIS Other

"the patient uses alcohol regularly in situations where it is a hazard to them physically (8)"

Repeated drinking in physically hazardous situations is a diagnostic criterion, distinct from a proven neural mechanism.

Tremor HP:0001337

Temporal: ACUTE

Show evidence (1 reference)

url:https://www.aafp.org/pubs/afp/issues/2021/0900/p253.pdf SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"leading to tremors, insomnia, nausea and vomiting, hallucinations, anxiety, and agitation."

Lists tremor as a core alcohol withdrawal sign.

Alcohol Withdrawal Seizures Bilateral tonic-clonic seizure HP:0002069

Temporal: ACUTE

Show evidence (1 reference)

url:https://www.aafp.org/pubs/afp/issues/2021/0900/p253.pdf SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"If untreated or inadequately treated, withdrawal can progress to generalized tonic-clonic seizures, delirium tremens, and death."

Identifies withdrawal seizures as a complication of untreated withdrawal.

Alcohol Withdrawal Delirium HP:0031258

Temporal: ACUTE Severity: SEVERE

Show evidence (1 reference)

url:https://www.aafp.org/pubs/afp/issues/2021/0900/p253.pdf SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"If untreated or inadequately treated, withdrawal can progress to generalized tonic-clonic seizures, delirium tremens, and death."

Establishes delirium tremens as the severe end of the withdrawal spectrum.

Withdrawal Hallucinations HP:0000738

Temporal: ACUTE

Show evidence (1 reference)

url:https://www.aafp.org/pubs/afp/issues/2021/0900/p253.pdf SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"leading to tremors, insomnia, nausea and vomiting, hallucinations, anxiety, and agitation."

Lists hallucinations among the withdrawal manifestations.

Insomnia HP:0100785

Show evidence (2 references)

url:https://www.aafp.org/pubs/afp/issues/2021/0900/p253.pdf SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"leading to tremors, insomnia, nausea and vomiting, hallucinations, anxiety, and agitation."

Lists insomnia among the withdrawal manifestations.

PMID:25307573 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"A common complaint among alcoholics is disruption in sleep, which typically emerges during early periods of abstinence and often extends to the more protracted phase of abstinence"

The clinical review describes sleep disruption during both early and protracted abstinence, supporting the timing of the insomnia claim.

Anxiety HP:0000739

Show evidence (2 references)

url:https://www.aafp.org/pubs/afp/issues/2021/0900/p253.pdf SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"leading to tremors, insomnia, nausea and vomiting, hallucinations, anxiety, and agitation."

Documents anxiety as an acute withdrawal feature.

PMID:27475769 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"Drug addiction can be defined as a chronically relapsing disorder, characterised by compulsion to seek and take the drug, loss of control in limiting intake, and emergence of a negative emotional state (eg, dysphoria, anxiety, irritability) when access to the drug is prevented."

Supports anxiety as part of the negative emotional state beyond acute withdrawal.

Depression HP:0000716

Show evidence (2 references)

PMID:32217228 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Patients with AUD spent more time depressed and had more suicide attempts during follow-up."

Five-year prospective psychiatric cohort links comorbid AUD to a worse depressive course.

PMID:26039070 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Significant associations were found between 12-month and lifetime AUD and other substance use disorders, major depressive and bipolar I disorders, and antisocial and borderline personality disorders across all levels of AUD severity, with odds ratios ranging from 1.2 (95% CI, 1.08-1.36) to 6.4..."

Nationally representative data quantify the association between AUD and major depressive disorder.

Impaired Executive Functioning HP:0033051

Show evidence (1 reference)

PMID:27475769 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

Identifies executive dysfunction as a defined domain of the addiction cycle.

Memory Impairment HP:0002354

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK436003/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"Chronic alcohol use leading to thiamine deficiency can result in Korsakoff syndrome marked by antero- and retrograde amnesia."

The clinical synthesis links thiamine-related Korsakoff syndrome to anterograde and retrograde memory impairment; this is a complication in a subset of patients.

Ataxia HP:0001251

Show evidence (1 reference)

url:https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"Patients with thiamine deficiency often present with signs and symptoms such as confusion, abnormal gaze patterns or nystagmus, ataxia, and possibly delirium."

The guideline lists ataxia among manifestations of thiamine deficiency, supporting the nutritional complication without making it a general AUD finding.

Peripheral Neuropathy HP:0009830

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK436003/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"Alcohol can also cause peripheral neuropathy of small fibers"

The quoted clinical observation supports alcohol-associated small-fiber neuropathy, without implying every neuropathy in an AUD patient has that cause.

Other 1

Craving

No `phenotype_term` is bound: HPO has no general craving term (only the food-specific HP:0030083, HP:0030221 and HP:6000785), and using one of those or a generic behavioural parent would misdescribe the claim. Needs term / NTR candidate.

Show evidence (1 reference)

PMID:37844924 SUPPORT REVIEW SYNTHESIS Other

"the patient has troublesome craving (desire or urges) to use alcohol (4)"

Craving is an explicit DSM-5-TR criterion, but it alone is insufficient for the diagnosis.

🧬

Genetic Associations

ADH1B (ADH1B*2 (rs1229984, His48) encodes an enzyme with increased ethanol-oxidizing activity and is associated with lower alcohol-dependence risk. Purified-enzyme turnover is not a fixed multiplier of whole-body clearance. The proposed aversive mechanism and magnitude of protection vary with genetic and environmental context.)

Gene: ADH1B hgnc:250 gene page relationship_type: PROTECTIVE

Show evidence (2 references)

PMID:17718394 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"The ADH1B*2 allele, which is associated with particularly rapid ethanol oxidation, has shown protective effects against alcohol dependence in a variety of populations."

The review summarizes human protective associations for ADH1B*2, separate from the purified-enzyme kinetics cited in the mechanism branch.

PMID:16822169 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Recruitment strategy and gender moderated the effect of ADH1B*2."

Meta-analysis of ADH1B in Asian populations establishes the association and identifies moderators of its magnitude.

ALDH2 (ALDH2*2 (rs671, Glu504Lys in the precursor protein) markedly reduces mitochondrial acetaldehyde clearance, promoting acetaldehyde accumulation and aversive symptoms after alcohol. It is strongly associated with lower dependence risk, especially in studied East Asian populations; neither ancestry nor genotype makes AUD impossible.)

Gene: ALDH2 hgnc:404 gene page relationship_type: PROTECTIVE

Show evidence (2 references)

PMID:17718394 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"The presence of even a single ALDH2*2 allele is strongly protective against alcohol dependence."

The reviewed human genetic observations support a protective ALDH2*2 association; allele-specific enzyme dysfunction is represented separately.

PMID:16822169 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Diagnostic criteria, recruitment strategy, and Japanese ethnicity moderated the effect of ALDH2*2."

Meta-analysis quantifying the ALDH2*2 protective effect in Asian populations and its moderators.

GABRA2 (A study of multiply affected families associated GABRA2 haplotypes with alcohol dependence and beta-frequency EEG oscillations. Lack of coding differences motivated a regulatory hypothesis, but this study did not establish altered receptor expression, currents or causal mediation of dependence.)

Gene: GABRA2 hgnc:4076 gene page relationship_type: SUSCEPTIBILITY

Show evidence (2 references)

PMID:15024690 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Thirty-one SNPs in GABRA2, but only 1 of the 20 SNPs in the flanking genes, showed significant association with alcoholism."

Family-based association study localizing the signal specifically to GABRA2 within the chromosome 4 p GABA-A receptor gene cluster.

PMID:15024690 SUPPORT INDIRECT PRIMARY RESULT Human Clinical

"No coding differences were found between the high-risk and low-risk haplotypes, suggesting that the effect is mediated through gene regulation."

The authors propose regulation from absence of coding differences; this is not a direct expression assay.

OPRM1 (The 2023 PAU GWAS confirms association of rs1799971 (A118G), distinct from the question of genotype-guided naltrexone treatment. Earlier pharmacogenetic proposals remain unvalidated for routine selection; the cited 147-person head-to-head trial found no genotype treatment interaction, which does not exclude every possible subgroup effect.)

Gene: OPRM1 hgnc:8156 gene page relationship_type: SUSCEPTIBILITY

Show evidence (3 references)

PMID:38062264 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"This is the first GWAS to confirm the association of rs1799971 in PAU; the risk allele is the same as for OUD."

The PAU GWAS confirms the OPRM1 association, which is distinct from predicting an individual's response to naltrexone.

PMID:22909206 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"Although screening of patients in a clinical setting remains premature, results suggest the A118G substitution may influence one etiological pathway to alcoholism, for which naltrexone pharmacotherapy is more effective."

Review supporting a modifier role while explicitly cautioning that clinical screening is premature.

PMID:38706338 REFUTE DIRECT PRIMARY RESULT Human Clinical

"Neither rs2832407 nor rs1799971 had effects on topiramate and naltrexone treatments, respectively."

This trial did not detect the proposed pharmacogenetic effects; it does not prove absence of effects in every population or treatment context.

GCKR (Statistical fine mapping in the European-ancestry PAU analysis nominated GCKR rs1260326 in a singleton credible set with posterior inclusion probability of at least 99%. This supports locus association and candidate-variant prioritization, without demonstrating a biochemical causal route to AUD.)

Gene: GCKR hgnc:4196 gene page relationship_type: SUSCEPTIBILITY

Show evidence (1 reference)

PMID:38062264 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Among the 85 regions, there were 5 credible sets that include only a single variant with PIP ≥99% (presumably indicating successful identification of specific causal variants): rs1260326 in GCKR, rs472140 and rs1229984 in ADH1B, rs2699453 (intergenic) and rs2098112 (intergenic)."

Fine-mapping concentrates posterior probability on a GCKR variant, providing statistical prioritization rather than an experimentally proven brain mechanism.

KLB (KLB was among genes computationally prioritized by PAU association, genetically predicted brain expression and chromatin interaction annotations in the European-ancestry analysis. This study did not experimentally establish a KLB–FGF21 liver–brain pathway or direction of clinical effect.)

Gene: KLB hgnc:15527 relationship_type: SUSCEPTIBILITY

Show evidence (1 reference)

PMID:38062264 SUPPORT DIRECT PRIMARY RESULT Computational

"Among the 130 genes associated with PAU in EUR, 62 were also implicated by TWAS findings either by single brain tissue (S-PrediXcan) or across brain tissues (S-MultiXcan), 82 have evidence of brain chromatin interaction and 51 have evidence from both TWAS and Hi-C annotations including ADH1B,..."

The KLB nomination combines European-ancestry transcriptome and chromatin annotations; it does not demonstrate endocrine mediation in patients.

💊

Medical Actions

Oral Naltrexone

Action: Pharmacotherapy NCIT:C15986

Agent: naltrexone CHEBI:7465

Platform: Small molecule

First-line opioid-receptor antagonist for adults with moderate to severe AUD seeking abstinence or reduced drinking. Oral 50 mg/day has the strongest formulation-specific trial evidence for reducing return to heavy drinking; pair with appropriate psychosocial support and patient-defined goals. Current opioid use and acute hepatitis or liver failure are important contraindications; assess future opioid analgesia needs.

Mechanism Target:

INHIBITS Alcohol-Evoked Endogenous Opioid Signaling — Opioid-receptor antagonism blocks signaling rather than proving that suppression of a particular endogenous peptide or dopamine relay mediates clinical response.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK436003/ SUPPORT INDIRECT REVIEW SYNTHESIS Human Clinical

"Naltrexone is a mu-opioid receptor antagonist that can be taken daily by mouth or as a monthly intramuscular injection administered in the clinic setting."

The clinical pharmacology summary identifies mu-opioid antagonism and the two delivery schedules; efficacy estimates still require formulation-specific trial evidence.

Show evidence (3 references)

PMID:37844924 SUPPORT REVIEW SYNTHESIS Human Clinical

"Adult patients with moderate to severe AUD should be offered naltrexone or acamprosate as a first-line pharmacotherapy to support achievement of patient-identified treatment goals."

The guideline recommends naltrexone or acamprosate as first-line options for adults with moderate to severe AUD, selected with the patient's goals.

url:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10630900/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"Compared with placebo, oral naltrexone (50 mg/d) was associated with lower rates of return to heavy drinking, with a number needed to treat of 11 (95% CI, 5-41)."

Pooled placebo-controlled human trials support oral 50-mg naltrexone for reducing return to heavy drinking; the estimate is specific to that outcome and formulation.

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK436003/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"Naltrexone is a mu-opioid receptor antagonist that can be taken daily by mouth or as a monthly intramuscular injection administered in the clinic setting."

The clinical pharmacology summary identifies mu-opioid antagonism and the two delivery schedules; efficacy estimates still require formulation-specific trial evidence.

Extended-Release Injectable Naltrexone

Action: Pharmacotherapy NCIT:C15986

Agent: naltrexone CHEBI:7465

Platform: Small molecule

Monthly intramuscular opioid antagonist that reduces the need for daily pill taking but still requires return visits and treatment engagement. Injectable-specific efficacy evidence is smaller and outcome-dependent; it should not be assumed superior to oral medication or to eliminate adherence problems. The same opioid-related precautions apply.

Mechanism Target:

INHIBITS Alcohol-Evoked Endogenous Opioid Signaling — The formulation delivers sustained opioid-receptor antagonism; the human PET experiment does not itself test this treatment.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK436003/ SUPPORT INDIRECT REVIEW SYNTHESIS Human Clinical

"Naltrexone is a mu-opioid receptor antagonist that can be taken daily by mouth or as a monthly intramuscular injection administered in the clinic setting."

The clinical pharmacology summary identifies mu-opioid antagonism and the two delivery schedules; efficacy estimates still require formulation-specific trial evidence.

Show evidence (2 references)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK436003/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"Naltrexone is a mu-opioid receptor antagonist that can be taken daily by mouth or as a monthly intramuscular injection administered in the clinic setting."

The clinical pharmacology summary identifies mu-opioid antagonism and the two delivery schedules; efficacy estimates still require formulation-specific trial evidence.

url:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10630900/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"Fewer data were available for the 100-mg/d oral and injectable doses."

The systematic review reports a smaller evidence base for injectable and higher-dose oral naltrexone, limiting transfer of the 50-mg oral estimate.

Acamprosate

Action: Pharmacotherapy NCIT:C15986

Agent: acamprosate CHEBI:51041

Platform: Small molecule

First-line medication for an abstinence goal, generally started after withdrawal and abstinence. Trial evidence supports reduced return to any drinking, without a clear benefit for preventing return to heavy drinking. The molecular mechanism remains uncertain; it is not curated as a proven reversal of a particular glutamate abnormality. Severe renal impairment is a contraindication and moderate impairment requires dose adjustment.

Show evidence (3 references)

PMID:37844924 SUPPORT REVIEW SYNTHESIS Human Clinical

"Adult patients with moderate to severe AUD should be offered naltrexone or acamprosate as a first-line pharmacotherapy to support achievement of patient-identified treatment goals."

The guideline recommends naltrexone or acamprosate as first-line options for adults with moderate to severe AUD, selected with the patient's goals.

url:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10630900/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"Acamprosate was not associated with benefit for return to heavy drinking (moderate strength of evidence)."

The pooled human evidence does not show benefit for return to heavy drinking, distinguishing that endpoint from acamprosate's abstinence-related benefits.

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK436003/ SUPPORT REVIEW SYNTHESIS Other

"[Acamprosate:] mechanism of action is unknown but likely modulates the GABAergic system."

The clinical chapter explicitly attributes the uncertain mechanism to acamprosate; it does not establish reversal of a specific glutamate abnormality.

Disulfiram

Action: Pharmacotherapy NCIT:C15986

Agent: disulfiram CHEBI:4659

Platform: Small molecule

An aldehyde-dehydrogenase inhibitor used as an aversive deterrent in selected patients pursuing abstinence. Informed agreement and support or observed dosing are important; drinking while taking it can cause a hazardous reaction. Supervised/open-label studies and blinded efficacy studies have different limitations. Avoid overstating comparative benefit from network estimates.

Mechanism Target:

ACTIVATES Acetaldehyde Accumulation — Inhibiting aldehyde clearance causes acetaldehyde accumulation if alcohol is consumed; this intended deterrent also creates reaction risk.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK436003/ SUPPORT INDIRECT REVIEW SYNTHESIS Human Clinical

"Mechanistically, the medication inhibits the enzyme acetaldehyde dehydrogenase, which causes an accumulation of acetaldehyde."

The pharmacology account identifies aldehyde dehydrogenase inhibition as the route by which disulfiram promotes acetaldehyde accumulation.

Show evidence (3 references)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK436003/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"Mechanistically, the medication inhibits the enzyme acetaldehyde dehydrogenase, which causes an accumulation of acetaldehyde."

The pharmacology account identifies aldehyde dehydrogenase inhibition as the route by which disulfiram promotes acetaldehyde accumulation.

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK436003/ SUPPORT REVIEW SYNTHESIS Other

"Treatment with disulfiram is best suited to those with a support person who can help administer or observe the patient taking the medication."

The clinical guidance emphasizes observed administration and support, reflecting the importance of adherence for disulfiram use.

url:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10630900/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"relatively limited evidence exists to support the efficacy of disulfiram compared with placebo for preventing return to any drinking or other alcohol consumption outcomes."

The review finds limited placebo-controlled evidence for disulfiram consumption outcomes, qualifying its place among available treatments.

Topiramate

Action: Pharmacotherapy NCIT:C15986

Agent: topiramate CHEBI:63631

Platform: Small molecule

An off-label alternative when first-line medication is ineffective, contraindicated or not preferred. The Canadian guideline gives a strong recommendation with moderate-certainty evidence; systematic review supports reduced consumption endpoints. Cognitive slowing, language difficulties, paresthesias and other adverse effects require consideration. A 147-person 12-week comparison with naltrexone did not establish formal equivalence or superiority on its primary heavy-drinking outcome.

Show evidence (3 references)

PMID:37844924 SUPPORT REVIEW SYNTHESIS Human Clinical

"Adult patients with moderate to severe AUD who do not benefit from, have contraindications to, or express a preference for an alternate to first-line medications can be offered topiramate or gabapentin."

The guideline places topiramate and gabapentin after first-line options are unsuitable or not preferred, rather than making them universal initial treatment.

url:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10630900/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"topiramate was associated with adverse effects that included cognitive dysfunction, dizziness, numbness and/or tingling, and taste abnormalities."

Pooled trial adverse-event findings support counseling about topiramate's cognitive, sensory and other tolerability effects.

PMID:38706338 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"For the number of heavy drinking days per week, there was a near-significant time-by-treatment interaction. For the number of standard drinks per drinking day per week, there was a significant time-by-treatment interaction, which favored topiramate."

The primary heavy-drinking-day comparison did not reach significance; the secondary drinks-per-drinking-day result favored topiramate. Neither result establishes formal equivalence.

Gabapentin

Action: Pharmacotherapy NCIT:C15986

Agent: gabapentin CHEBI:42797

Platform: Small molecule

An off-label alternative for ongoing AUD care when first-line agents are unsuitable, with a conditional recommendation and low-certainty evidence in the Canadian guideline. Sedation, dizziness, renal function and concurrent opioids or other depressants matter. Use for ongoing AUD and use in selected mild withdrawal are separate indications; it does not replace monitored treatment for high-risk withdrawal.

Mechanism Target:

INHIBITS Withdrawal-Associated Negative Affect — In ethanol-dependent rats, gabapentin acts on central amygdala GABAergic transmission and reverses the anxiety-like state of abstinence. Its molecular mechanism in AUD is otherwise unsettled.

Show evidence (1 reference)

PMID:18509038 SUPPORT INDIRECT PRIMARY RESULT Model Organism

"Systemic gabapentin reduced ethanol intake in dependent, but not in nondependent, rats and reversed the anxiogenic-like effects of ethanol abstinence using an acute dependence model."

The effect is selective for the dependent state and reverses the abstinence-related negative affect this node describes. Indirect because it is a rat model.

Show evidence (2 references)

PMID:37844924 SUPPORT REVIEW SYNTHESIS Human Clinical

The guideline places topiramate and gabapentin after first-line options are unsuitable or not preferred, rather than making them universal initial treatment.

url:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10630900/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"Studies of baclofen and gabapentin had low strength of evidence for benefit in at least 1 outcome."

The review grades gabapentin's outcome evidence as low strength, limiting certainty about its benefits.

Baclofen

Action: Pharmacotherapy NCIT:C15986

Agent: baclofen CHEBI:2972

Platform: Small molecule

A GABA-B agonist studied as an off-label option. The conventional systematic review found low-certainty evidence for preventing return to any drinking because results were inconsistent and imprecise; network ranking alone does not establish first-line status or broad safety. Sedation and tolerability require attention. ASAM finds insufficient evidence for treating alcohol withdrawal with baclofen.

Show evidence (2 references)

url:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10630900/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"Because of imprecision of the effect estimate and inconsistency of results, baclofen data were graded as having low strength of evidence."

Imprecision and inconsistent human trial results explain the low-strength assessment of baclofen for ongoing AUD care.

url:https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf SUPPORT REVIEW SYNTHESIS Human Clinical

"There is insufficient evidence to support the use of baclofen for the treatment of alcohol withdrawal."

The withdrawal guideline finds insufficient supporting evidence for baclofen in acute withdrawal, a different indication from ongoing AUD treatment.

Benzodiazepine Withdrawal Management

Action: Pharmacotherapy NCIT:C15986

Agent: benzodiazepine NCIT:C1012

Platform: Small molecule

First-line medication for moderate to severe alcohol withdrawal and prevention or treatment of withdrawal seizures and delirium, with monitoring for oversedation and respiratory depression. Symptom-triggered protocols require reliable assessment; fixed or front-loading approaches may be appropriate. Agent selection and dosing depend on liver function, comorbidity and setting. This is a short-course withdrawal treatment, not ongoing AUD pharmacotherapy.

Mechanism Target:

INHIBITS Withdrawal-Associated CNS Hyperexcitability — Enhancing inhibitory signaling controls withdrawal and reduces severe complications; ongoing relapse prevention requires additional care.

Show evidence (1 reference)

url:https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf SUPPORT INDIRECT REVIEW SYNTHESIS Human Clinical

"Benzodiazepines are first-line treatment because of their well-documented effectiveness in reducing the signs and symptoms of withdrawal including the incidence of seizure and delirium."

The guideline's synthesis of clinical treatment evidence supports benzodiazepines for withdrawal symptoms and prevention of seizures and delirium.

Show evidence (2 references)

url:https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"Benzodiazepines are first-line treatment because of their well-documented effectiveness in reducing the signs and symptoms of withdrawal including the incidence of seizure and delirium."

The guideline's synthesis of clinical treatment evidence supports benzodiazepines for withdrawal symptoms and prevention of seizures and delirium.

PMID:37844924 SUPPORT REVIEW SYNTHESIS Other

"Benzodiazepines should not be prescribed as ongoing treatment for AUD"

The guideline separates short withdrawal treatment from ongoing prescribing for AUD and advises against the latter.

Thiamine Repletion

Action: Supportive Care NCIT:C15747

Agent: thiamine CHEBI:18385

Platform: Small molecule

Give thiamine promptly to prevent or treat deficiency-related neurologic injury. ASAM favors parenteral administration for poor nutrition, malabsorption or severe withdrawal complications. Prevention and treatment of suspected Wernicke encephalopathy require appropriate clinical protocols. Glucose can be given before, after or concurrently; urgent glucose should not be delayed while awaiting thiamine.

Mechanism Target:

INHIBITS Thiamine Deficiency — Replenishes a deficient vitamin to prevent or treat its complications; it does not directly treat reinforcement or craving.

Show evidence (1 reference)

url:https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf SUPPORT REVIEW SYNTHESIS Other

"Thiamine should be provided to prevent Wernicke encephalopathy."

The guideline recommends replacement to prevent thiamine-related encephalopathy in the withdrawal-care setting.

Show evidence (3 references)

url:https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf SUPPORT REVIEW SYNTHESIS Other

"Thiamine should be provided to prevent Wernicke encephalopathy."

The guideline recommends replacement to prevent thiamine-related encephalopathy in the withdrawal-care setting.

url:https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf SUPPORT REVIEW SYNTHESIS Other

"it is important that glucose delivery not be delayed in patients who are nutritionally compromised."

The recommendation explicitly prioritizes timely glucose delivery when needed, correcting a rigid thiamine-before-glucose sequence.

url:https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf SUPPORT REVIEW SYNTHESIS Other

"these could be provided in any order or concurrently in order to not delay treatment."

The guideline permits concurrent administration or either order, supporting prompt treatment of both nutritional risks.

Cognitive Behavioral Therapy

Action: Cognitive Behavior Therapy NCIT:C64345

Platform: Behavioral / lifestyle

Structured therapy addresses coping, drinking-related cognitions and relapse prevention. The cited 30-trial meta-analysis included alcohol and other drug disorders; effects were larger against minimal care than against active treatments, with early benefits against nonspecific controls less clear at later follow-up. Lack of a significant difference from another active therapy is not formal equivalence.

Show evidence (2 references)

PMID:31599606 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"The current meta-analysis shows that CBT is more effective than a no treatment, minimal treatment, or nonspecific control."

The human trial meta-analysis favors CBT over minimal or nonspecific care, rather than demonstrating superiority over every active therapy.

PMID:31599606 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"CBT effects in contrast to a specific therapy were consistently nonsignificant across outcomes and follow-up time points."

The same analysis found no consistent advantage over specific active therapies, qualifying the comparative claim for CBT.

Alcoholics Anonymous and Twelve-Step Facilitation

Action: Behavioral Counseling NCIT:C181743

Platform: Behavioral / lifestyle

Offer peer support and, when consistent with patient preferences, structured professional facilitation of AA participation. In the 2020 Cochrane review, manualized TSF improved continuous abstinence at 12 months compared with other clinical approaches (two studies, 1936 participants; RR 1.21, 95% CI 1.03–1.42). Evidence for drinking intensity and consequences was less certain and generally did not show clear differences. These mostly US, noncoerced studies do not establish equal efficacy of every mutual-help format or an obligation to attend AA.

Show evidence (2 references)

PMID:32159228 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"RCTs comparing manualized AA/TSF to other clinical interventions (e.g. CBT), showed AA/TSF improves rates of continuous abstinence at 12 months (risk ratio (RR) 1.21, 95% confidence interval (CI) 1.03 to 1.42; 2 studies, 1936 participants; high-certainty evidence)."

The pooled randomized trials support manualized AA/TSF for continuous abstinence at 12 months, with an endpoint- and comparator-specific effect.

PMID:32159228 SUPPORT REVIEW SYNTHESIS Other

"If people with AUD are opposed to attending AA, despite the strong evidence for its potential to aid recovery, clinicians might consider linkage to alternative mutual‐help organizations as they may confer benefits at similar levels of engagement."

The review recommends alternatives when AA is not acceptable; this is a care preference statement rather than a direct equivalence trial of all mutual-help groups.

Semaglutide (investigational)

Action: Pharmacotherapy NCIT:C15986

Agent: semaglutide CHEBI:167574

Platform: Peptide

GLP-1 receptor agonism remains under investigation for AUD. The 2025 phase 2 trial randomized 48 nontreatment-seeking adults with BMI≥23; paired laboratory self-administration analyses involved 25 participants, while weekly drinking models used the randomized sample. Drinks per calendar day and number of drinking days did not significantly improve; craving and drinks per drinking day were exploratory findings. A separate 26-week trial randomized 108 treatment-seeking adults with moderate/severe AUD and obesity to semaglutide or placebo plus CBT, finding a 13.7-percentage-point adjusted between-group reduction in heavy-drinking days.

Mechanism Target:

INHIBITS Mesolimbic Dopamine Reinforcement — In rodents, GLP-1 receptor agonism reduces alcohol-evoked dopamine release in the nucleus accumbens. Whether this mediates the reduction in heavy drinking seen in human trials has not been tested.

Show evidence (1 reference)

PMID:37295046 SUPPORT INDIRECT PRIMARY RESULT Model Organism

"semaglutide attenuated the ability of alcohol to cause hyperlocomotion and to elevate dopamine in NAc in male mice"

Mouse microdialysis shows semaglutide blunts the alcohol-evoked accumbens dopamine rise that this node describes. Indirect because the measurement is in mice, not in people with AUD.

Show evidence (2 references)

PMID:39937469 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Semaglutide treatment did not affect average drinks per calendar day or number of drinking days, but significantly reduced drinks per drinking day"

The small randomized trial found an effect on drinks per drinking day but not all consumption endpoints, limiting a blanket efficacy claim.

PMID:42070571 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Semaglutide was associated with a reduction in heavy drinking days (-41·1 percentage points from baseline, 95% CI -48·7 to -33·5) compared with placebo (-26·4, -34·1 to -18·6; estimated treatment difference -13·7 percentage points, -22·0 to -5·4; p=0·0015), and had substantial effects on..."

A 26-week randomized placebo-controlled trial quantifies the reduction in heavy drinking days in patients with AUD and comorbid obesity.

Shared-Decision Ongoing AUD Care

Platform: Behavioral / lifestyle

Develop a plan around patient goals, which may include abstinence or reduced drinking, and integrate medical, psychiatric and social needs. Offer ongoing care after withdrawal and adjust treatment as circumstances change.

Show evidence (2 references)

PMID:37844924 SUPPORT REVIEW SYNTHESIS Other

"All patients who complete withdrawal management should be offered ongoing AUD care."

The guideline distinguishes completing withdrawal from treating AUD and recommends continued care after stabilization.

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK436003/ SUPPORT REVIEW SYNTHESIS Other

"Goal setting may include abstinence or reduction in drinking."

The clinical guidance permits abstinence or reduction goals, supporting individualized shared decisions.

Brief Motivational Intervention

Platform: Behavioral / lifestyle

Offer a brief collaborative intervention after high-risk screening or diagnosis to discuss concerns, goals and treatment options. Its evidence in unhealthy drinking should not be mistaken for adequate stand-alone treatment of every severe AUD presentation.

Show evidence (1 reference)

PMID:37844924 SUPPORT REVIEW SYNTHESIS Human Clinical

"All patients who screen positive for high-risk alcohol use should be offered brief intervention"

The guideline recommends brief intervention after a positive high-risk screen; screening positivity alone is not a diagnosis of AUD.

Specialist Psychosocial and Family Support

Platform: Behavioral / lifestyle

Offer access to structured psychosocial treatment, including family-based approaches where appropriate and acceptable to the patient. Support social needs and referrals alongside medication rather than making medication access depend on participation in a single therapy format.

Show evidence (1 reference)

PMID:37844924 SUPPORT REVIEW SYNTHESIS Human Clinical

"Adult and youth patients with mild to severe AUD should be offered information about and referrals to specialist-led psychosocial treatment interventions in the community"

The recommendation supports referral to structured psychosocial care across youth and adult AUD populations.

Monitored Withdrawal and Level-of-Care Selection

Platform: Other

Assess prior complicated withdrawal, current symptoms, medical/psychiatric illness and home support. Ambulatory care is for appropriately selected patients with reassessment; severe or complicated withdrawal requires an adequately monitored setting. Withdrawal management should connect directly to ongoing AUD care.

Show evidence (2 references)

url:https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf SUPPORT REVIEW SYNTHESIS Other

"Most withdrawal severity scales reflect current signs and symptoms and should not be used alone to determine level of care."

A current symptom score is not a complete risk or placement assessment, supporting the additional clinical factors described here.

url:https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf SUPPORT REVIEW SYNTHESIS Other

"should be provided close nursing observation and supportive care, which often necessitates admission to an intensive or critical care unit."

The recommendation links withdrawal delirium to close observation and often critical care, rather than routine unsupervised management.

Selected Nonbenzodiazepine Withdrawal Options

Platform: Small molecule

Gabapentin or carbamazepine can be considered for selected mild withdrawal at low risk of complications. Phenobarbital is an alternative or adjunct for experienced clinicians with appropriate monitoring; parenteral use requires highly supervised care because of oversedation and respiratory risk.

Show evidence (1 reference)

url:https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf SUPPORT REVIEW SYNTHESIS Other

"Phenobarbital can be used for some patients in inpatient settings; however, it should only be used by clinicians experienced with its use given its narrow therapeutic window and side effects."

The guideline restricts phenobarbital use to suitably experienced clinicians and settings because of its therapeutic window and adverse effects.

Adjunct Control of Withdrawal Autonomic Symptoms

Platform: Small molecule

Alpha-2 agonists or beta-blockers may be added for persistent autonomic symptoms in selected patients. They do not prevent or treat withdrawal seizures or delirium and must not replace effective withdrawal therapy.

Mechanism Target:

INHIBITS Withdrawal-Associated Autonomic Activation — Adjunctive symptom control does not correct the entire withdrawal process or protect against its severe neurologic complications.

Show evidence (2 references)

url:https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf SUPPORT REVIEW SYNTHESIS Other

"Alpha2-adrenergic agonists (AA2 s) such as clonidine and dexmedetomidine can be used as an adjunct to benzodiazepine therapy to control autonomic hyperactivity and anxiety when these signs are not controlled by benzodiazepines alone. They should not be used alone to prevent or treat..."

ASAM recommends alpha-2 agonists for adjunctive control of autonomic hyperactivity and anxiety, while explicitly excluding their use alone for seizures or delirium.

url:https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf SUPPORT REVIEW SYNTHESIS Other

"Beta-adrenergic antagonists (beta-blockers) can be used as an adjunct to benzodiazepines in select patients for control of persistent hypertension or tachycardia"

ASAM supports adjunct beta-blockers for persistent hypertension or tachycardia after benzodiazepines; this symptom control does not treat the underlying withdrawal process.

Show evidence (2 references)

url:https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf SUPPORT REVIEW SYNTHESIS Other

ASAM recommends alpha-2 agonists for adjunctive control of autonomic hyperactivity and anxiety, while explicitly excluding their use alone for seizures or delirium.

url:https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf SUPPORT REVIEW SYNTHESIS Other

"Beta-adrenergic antagonists (beta-blockers) can be used as an adjunct to benzodiazepines in select patients for control of persistent hypertension or tachycardia"

ASAM supports adjunct beta-blockers for persistent hypertension or tachycardia after benzodiazepines; this symptom control does not treat the underlying withdrawal process.

🌍

Environmental Factors

Alcohol consumption

Alcohol intake supplies the exposure required for alcohol-related reinforcement and complications. Repeated heavy exposure can produce receptor adaptations in experimental paradigms, but exposure does not inevitably lead to AUD. Effects depend on dose, timing and host context.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK436003/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"The fact that not every person who drinks alcohol will necessarily experience a loss of control and progression to addiction indicates that AUD is not solely driven by exposure to alcohol."

The clinical synthesis distinguishes alcohol exposure from the additional susceptibility required for impaired control and addiction.

Mechanism Target:

TRIGGERS Repeated Ethanol Exposure — Repeated consumption supplies ethanol exposure.

TRIGGERS GABA-A Receptor Redistribution — Repeated exposure promotes longer-lasting receptor remodeling in reviewed rodent protocols; the intermediate steps and human time course are unresolved.

Show evidence (1 reference)

PMID:28931433 SUPPORT INDIRECT REVIEW SYNTHESIS Model Organism

"After chronic intermittent ethanol (CIE) treatment the same changes are observed but they become persistent after 30 or more doses, lasting for at least 120 days in the rat"

The reviewed rat regimen produces persistent receptor changes after repeated doses; the observation should not be generalized to all human drinking histories.

🔬

Biochemical Markers

Phosphatidylethanol (PEth) (Elevated with recent heavy alcohol consumption)

Show evidence (2 references)

PMID:37569551 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"In recent years, phosphatidylethanol (PEth) in blood has emerged as a marker of unhealthy alcohol use."

Systematic review establishes PEth as a biomarker of unhealthy alcohol use.

PMID:37569551 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"PEth interpretative cut-offs varied greatly among the included records, ranging from 4.2 ng/mL to 250 ng/mL, with sensitivity and specificity in the ranges of 58-100% and 64-100%, respectively."

Quantifies the wide variation in reported cut-offs and diagnostic accuracy, which limits how prescriptively the marker can be used.

Gamma-Glutamyltransferase (GGT) (Elevated with sustained heavy alcohol consumption)

Reference Ranges

Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma ≤ 85.0 U/L (males; screening cutoff for heavy drinking)

Study-specific assay decision threshold for classifying alcohol exposure, not a universal clinical reference interval or diagnostic cutoff for AUD.

Show evidence (1 reference)

PMID:17767129 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"The GGT test used a cutoff of 85 U/L for males and 65 U/L for females."

Source of the sex-specific GGT cutoffs used to screen for heavy drinking.

Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma ≤ 65.0 U/L (females; screening cutoff for heavy drinking)

Study-specific assay decision threshold for classifying alcohol exposure, not a universal clinical reference interval or diagnostic cutoff for AUD.

Show evidence (1 reference)

PMID:17767129 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"The GGT test used a cutoff of 85 U/L for males and 65 U/L for females."

Source of the sex-specific GGT cutoffs used to screen for heavy drinking.

Show evidence (5 references)

PMID:16799164 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"The sensitivity of GGT-CDT (90%) in correctly classifying heavy drinkers exceeded that of CDT (63%), GGT (58%), mean corpuscular volume (MCV) (45%), aspartate aminotransferase (AST) (47%), and alanine aminotransferase (ALT) (50%), being also essentially similar for alcoholics with (93%) or..."

Quantifies the sensitivity of each conventional marker and of the combined GGT-CDT index in a cohort of 165 heavy drinkers against moderate-drinker and abstainer references.

PMID:16799164 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"GGT-CDT improves the sensitivity of detecting excessive ethanol consumption as compared with the traditional markers of ethanol consumption."

States the study's conclusion that the combined GGT-CDT index outperforms the individual conventional markers.

PMID:17767129 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"The results showed that 30% of males reporting heavy drinking tested GGT positive compared to 65% who tested EDAC positive."

The male heavy-drinking subgroup had low GGT positivity at the study threshold, demonstrating that a normal result cannot exclude substantial consumption.

+ 2 more references

Carbohydrate-Deficient Transferrin (CDT) (Elevated with sustained heavy alcohol consumption)

Reference Ranges

Transferrin.carbohydrate deficient/Transferrin.total in Serum or Plasma ≤ 1.7 % (adults; %disialotransferrin by HPLC candidate reference method)

Study-specific assay decision threshold for classifying alcohol exposure, not a universal clinical reference interval or diagnostic cutoff for AUD.

Show evidence (1 reference)

PMID:25698630 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Serum CDT was measured by the candidate HPLC reference method and expressed as relative amount of disialotransferrin (%DST: cutoff 1.7%)."

Source of the % CDT (disialotransferrin) upper-limit cutoff used clinically.

Show evidence (2 references)

PMID:16799164 SUPPORT DIRECT PRIMARY RESULT Human Clinical

The heavy-drinker cohort supplies the CDT sensitivity and combined GGT-CDT estimate, separate from the HPLC decision threshold below.

PMID:36983134 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"[In the CDT row:] The most specific marker available today. The specificity is reduced by rare genetic defects in transferrin. ... Certain diseases reduce the specificity of the CDT test. These include non-alcoholic liver diseases (primary biliary cirrhosis, chronic active inflammation, -HCV,..."

The review describes relatively high CDT specificity among conventional markers, while identifying rare transferrin variants and several non-alcoholic conditions that reduce it.

Mean Corpuscular Volume (MCV) (Elevated with sustained heavy alcohol consumption (macrocytosis))

Reference Ranges

MCV [Entitic mean volume] in Red Blood Cells ≤ 96.0 fL (abstainers (NORIP reference data))

The LOINC code was verified against the NLM clinical-tables LOINC service; LOINC is not covered by the repository's OAK term validation.

Show evidence (1 reference)

PMID:16581347 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"the upper normal limit for MCV based on the data from moderate drinkers was 98 fl, as compared with 96 fl from abstainers"

Source of the abstainer upper normal limit for MCV, derived from NORIP reference data.

MCV [Entitic mean volume] in Red Blood Cells ≤ 98.0 fL (moderate drinkers (NORIP reference data))

The higher upper limit in moderate drinkers versus abstainers itself reflects a dose-related response of MCV to ethanol intake. The LOINC code was verified against the NLM clinical-tables LOINC service; LOINC is not covered by the repository's OAK term validation.

Show evidence (1 reference)

PMID:16581347 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"the upper normal limit for MCV based on the data from moderate drinkers was 98 fl, as compared with 96 fl from abstainers"

Source of the moderate-drinker upper normal limit for MCV, derived from NORIP reference data.

Show evidence (2 references)

PMID:16799164 SUPPORT DIRECT PRIMARY RESULT Human Clinical

Quantifies MCV's individual sensitivity (45%) for classifying heavy drinkers, well below the combined GGT-CDT index.

PMID:36983134 SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"The possible false positive increases in MCV include vitamin B12 and folic acid deficiency, hypothyroidism, hemolytic disease with reticulocytosis, non-alcoholic liver disease"

The review identifies alternative causes of macrocytosis; the heavy-drinker sensitivity estimate alone does not establish this specificity caveat.

🔬

Diagnosis

DSM-5-TR clinical diagnosis

A problematic pattern causing clinically significant impairment or distress with any two or more of eleven criteria within a year supports diagnosis. Two or three criteria indicate mild, four or five moderate, and six or more severe AUD. Tolerance and withdrawal are optional criteria. Review history, functional impact, other substance use and psychiatric or medical explanations; exposure biomarkers alone do not diagnose AUD.

Show evidence (2 references)

PMID:37844924 SUPPORT REVIEW SYNTHESIS Other

The guideline states the DSM-5-TR clinical threshold, supporting the diagnostic construct rather than a molecular cause of addiction.

PMID:37844924 SUPPORT REVIEW SYNTHESIS Other

"Patients are diagnosed with mild AUD if they have 2–3 criteria; moderate AUD with 4–5 criteria; and severe AUD with 6 or more criteria."

The DSM-5-TR severity bands count diagnostic criteria, rather than biological subtypes or withdrawal severity.

ICD-11 alcohol diagnoses

ICD-11 distinguishes alcohol dependence and harmful pattern of use; hazardous use is a separately listed health-risk factor. These categories should not be treated as exact synonyms for the DSM-5-TR severity spectrum.

Show evidence (1 reference)

PMID:31194891 SUPPORT REVIEW SYNTHESIS Other

Authoritative description of the ICD-11 alcohol diagnostic structure.

AUDIT, AUDIT-C and brief screening

Validated questionnaires identify unhealthy or high-risk drinking and prompt a diagnostic interview. Thresholds depend on the population and screening purpose. AUDIT-C assesses consumption, whereas the AUDIT problems subscale used in PAU genetics is a different measure. Neither is a stand-alone molecular or clinical confirmation of AUD.

Show evidence (2 references)

PMID:37844924 SUPPORT REVIEW SYNTHESIS Other

"The AUDIT and AUDIT-C tools were designed to screen for hazardous or harmful alcohol use, using a cut-off score of 8 (for AUDIT) or 3 and 4 for women and men, respectively (for AUDIT-C)."

The guideline provides screening thresholds for hazardous or harmful use, which require clinical follow-up rather than automatic AUD diagnosis.

PMID:37844924 SUPPORT REVIEW SYNTHESIS Other

"Adults and youth who screen positive for high-risk drinking should undergo a diagnostic interview for mild, moderate or severe AUD using the DSM-5-TR criteria"

A positive screen prompts a diagnostic interview, explicitly separating screening from diagnosis.

Withdrawal risk and severity assessment

History of seizures or delirium, current findings, coexisting disease and available support guide the level of care. PAWSS predicts risk in studied medically ill populations; CIWA-Ar measures current withdrawal symptoms and can be confounded by other illness. CIWA-Ar depends on patient report and should not be used to assess delirium.

Show evidence (2 references)

url:https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf SUPPORT REVIEW SYNTHESIS Other

"Most withdrawal severity scales reflect current signs and symptoms and should not be used alone to determine level of care."

A current symptom score is not a complete risk or placement assessment, supporting the additional clinical factors described here.

url:https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf SUPPORT REVIEW SYNTHESIS Other

"It is not recommended to use the CIWA-Ar in patients with delirium because it relies on patient-reported symptoms."

The guideline excludes CIWA-Ar in delirium because reliable patient-reported symptoms are required.

AUDIT total-score zones

The full Alcohol Use Disorders Identification Test. Its total score is used as a screen at a cut-off of 8 and is graded into the zones suggested by the World Health Organization. In alcohol-dependent outpatients, indicators of dependence severity increased across those zones.

AUDIT NCIT:C188039

AUDIT LOINC:72110-0

Reference Ranges

Total score [AUDIT] (WHO AUDIT zones as applied in the COMBINE study: alcohol-dependent individuals (n = 1335) entering out-patient treatment at eleven academic clinical research centers across the United States)

Below the screening cut-off of 8 (< 8 {score}) AUDIT zone 8-15 (8–16 {score}) AUDIT zone 16-19 (16–20 {score}) AUDIT zone 20-40 (≥ 20 {score})

The COMBINE abstract states the zones as "AUDIT total score = 8-15, 16-19, 20-40", and reports that "the highest zone, with scores of 20 and above, was markedly different with respect to severity". The AUDIT score is an integer, so the half-open bands [8, 16), [16, 20) and [20, ) match those zones exactly. The band below 8 is not a zone named in that abstract; its boundary is the AUDIT screening cut-off of 8 stated in the Canadian guideline (PMID:37844924). Because the COMBINE sample had already met dependence criteria, the zones there index severity among dependent patients rather than screening yield. The severity values follow the zones' order; the abstract does not use the words mild, moderate or severe.

Show evidence (3 references)

PMID:17156168 SUPPORT PRIMARY RESULT Human Clinical

"Participants were classified into AUDIT zones (AUDIT total score = 8-15, 16-19, 20-40)"

States the three AUDIT total-score zones used to grade severity.

PMID:17156168 SUPPORT PRIMARY RESULT Human Clinical

"Indicators of severity of dependence and alcohol-related problems increased linearly with total score and differed significantly across AUDIT zones."

Shows that the zones are ordered by severity of dependence and alcohol-related problems.

PMID:37844924 SUPPORT REVIEW SYNTHESIS Other

"The AUDIT and AUDIT-C tools were designed to screen for hazardous or harmful alcohol use, using a cut-off score of 8 (for AUDIT) or 3 and 4 for women and men, respectively (for AUDIT-C)."

Gives the AUDIT screening cut-off of 8 that bounds the lowest band.

Copyright © 2001 World Health Organization. Used with permission. The instrument is bound at its LOINC panel code and the zones at its total-score code. The instrument's items are not reproduced in this entry; only published thresholds are recorded. This row and the AUDIT-C row below carry one instrument each; the screening-pathway row above names both and is unchanged. The diagnosis_term is the NCIT term for the AUDIT itself.

Show evidence (1 reference)

PMID:17156168 SUPPORT PRIMARY RESULT Human Clinical

"The AUDIT total score is a brief measure that appears to provide an index of severity of dependence in a sample of alcohol-dependent individuals seeking out-patient treatment"

Supports the AUDIT total score as a severity measure in alcohol dependence, beyond its screening role.

AUDIT-C consumption screen

The consumption questions of the AUDIT, used as a brief screen for alcohol misuse. Its primary-care validation study derived sex-specific screening thresholds against an interview reference standard. A positive screen prompts a diagnostic interview rather than establishing AUD.

AUDIT-C LOINC:72109-2

Reference Ranges

Total score [AUDIT-C] (Men among adult outpatients at an academic family practice clinic, 1993 to 1994 (392 men in the validation sample))

Below the threshold for men (< 4 {score}) At or above the threshold for men (screen positive) (≥ 4 {score})

The abstract states the threshold as "> or =4 in men", so 4 is in the positive tier. The reference standard was alcohol misuse, defined as a DSM-IV alcohol use disorder and/or drinking above recommended limits in the past year, not AUD alone.

Show evidence (1 reference)

PMID:17451397 SUPPORT PRIMARY RESULT Human Clinical

"The AUDIT-C screening thresholds that simultaneously maximized sensitivity and specificity were > or =4 in men (sensitivity 0.86, specificity 0.89)"

States the AUDIT-C screening threshold for men.

Total score [AUDIT-C] (Women among adult outpatients at an academic family practice clinic, 1993 to 1994 (927 women in the validation sample))

Below the threshold for women (< 3 {score}) At or above the threshold for women (screen positive) (≥ 3 {score})

The abstract states the threshold as "> or =3 in women", so 3 is in the positive tier. The reference standard was alcohol misuse, defined as a DSM-IV alcohol use disorder and/or drinking above recommended limits in the past year, not AUD alone.

Show evidence (1 reference)

PMID:17451397 SUPPORT PRIMARY RESULT Human Clinical

"> or =3 in women (sensitivity 0.73, specificity 0.91)"

States the AUDIT-C screening threshold for women.

The instrument is bound at its LOINC panel code and the thresholds at its total-score code. Neither code carries a third-party copyright notice in the LOINC 2.83 table (the Tuva Project release pinned in data/loinc/MANIFEST.yaml). The instrument's items are not reproduced in this entry; only published thresholds are recorded. No diagnosis_term is bound: NCIT label searches for "AUDIT-C" return only question-level and CDISC codelist terms, not a term for the instrument.

Show evidence (1 reference)

PMID:17451397 SUPPORT PRIMARY RESULT Human Clinical

"The AUDIT-C was an effective screening test for alcohol misuse in this primary care sample."

Supports the AUDIT-C as a validated primary-care screen for alcohol misuse.

📊

Prevalence

US adults (NESARC-III, 2012-2013, DSM-5 criteria), 12-month

Period Prevalence 13900.0 per 100,000 >1 in 1,000

12-month prevalence of DSM-5 AUD in a nationally representative US adult sample (N = 36,309). These are historical weighted estimates from 36,309 US civilian noninstitutionalized adults interviewed in 2012–2013 (60.1% response), not current global prevalence.

Show evidence (1 reference)

PMID:26039070 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Twelve-month and lifetime prevalences of AUD were 13.9% and 29.1%, respectively."

NESARC-III provides the reference US 12-month prevalence estimate for DSM-5 AUD.

US adults (NESARC-III, 2012-2013, DSM-5 criteria), lifetime

Lifetime Prevalence 29100.0 per 100,000 >1 in 1,000

Lifetime prevalence of DSM-5 AUD; prevalence was highest in men (36.0% lifetime) and in younger and never-married adults. These are historical weighted estimates from 36,309 US civilian noninstitutionalized adults interviewed in 2012–2013 (60.1% response), not current global prevalence.

Show evidence (2 references)

PMID:26039070 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Twelve-month and lifetime prevalences of AUD were 13.9% and 29.1%, respectively."

The same NESARC-III survey reports the lifetime figure alongside the 12-month figure.

PMID:26039070 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Prevalence was generally highest for men (17.6% and 36.0%, respectively), white (14.0% and 32.6%, respectively) and Native American (19.2% and 43.4%, respectively), respondents, and younger (26.7% and 37.0%, respectively) and previously married (11.4% and 27.1%, respectively) or never married..."

Documents the demographic stratification underlying the pooled lifetime estimate.

⚖️

Clinical Burden

High

AUD can cause substantial functional impairment and exposure-related medical complications. The cited 2016 GBD figures concern all alcohol consumption, not mortality among a cohort with diagnosed AUD. In NESARC-III, 19.8% of adults with lifetime AUD reported ever receiving treatment or help, broadly defined to include mutual-help services; this is a historical survey estimate.

Show evidence (4 references)

PMID:30146330 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Globally, alcohol use was the seventh leading risk factor for both deaths and DALYs in 2016"

Models population burden attributable to alcohol exposure in 2016; it does not estimate an AUD-specific case-fatality rate.

PMID:30146330 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Among the population aged 15-49 years, alcohol use was the leading risk factor globally in 2016, with 3·8% (95% UI 3·2-4·3) of female deaths and 12·2% (10·8-13·6) of male deaths attributable to alcohol use."

Models population burden attributable to alcohol exposure in 2016; it does not estimate an AUD-specific case-fatality rate.

PMID:26039070 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Only 19.8% of respondents with lifetime AUD were ever treated."

Quantifies the treatment gap that compounds the burden of the disorder.

+ 1 more reference

🔬

Clinical Trials

clinicaltrials:NCT05520775 PHASE_II COMPLETED

Completed phase 2 trial randomized 48 nontreatment-seeking adults 21–65 with AUD and BMI≥23. Semaglutide 0.25 mg/week for 4 weeks then 0.5 mg/week for 4 weeks preceded the primary laboratory assessment; week 9 dose escalation followed primary collection. Paired laboratory analyses included 25 participants, so this was not a complete-case 48-person primary outcome. Registered calendar-day drinking was null; other weekly quantity/craving outcomes were exploratory.

Target Phenotypes: Addictive alcohol use HP:0030955

Show evidence (2 references)

PMID:39937469 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Low-dose semaglutide reduced the amount of alcohol consumed during a posttreatment laboratory self-administration task, with evidence of medium to large effect sizes for grams of alcohol consumed"

Reports the primary laboratory self-administration outcome of this trial.

clinicaltrials:NCT05520775 SUPPORT Other

"This is an early-Phase II human laboratory trial using a randomized, placebo-controlled, dose-ranging design to investigate the effects of semaglutide, a GLP-1 receptor agonist, on alcohol-related outcomes in adults with alcohol use disorder (AUD)."

The registry summary describes study design; current status was separately checked through the live registry API and efficacy comes from the published report.

clinicaltrials:NCT05895643 PHASE_II COMPLETED

Completed single-center 26-week phase 2 trial randomized 108 treatment-seeking adults with moderate/severe AUD and obesity (54 per group) to weekly semaglutide up to 2.4 mg or placebo, both with CBT. 88 completed; intention-to-treat primary analysis used multiple imputation. Adjusted heavy-drinking-day difference was −13.7 percentage points, not a relative 70% treatment benefit; long-term/general-population effects remain uncertain.

Target Phenotypes: Problematic alcohol consumption HP:5200329

Show evidence (2 references)

PMID:42070571 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Semaglutide showed robust therapeutic effects in treatment-seeking participants with obesity and alcohol use disorder and this trial supports previous preclinical and clinical findings suggesting GLP-1 receptor agonists as a potential novel treatment target for alcohol use disorder."

States the trial's overall conclusion for its treatment-seeking, comorbid-obesity population.

clinicaltrials:NCT05895643 SUPPORT Other

"The medication will be provided as a supplement to standardised cognitive behavioural therapy."

The registry summary describes study design; current status was separately checked through the live registry API and efficacy comes from the published report.

🧫

Experimental Models

Neonatal rodent astrocyte TLR4 perturbations PRIMARY_CELL_CULTURE

Highly enriched astrocyte cultures were exposed to ethanol with non-targeting siRNA and LPS-related controls. Rat knockdown experiments used 50 mM ethanol, whereas mouse knockout cultures used 10 mM. Nuclear p65, pERK and inflammatory readouts support TLR4 dependence. Lipopolysaccharide contamination controls were performed, but direct ethanol–TLR4 binding was not resolved.

Cell source

Neonatal rat astrocytes with TLR4, CD14 or MD-2 siRNA; separate wild-type and Tlr4-knockout mouse astrocytes

Publication

url:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6634595/

Pathograph links

Astrocytic NF-kappa-B Activation measures fidelity: moderate TLR4 knockdown attenuates ethanol-associated nuclear p65 signaling.

Limitations: Neonatal cell culture is distinct from intact adult human cortex and clinical addiction.

Readouts

Nuclear NF-kappa-B p65 after TLR4 knockdown

Direction: DECREASED

Interpretation: TLR4 knockdown attenuates ethanol-associated nuclear p65 signaling.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6634595/ SUPPORT DIRECT PRIMARY RESULT In Vitro

"Gene silencing of TLR4 downregulates the TLR4 expression and reduces NFκB activation induced by ethanol in astrocytes in culture."

TLR4 knockdown reduces ethanol-induced NF-kappa-B activation in cultured astrocytes, establishing a perturbation result within that cell preparation.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6634595/ SUPPORT DIRECT PRIMARY RESULT In Vitro

"Gene silencing of TLR4 downregulates the TLR4 expression and reduces NFκB activation induced by ethanol in astrocytes in culture."

TLR4 knockdown reduces ethanol-induced NF-kappa-B activation in cultured astrocytes, establishing a perturbation result within that cell preparation.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6634595/ SUPPORT DIRECT PRIMARY RESULT In Vitro

"Gene silencing of TLR4 downregulates the TLR4 expression and reduces NFκB activation induced by ethanol in astrocytes in culture."

TLR4 knockdown reduces ethanol-induced NF-kappa-B activation in cultured astrocytes, establishing a perturbation result within that cell preparation.

🐁

Animal Models

Alcohol-preferring P rats

Review of selected rats with voluntary ethanol intake, reinforcement and protocol-dependent binge/deprivation responses. The historical animal criteria are not DSM-5-TR criteria, and neither human age at onset nor all AUD domains are reproduced. Intoxicating concentrations depend on the access paradigm.

Species

Rattus norvegicus

Genotype

Selectively bred P line

Pathograph links

Repeated Ethanol Exposure measures fidelity: moderate Voluntary intake and binge-access endpoints model high alcohol exposure.

Limitations: Selection for intake is not a model of every clinical criterion or an established human causal allele.

Readouts

Voluntary ethanol intake

Direction: INCREASED

Interpretation: Voluntary intake and binge-access endpoints model high alcohol exposure.

Show evidence (1 reference)

PMID:24268381 SUPPORT DIRECT REVIEW SYNTHESIS Model Organism

"Under 24-h free-choice conditions, the P rat will voluntarily consume 5–8 g/kg/day and produce BACs in the range of 50–200 mg%"

The review reports voluntary ethanol intake and attained blood alcohol concentrations under a specified free-choice protocol.

Show evidence (1 reference)

PMID:24268381 SUPPORT DIRECT REVIEW SYNTHESIS Model Organism

"Under 24-h free-choice conditions, the P rat will voluntarily consume 5–8 g/kg/day and produce BACs in the range of 50–200 mg%"

The review reports voluntary ethanol intake and attained blood alcohol concentrations under a specified free-choice protocol.

Show evidence (2 references)

PMID:24268381 SUPPORT DIRECT REVIEW SYNTHESIS Model Organism

"The P line of rats meets all of the originally proposed criteria for a suitable animal model of alcoholism."

The review characterizes the selectively bred P rat as an experimental alcoholism model; model criteria are not equivalent to a human diagnosis.

PMID:24268381 SUPPORT DIRECT REVIEW SYNTHESIS Model Organism

"The P line also exhibits excessive binge-like alcohol drinking, attaining blood alcohol concentrations (BACs) of 200 mg% on a daily basis."

Reported high blood alcohol levels support the line's binge-like exposure phenotype under the reviewed experimental conditions.

High-alcohol-drinking HAD rat lines

The reviewed HAD lines show high intake and deprivation-related responses under specific protocols. The review reports four of six historical animal criteria, with tolerance and withdrawal not examined; the P-line completeness statement must not be transferred to HAD.

Species

Rattus norvegicus

Genotype

Selectively bred HAD1 and HAD2 lines

Pathograph links

Repeated Ethanol Exposure measures fidelity: moderate Selected high-drinking lines model voluntary exposure.

Limitations: Unexamined tolerance and withdrawal domains limit correspondence to physiological dependence.

Readouts

Voluntary ethanol intake

Direction: INCREASED

Interpretation: Selected high-drinking lines model voluntary exposure.

Show evidence (1 reference)

PMID:24268381 SUPPORT DIRECT REVIEW SYNTHESIS Model Organism

"The HAD1,2 rats satisfy several of the criteria for an animal model of alcoholism, e.g., these rats will voluntarily consume ethanol in a free-choice situation to produce BACs between 50 and 200 mg%."

Voluntary drinking in HAD lines produces substantial blood alcohol concentrations, supporting an exposure model without implying all human AUD features.

Show evidence (1 reference)

PMID:24268381 SUPPORT DIRECT REVIEW SYNTHESIS Model Organism

Voluntary drinking in HAD lines produces substantial blood alcohol concentrations, supporting an exposure model without implying all human AUD features.

Show evidence (1 reference)

PMID:24268381 SUPPORT DIRECT REVIEW SYNTHESIS Model Organism

Voluntary drinking in HAD lines produces substantial blood alcohol concentrations, supporting an exposure model without implying all human AUD features.

HAP/LAP preference QTL mouse cross

The 2006 study used a 432-animal F2 cross derived from selectively bred, outbred high- and low-preference lines. A chromosome 9 QTL had stronger support in females. Historical wording about the only extant lines is not a current inventory claim, and mouse preference mapping does not identify a human causal AUD gene.

Species

Mus musculus

Genotype

High Alcohol Preferring (HAP1, HAP2) and Low Alcohol Preferring (LAP1, LAP2) lines

Pathograph links

Repeated Ethanol Exposure measures fidelity: moderate Alcohol preference varied in a segregating HAP1 × LAP1 F2 cross and was linked to a chromosome 9 QTL; no single increase relative to a control is asserted.

Limitations: Preference is not equivalent to clinical compulsivity, withdrawal or DSM diagnosis.

Readouts

Alcohol preference

Interpretation: Alcohol preference varied in a segregating HAP1 × LAP1 F2 cross and was linked to a chromosome 9 QTL; no single increase relative to a control is asserted.

Show evidence (1 reference)

PMID:16482403 SUPPORT DIRECT PRIMARY RESULT Model Organism

"In Study 2, a genome-wide screen was performed in a sample of 432 HAP1xLAP1 F2 animals and a QTL on chromosome 9 (LOD=5.04) was found which met criteria for genome wide significance (p<0.001). ... This study provides additional evidence and confirmation that specific regions on chromosomes 9 and..."

The study maps alcohol-preference variation in the F2 cross; it does not report a uniformly increased phenotype in that cross.

Show evidence (1 reference)

PMID:16482403 SUPPORT DIRECT PRIMARY RESULT Model Organism

The study maps alcohol-preference variation in the F2 cross; it does not report a uniformly increased phenotype in that cross.

Show evidence (1 reference)

PMID:16482403 SUPPORT DIRECT PRIMARY RESULT Model Organism

"The High- and Low-Alcohol Preferring (HAP1/LAP1 and HAP2/LAP2) mouse lines were developed by selective breeding for differences in alcohol preference."

Selective breeding establishes genetically divergent preference lines for QTL analysis, rather than a single-gene model of human addiction.

HDID selected-line aversion and reward assays

Two selected replicates were compared with concurrent heterogeneous-stock controls. Conditioned taste aversion was attenuated at a moderate 2 g/kg ethanol dose but not at 4 g/kg; details varied by replicate and analysis. Conditioned place preference at the tested 2 g/kg dose did not differ. This genetic co-occurrence does not prove reduced aversion mediates every animal’s intake or absence of all reward differences.

Species

Mus musculus

Genotype

High Drinking in the Dark (HDID-1, HDID-2) selected lines, from an HS/Npt heterogeneous stock

Pathograph links

Repeated Ethanol Exposure measures fidelity: moderate Blood ethanol concentrations after a four-hour drinking-in-the-dark test increased in both selected replicate lines relative to the founding generation; aversion and reward were assessed in separate experiments.

Limitations: Separate animals and dose-specific conditioning endpoints do not resolve a universal reward mechanism.

Readouts

Blood alcohol after limited-access drinking

Direction: INCREASED

Interpretation: Blood ethanol concentrations after a four-hour drinking-in-the-dark test increased in both selected replicate lines relative to the founding generation; aversion and reward were assessed in separate experiments.

Show evidence (1 reference)

PMID:24219304 SUPPORT DIRECT PRIMARY RESULT Model Organism

"High Drinking in the Dark (HDID-1) mice have been bred for 27 selected generations (S27) for elevated blood ethanol concentrations (BECs) after a 4-h period of access to 20% ethanol. A second replicate line (HDID-2) was started later from the same founder population and is currently in S20. ......"

Both HDID replicate lines showed increased blood ethanol concentrations across selection generations; this is a drinking measurement, separate from the conditioning assays.

Show evidence (1 reference)

PMID:24219304 SUPPORT DIRECT PRIMARY RESULT Model Organism

Both HDID replicate lines showed increased blood ethanol concentrations across selection generations; this is a drinking measurement, separate from the conditioning assays.

Show evidence (2 references)

PMID:23910826 SUPPORT DIRECT PRIMARY RESULT Model Organism

"These results indicate that high blood alcohol levels after drinking in the HDID mice is genetically related to attenuated aversion to alcohol, while sensitivity to alcohol reward is not altered in these mice."

Selected HDID mice show reduced conditioned aversion without increased reward sensitivity, separating those candidate contributors to high blood alcohol levels.

PMID:23910826 SUPPORT DIRECT PRIMARY RESULT Model Organism

"HDID and HS mice showed comparable development of alcohol-induced conditioned place preference."

Comparable conditioned place preference constrains the interpretation that HDID selection simply increased alcohol reward.

P-rat seeking-taking and outcome-devaluation paradigm

After intermittent two-bottle pre-exposure and seeking-taking training, devaluation-resistant seeking predicted punishment resistance and quinine-adulterated drinking. Similar earlier preference/intake did not account for all later differences. Available evidence here is the abstract; the study does not directly demonstrate a dorsal-striatal dopamine measurement in its reported experiments.

Species

Rattus norvegicus

Genotype

Male alcohol-preferring rats

Pathograph links

Habitual Alcohol Seeking measures fidelity: moderate Behavioral devaluation sensitivity and punishment resistance are related.

Limitations: Predictive association does not by itself prove a particular circuit mediator or a human clinical route.

Readouts

Punishment-resistant alcohol seeking

Direction: INCREASED

Interpretation: Behavioral devaluation sensitivity and punishment resistance are related.

Show evidence (1 reference)

PMID:33955649 SUPPORT DIRECT PRIMARY RESULT Model Organism

Outcome-devaluation resistance predicted punishment-resistant seeking in selected rats; the association does not prove that habitual control alone causes human compulsive drinking.

Show evidence (1 reference)

PMID:33955649 SUPPORT DIRECT PRIMARY RESULT Model Organism

Outcome-devaluation resistance predicted punishment-resistant seeking in selected rats; the association does not prove that habitual control alone causes human compulsive drinking.

Show evidence (1 reference)

PMID:33955649 SUPPORT DIRECT PRIMARY RESULT Model Organism

Outcome-devaluation resistance predicted punishment-resistant seeking in selected rats; the association does not prove that habitual control alone causes human compulsive drinking.

Chronic intermittent ethanol rodent paradigms

The review synthesizes hippocampal receptor redistribution and endpoint-dependent behavioral adaptation. Persistence was measured for 40–120 days in cited rat protocols; the quotation’s lifelong extension is speculation. Sedative and tonic-current tolerance does not imply tolerance to every anxiolytic or anticonvulsant effect. PTZ susceptibility is not a demonstrated spontaneous withdrawal seizure phenotype.

Species

Rattus norvegicus

Genotype

Repeated high-dose intermittent ethanol and withdrawal

Pathograph links

GABA-A Receptor Redistribution measures fidelity: moderate Repeated exposure changes receptor composition and localization over measured follow-up.

Limitations: Region-, compartment- and time-specific rodent changes are not a validated irreversible human threshold.

Readouts

GABA-A receptor surface composition

Direction: ALTERED

Interpretation: Repeated exposure changes receptor composition and localization over measured follow-up.

Show evidence (1 reference)

PMID:28931433 SUPPORT DIRECT REVIEW SYNTHESIS Model Organism

"After chronic intermittent ethanol (CIE) treatment the same changes are observed but they become persistent after 30 or more doses, lasting for at least 120 days in the rat, and probably for life."

The reviewed rat regimen documents persistence for at least 120 days; the source's additional lifetime speculation is not treated as an observed endpoint.

Show evidence (1 reference)

PMID:28931433 SUPPORT DIRECT REVIEW SYNTHESIS Model Organism

"After chronic intermittent ethanol (CIE) treatment the same changes are observed but they become persistent after 30 or more doses, lasting for at least 120 days in the rat, and probably for life."

The reviewed rat regimen documents persistence for at least 120 days; the source's additional lifetime speculation is not treated as an observed endpoint.

Show evidence (1 reference)

PMID:28931433 SUPPORT DIRECT REVIEW SYNTHESIS Model Organism

"After chronic intermittent ethanol (CIE) treatment the same changes are observed but they become persistent after 30 or more doses, lasting for at least 120 days in the rat, and probably for life."

The reviewed rat regimen documents persistence for at least 120 days; the source's additional lifetime speculation is not treated as an observed endpoint.

Regional CRF pharmacology in DID and intermittent-access mice

VTA CRF6–33 and astressin 2-B reduced DID intake under selected doses; co-infusion supported additive modulation. CRF6–33 had no significant VTA effect in IAA and no CeA effect in either paradigm. Only IAA increased withdrawal handling-induced convulsions. Water intake and weight were assessed, but comprehensive locomotor or alternative-reward specificity was not established.

Species

Mus musculus

Genotype

Male C57BL/6J mice; separate nondependent DID and four-week IAA cohorts

Pathograph links

VTA CRF2-Associated Drinking Modulation measures fidelity: moderate VTA antagonism reduces intake in the tested DID context.

Limitations: Does not establish dependent negative-reinforcement signaling, central-amygdala benefit, a dopamine intermediary or clinical efficacy.

Readouts

DID ethanol intake

Direction: DECREASED

Interpretation: VTA antagonism reduces intake in the tested DID context.

Show evidence (1 reference)

PMID:26247973 SUPPORT DIRECT PRIMARY RESULT Model Organism

"Here, we present the first evidence that the CRFBP antagonist CRF6–33 and the CRF2 antagonist A2B microinjected into the VTA dose-dependently attenuated alcohol consumption in mice exposed to a binge drinking procedure (DID)."

Intra-VTA CRF2 antagonism reduced intake in the DID experiment; the separate CeA null result supports the regional limitation only.

Show evidence (1 reference)

PMID:26247973 SUPPORT DIRECT PRIMARY RESULT Model Organism

Intra-VTA CRF2 antagonism reduced intake in the DID experiment; the separate CeA null result supports the regional limitation only.

Show evidence (2 references)

PMID:26247973 SUPPORT DIRECT PRIMARY RESULT Model Organism

"These results indicate that VTA CRF2 receptors modulate ethanol binge drinking, and CRFBP may add to the anti-alcohol effect of A2B."

Local VTA pharmacology modifies drinking in the nondependent binge paradigm; the result does not establish the same effect in dependence or in all brain regions.

PMID:26247973 SUPPORT DIRECT PRIMARY RESULT Model Organism

"Intra-CeA CRF6–33 neither affected ethanol binge drinking nor escalated ethanol consumption in mice given IAA."

The central-amygdala null result limits regional generalization of the VTA CRF-binding-protein finding.

Chronic ethanol exposure in constitutive Tlr4-knockout mice

Starting at 7 weeks, mice received 10% ethanol in drinking water for 5 months; reported intake and blood alcohol concentrations were similar between genotypes. Cortical inflammatory proteins/transcripts, glial immunoreactivity and cleaved caspase-3 were measured. Knockout attenuated outcomes, with residual GFAP response. Neither alcohol seeking, cognition nor neuron-specific death was directly tested.

Species

Mus musculus

Genotype

Female C57BL/6 wild-type versus constitutive Tlr4-knockout

Pathograph links

Cortical Inflammatory Mediator Induction measures fidelity: moderate Chronic ethanol increases the measured endpoint in wild-type mice, with attenuation in Tlr4-deficient mice.

Limitations: Whole-body deletion and whole-tissue measurements do not establish cell autonomy or a human AUD phenotype.

Readouts

Cortical cytokine protein or transcript abundance

Direction: INCREASED

Interpretation: Chronic ethanol increases the measured endpoint in wild-type mice, with attenuation in Tlr4-deficient mice.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6634595/ SUPPORT DIRECT PRIMARY RESULT Model Organism

The wild-type versus knockout comparison shows TLR4-dependent cortical cytokine changes in mice; homogenate measurements do not identify every producing cell.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6634595/ SUPPORT DIRECT PRIMARY RESULT Model Organism

The wild-type versus knockout comparison shows TLR4-dependent cortical cytokine changes in mice; homogenate measurements do not identify every producing cell.

Cortical Glial Reactivity measures fidelity: moderate Chronic ethanol increases the measured endpoint in wild-type mice, with attenuation in Tlr4-deficient mice.

Limitations: Whole-body deletion and whole-tissue measurements do not establish cell autonomy or a human AUD phenotype.

Readouts

Cortical GFAP and CD11b immunoreactivity

Direction: INCREASED

Interpretation: Chronic ethanol increases the measured endpoint in wild-type mice, with attenuation in Tlr4-deficient mice.

Show evidence (2 references)

url:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6634595/ SUPPORT DIRECT PRIMARY RESULT Model Organism

The GFAP increase is attenuated but persists in knockout mice, supporting a partial TLR4 contribution rather than complete prevention of glial reactivity.

+ 1 more reference

Show evidence (2 references)

url:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6634595/ SUPPORT DIRECT PRIMARY RESULT Model Organism

The GFAP increase is attenuated but persists in knockout mice, supporting a partial TLR4 contribution rather than complete prevention of glial reactivity.

+ 1 more reference

Cortical Caspase-3 Activation measures fidelity: moderate Chronic ethanol increases the measured endpoint in wild-type mice, with attenuation in Tlr4-deficient mice.

Limitations: Whole-body deletion and whole-tissue measurements do not establish cell autonomy or a human AUD phenotype.

Readouts

Cortical cleaved caspase-3

Direction: INCREASED

Interpretation: Chronic ethanol increases the measured endpoint in wild-type mice, with attenuation in Tlr4-deficient mice.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6634595/ SUPPORT DIRECT PRIMARY RESULT Model Organism

The passage compares ethanol-exposed wild-type and Tlr4-knockout cortices, supporting genotype-dependent caspase-3 activation without identifying a dying cell type.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6634595/ SUPPORT DIRECT PRIMARY RESULT Model Organism

The passage compares ethanol-exposed wild-type and Tlr4-knockout cortices, supporting genotype-dependent caspase-3 activation without identifying a dying cell type.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6634595/ SUPPORT DIRECT PRIMARY RESULT Model Organism

"Our findings support the critical role of the TLR4 response in the neuroinflammation, brain injury, and possibly in the neurodegeneration induced by chronic ethanol intake."

The mouse study supports receptor dependence of measured inflammatory and injury markers; neurodegeneration was proposed rather than a measured clinical outcome.

{ }

Source YAML

click to show

name: Alcohol Use Disorder
creation_date: '2026-08-09T14:40:00Z'
category: Psychiatric
description: Alcohol use disorder (AUD) is a heterogeneous pattern of alcohol use causing clinically significant impairment or distress. DSM-5-TR diagnosis requires at least two of eleven criteria within a year and grades severity by criterion count; tolerance and withdrawal are possible criteria rather than requirements. Genetic liability, environment, reinforcement, learning and exposure-related adaptations contribute probabilistically. The three-stage addiction framework organizes relevant mechanisms but is not a necessary linear course for every patient. Remission, recurrence and sustained recovery all occur.
disease_term:
  preferred_term: alcohol use disorder
  term:
    id: MONDO:0007079
    label: alcohol dependence
synonyms:
- Alcoholism
- Alcohol dependence
- Alcohol addiction
- Problematic alcohol use
parents:
- Substance Use Disorder
- Mental Health Disorder
notes: The entry uses the DSM-5-TR clinical construct while its MONDO binding is the narrower alcohol dependence term (MONDO:0007079); ICD-11 retains separate harmful-pattern and dependence diagnoses. Studies of dependence, heavy drinking, alcohol preference and problematic alcohol use are identified at their actual scope. Exposure-related organ complications are represented without implying they are diagnostic or inevitable, and detailed liver mechanisms are curated separately in Alcoholic_Liver_Disease. The ASAM, AAFP, StatPearls and two PMC URL references retain their generated titles; the underlying publications are PMID:32511109, PMID:34523874, PMID:28613774, PMID:37934220 and PMID:20554880, respectively. Primary human, animal and cell observations are distinguished from review frameworks and mechanistic hypotheses. Hazardous use is retained as a diagnostic behavior without a specific causal edge; depression is retained as a potentially bidirectional associated finding rather than assigned an unsupported alcohol-to-depression mechanism.
prevalence:
- population: US adults (NESARC-III, 2012-2013, DSM-5 criteria), 12-month
  measure_type: PERIOD_PREVALENCE
  prevalence_class: ABOVE_1_IN_1000
  rate_per_100000: 13900.0
  notes: 12-month prevalence of DSM-5 AUD in a nationally representative US adult sample (N = 36,309). These are historical weighted estimates from 36,309 US civilian noninstitutionalized adults interviewed in 2012–2013 (60.1% response), not current global prevalence.
  evidence:
  - reference: PMID:26039070
    reference_title: 'Epidemiology of DSM-5 Alcohol Use Disorder: Results From the National Epidemiologic Survey on Alcohol and Related Conditions III.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Twelve-month and lifetime prevalences of AUD were 13.9% and 29.1%, respectively.
    explanation: NESARC-III provides the reference US 12-month prevalence estimate for DSM-5 AUD.
    directness: DIRECT
    quote_role: PRIMARY_RESULT
- population: US adults (NESARC-III, 2012-2013, DSM-5 criteria), lifetime
  measure_type: LIFETIME_PREVALENCE
  prevalence_class: ABOVE_1_IN_1000
  rate_per_100000: 29100.0
  notes: Lifetime prevalence of DSM-5 AUD; prevalence was highest in men (36.0% lifetime) and in younger and never-married adults. These are historical weighted estimates from 36,309 US civilian noninstitutionalized adults interviewed in 2012–2013 (60.1% response), not current global prevalence.
  evidence:
  - reference: PMID:26039070
    reference_title: 'Epidemiology of DSM-5 Alcohol Use Disorder: Results From the National Epidemiologic Survey on Alcohol and Related Conditions III.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Twelve-month and lifetime prevalences of AUD were 13.9% and 29.1%, respectively.
    explanation: The same NESARC-III survey reports the lifetime figure alongside the 12-month figure.
    directness: DIRECT
    quote_role: PRIMARY_RESULT
  - reference: PMID:26039070
    reference_title: 'Epidemiology of DSM-5 Alcohol Use Disorder: Results From the National Epidemiologic Survey on Alcohol and Related Conditions III.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Prevalence was generally highest for men (17.6% and 36.0%, respectively), white (14.0% and 32.6%, respectively) and Native American (19.2% and 43.4%, respectively), respondents, and younger (26.7% and 37.0%, respectively) and previously married (11.4% and 27.1%, respectively) or never married (25.0% and 35.5%, respectively) adults.
    explanation: Documents the demographic stratification underlying the pooled lifetime estimate.
    directness: DIRECT
    quote_role: PRIMARY_RESULT
clinical_burden:
  burden_level: HIGH
  rationale: AUD can cause substantial functional impairment and exposure-related medical complications. The cited 2016 GBD figures concern all alcohol consumption, not mortality among a cohort with diagnosed AUD. In NESARC-III, 19.8% of adults with lifetime AUD reported ever receiving treatment or help, broadly defined to include mutual-help services; this is a historical survey estimate.
  evidence:
  - reference: PMID:30146330
    reference_title: 'Alcohol use and burden for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Globally, alcohol use was the seventh leading risk factor for both deaths and DALYs in 2016
    explanation: Models population burden attributable to alcohol exposure in 2016; it does not estimate an AUD-specific case-fatality rate.
    directness: DIRECT
    quote_role: PRIMARY_RESULT
  - reference: PMID:30146330
    reference_title: 'Alcohol use and burden for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Among the population aged 15-49 years, alcohol use was the leading risk factor globally in 2016, with 3·8% (95% UI 3·2-4·3) of female deaths and 12·2% (10·8-13·6) of male deaths attributable to alcohol use.
    explanation: Models population burden attributable to alcohol exposure in 2016; it does not estimate an AUD-specific case-fatality rate.
    directness: DIRECT
    quote_role: PRIMARY_RESULT
  - reference: PMID:26039070
    reference_title: 'Epidemiology of DSM-5 Alcohol Use Disorder: Results From the National Epidemiologic Survey on Alcohol and Related Conditions III.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Only 19.8% of respondents with lifetime AUD were ever treated.
    explanation: Quantifies the treatment gap that compounds the burden of the disorder.
    directness: DIRECT
    quote_role: PRIMARY_RESULT
  - reference: PMID:26039070
    reference_title: 'Epidemiology of DSM-5 Alcohol Use Disorder: Results From the National Epidemiologic Survey on Alcohol and Related Conditions III.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: All measures of current disability were strongly related to 12-month AUD, increasing with AUD severity.
    explanation: The survey directly associates diagnosed AUD severity with functional disability, complementing the alcohol-exposure GBD estimates.
inheritance:
- name: Polygenic (multifactorial) liability
  inheritance_term:
    preferred_term: polygenic inheritance
    term:
      id: HP:0010982
      label: Polygenic inheritance
  description: Liability is polygenic and depends on environmental exposure. Protective ADH1B and ALDH2 alleles affect ethanol metabolism; their effects do not make this a Mendelian disorder. Twin and adoption meta-analysis estimates roughly 50% heritability in the studied populations, with a modest shared-environment component. Heritability is a population variance estimate, not the fraction of an individual case caused by genes.
  evidence:
  - reference: PMID:25171596
    reference_title: 'The heritability of alcohol use disorders: a meta-analysis of twin and adoption studies.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: AUD is approximately 50% heritable.
    explanation: Meta-analysis of 12 twin and 5 adoption studies gives the reference heritability estimate for AUD liability.
    directness: DIRECT
    quote_role: PRIMARY_RESULT
  - reference: PMID:25171596
    reference_title: 'The heritability of alcohol use disorders: a meta-analysis of twin and adoption studies.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: We also found evidence for modest shared environmental effects suggesting that environmental factors also contribute to the familial aggregation of AUDs.
    explanation: 'Supports the multifactorial framing: familial aggregation is not purely genetic.'
    directness: DIRECT
    quote_role: PRIMARY_RESULT
  - reference: PMID:38062264
    reference_title: Multi-ancestry study of the genetics of problematic alcohol use in over 1 million individuals.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: We observed a high degree of cross-ancestral similarity in the genetic architecture of PAU and identified 110 independent risk variants in within- and cross-ancestry analyses.
    explanation: The largest multi-ancestry GWAS of problematic alcohol use demonstrates the highly polygenic architecture expected under multifactorial inheritance.
    directness: DIRECT
    quote_role: PRIMARY_RESULT
pathophysiology:
- name: Polygenic Liability
  biological_scale: MOLECULAR
  description: Common-variant associations contribute to liability rather than determining disease. The 2023 meta-analysis combines 165,952 AUD or dependence cases, controls and AUDIT problems scores in 1,079,947 participants; it is not a cohort of one million diagnosed cases. The 110 variants are the union of within- and cross-ancestry results, and most data are European ancestry. Specific nonmetabolic variant-to-neural causal routes remain unresolved.
  evidence:
  - reference: PMID:38062264
    reference_title: Multi-ancestry study of the genetics of problematic alcohol use in over 1 million individuals.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: In total, 110 unique variants were associated with PAU in either the within-ancestry or cross-ancestry analyses (Fig. 1b and Supplementary Table 1).
    explanation: The union of within- and cross-ancestry signals supports distributed susceptibility; it does not identify a single necessary mechanism of impaired control.
  - reference: PMID:38062264
    reference_title: Multi-ancestry study of the genetics of problematic alcohol use in over 1 million individuals.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: Despite the high genetic correlation between AUD and AUDIT–P, they are not identical traits, which introduces heterogeneity.
    explanation: The authors explicitly distinguish diagnosed AUD from AUDIT-P, limiting disease-specific interpretation of the combined PAU analysis.
  downstream:
  - target: Impaired Control over Alcohol Use
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Association establishes probabilistic liability; the intervening molecular and behavioral mechanisms are incompletely resolved.
    evidence:
    - reference: PMID:38062264
      reference_title: Multi-ancestry study of the genetics of problematic alcohol use in over 1 million individuals.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: PRIMARY_RESULT
      directness: INDIRECT
      snippet: In total, 110 unique variants were associated with PAU in either the within-ancestry or cross-ancestry analyses (Fig. 1b and Supplementary Table 1).
      explanation: The union of within- and cross-ancestry signals supports distributed susceptibility; it does not identify a single necessary mechanism of impaired control.
    - reference: PMID:38062264
      reference_title: Multi-ancestry study of the genetics of problematic alcohol use in over 1 million individuals.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: PRIMARY_RESULT
      directness: INDIRECT
      snippet: Despite the high genetic correlation between AUD and AUDIT–P, they are not identical traits, which introduces heterogeneity.
      explanation: The authors explicitly distinguish diagnosed AUD from AUDIT-P, limiting disease-specific interpretation of the combined PAU analysis.
- name: Repeated Ethanol Exposure
  biological_scale: ORGANISM
  description: Repeated alcohol intake supplies the exposure for intoxication, neuroadaptation and medical complications. Dose, timing, host susceptibility and environment influence outcomes; exposure alone does not establish AUD. This exposure node is separate from enzymatic metabolism and from the impaired-control phenotype.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK436003/
    reference_title: 'Alcohol Use Disorder: Screening, Evaluation, and Management - StatPearls - NCBI Bookshelf'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: The fact that not every person who drinks alcohol will necessarily experience a loss of control and progression to addiction indicates that AUD is not solely driven by exposure to alcohol.
    explanation: The clinical synthesis distinguishes alcohol exposure from the additional susceptibility required for impaired control and addiction.
  chemical_entities:
  - preferred_term: ethanol
    term:
      id: CHEBI:16236
      label: ethanol
  triggers:
  - preferred_term: exposure to alcohol consumption
    term:
      id: ECTO:0001082
      label: exposure to alcohol consumption
  downstream:
  - target: Acute GABA-A Signaling Modulation
    causal_link_type: DIRECT
    description: Ethanol acutely modulates inhibitory GABA-A signaling in neuronal preparations. This pharmacological effect is distinct from chronic receptor redistribution and does not imply identical effects at every receptor subtype.
    evidence:
    - reference: PMID:25954150
      reference_title: Targeting glutamate uptake to treat alcohol use disorders.
      supports: SUPPORT
      evidence_source: IN_VITRO
      quote_role: REVIEW_SYNTHESIS
      directness: DIRECT
      snippet: the acute actions of ethanol are to inhibit glutamatergic activity and potentiate GABAergic activity.
      explanation: The review describes acute enhancement of inhibitory GABA signaling; receptor subtype, cellular compartment and experimental preparation determine the response.
  - target: Acute NMDA Receptor Inhibition
    causal_link_type: DIRECT
    description: Ethanol inhibits NMDA-receptor-mediated calcium influx in the reviewed neuronal experiments; the acute receptor action is separate from chronic glutamate adaptation.
    evidence:
    - reference: PMID:25954150
      reference_title: Targeting glutamate uptake to treat alcohol use disorders.
      supports: SUPPORT
      evidence_source: IN_VITRO
      quote_role: REVIEW_SYNTHESIS
      directness: DIRECT
      snippet: Intracellularly, ethanol inhibits, non-competitively, the NMDAR-mediated calcium influx in the cortex, Acb, amygdala, hippocampus, and VTA (Nie et al., 1994; Wirkner et al., 2000; Roberto et al., 2004; Stobbs et al., 2004; Zhu et al., 2007).
      explanation: The reviewed neuronal experiments identify inhibition of NMDA-mediated calcium influx, supporting the acute receptor effect rather than chronic glutamate depletion.
  - target: Alcohol-Evoked Endogenous Opioid Signaling
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Drinking produces an opioid-sensitive PET ligand-displacement response in human accumbens and orbitofrontal cortex; the intervening release machinery is not resolved by this experiment.
    evidence:
    - reference: PMID:22238334
      reference_title: Alcohol consumption induces endogenous opioid release in the human orbitofrontal cortex and nucleus accumbens.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: PRIMARY_RESULT
      directness: INDIRECT
      snippet: Drinking alcohol induced opioid release in the nucleus accumbens and orbitofrontal cortex, areas of the brain implicated in reward valuation.
      explanation: Human ligand-displacement PET supports alcohol-evoked endogenous opioid release in accumbens and orbitofrontal cortex, without resolving a peptide or downstream dopamine relay.
  - target: Mesolimbic Dopamine Reinforcement
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Alcohol engages mesolimbic reinforcement circuitry through several neuronal and receptor routes; the dopamine synthesis does not establish one exclusive upstream relay.
    evidence:
    - reference: PMID:25307573
      reference_title: Neurochemical mechanisms of alcohol withdrawal.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      quote_role: REVIEW_SYNTHESIS
      directness: INDIRECT
      snippet: Dopamine, through its actions via mesolimbic and mesocortical pathways, has long been viewed as playing a central role in mediating alcohol reward (Gonzales et al., 2004; Spanagel, 2009).
      explanation: The experimental synthesis assigns mesolimbic and mesocortical dopamine a reinforcement role; extension to loss of control requires additional circuit and behavioral steps.
  - target: GABA-A Receptor Redistribution
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Single and repeated ethanol regimens alter receptor trafficking and surface composition in rodents. The exact signaling route and persistence depend on the regimen and neuronal compartment.
    evidence:
    - reference: PMID:28931433
      reference_title: Role of GABA(A) receptors in alcohol use disorders suggested by chronic intermittent ethanol (CIE) rodent model.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      quote_role: REVIEW_SYNTHESIS
      directness: INDIRECT
      snippet: One-dose ethanol exposure induces transient plastic changes in GABAA receptor subunit levels, composition, and regional and subcellular localization.
      explanation: Rodent exposure experiments summarized here show receptor redistribution after one dose, supporting plasticity without implying permanent or uniform receptor loss.
    - reference: PMID:28931433
      reference_title: Role of GABA(A) receptors in alcohol use disorders suggested by chronic intermittent ethanol (CIE) rodent model.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      quote_role: REVIEW_SYNTHESIS
      directness: INDIRECT
      snippet: One-dose ethanol exposure induces transient plastic changes in GABA A receptor subunit levels, composition, and regional and subcellular localization. ... After chronic intermittent ethanol (CIE) treatment the same changes are observed but they become persistent after 30 or more doses, lasting for at least 120 days in the rat
      explanation: The review distinguishes persistent receptor remodeling after repeated exposure from the reversible single-dose changes; this is a rat result, not a human threshold.
  - target: Altered Glutamate Homeostasis
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Exposure and withdrawal are associated with altered glutamate regulation. Human regional measurements and repeated-vapor rodent experiments do not imply a single uniform trajectory.
    evidence:
    - reference: PMID:25307573
      reference_title: Neurochemical mechanisms of alcohol withdrawal.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      directness: INDIRECT
      snippet: Some studies have reported reduced cortical glutamate levels associated with dependence and acute withdrawal (Mon et al., 2012; Ende et al., 2013), while other studies have shown elevated glutamate activity in anterior cingulate and striatum in alcohol-dependent subjects (Hermann et al., 2012; Bauer et al., 2013).  # codespell:ignore-line
      explanation: Human measurements differ by brain region and withdrawal timing, supporting altered glutamate regulation rather than a universal increase or decrease.
    - reference: PMID:25307573
      reference_title: Neurochemical mechanisms of alcohol withdrawal.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      quote_role: REVIEW_SYNTHESIS
      directness: INDIRECT
      snippet: Repeated cycles of chronic intermittent exposure to alcohol vapor were shown to increase basal levels of glutamate in the nucleus accumbens (NAc) at time points beyond acute withdrawal.
      explanation: Repeated vapor exposure increases accumbal glutamate in the reviewed rodent experiments beyond the acute withdrawal period.
  - target: CRF-Associated Stress Signaling
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: The withdrawal framework recruits extended-amygdala CRF systems after repeated drug exposure; complete mediation of the human stress response remains unresolved.
    evidence:
    - reference: PMID:27475769
      reference_title: 'Neurobiology of addiction: a neurocircuitry analysis.'
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      quote_role: REVIEW_SYNTHESIS
      directness: INDIRECT
      snippet: The increases in negative emotional states and dysphoric and stress-like responses in the withdrawal/negative affect stage involve decreases in the function of the dopamine component of the reward system and recruitment of brain stress neurotransmitters, such as corticotropin-releasing factor and dynorphin, in the neurocircuitry of the extended amygdala.
      explanation: The review places CRF, dynorphin and reduced reward signaling within the extended-amygdala withdrawal framework; their contributions are not an obligatory sequence in every patient.
  - target: Dynorphin–Kappa-Opioid Signaling
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Dependent-animal and neurocircuitry evidence implicates dynorphin signaling in withdrawal-related stress, without establishing its recruitment as universal in AUD.
    evidence:
    - reference: PMID:27475769
      reference_title: 'Neurobiology of addiction: a neurocircuitry analysis.'
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      quote_role: REVIEW_SYNTHESIS
      directness: INDIRECT
      snippet: The increases in negative emotional states and dysphoric and stress-like responses in the withdrawal/negative affect stage involve decreases in the function of the dopamine component of the reward system and recruitment of brain stress neurotransmitters, such as corticotropin-releasing factor and dynorphin, in the neurocircuitry of the extended amygdala.
      explanation: The review places CRF, dynorphin and reduced reward signaling within the extended-amygdala withdrawal framework; their contributions are not an obligatory sequence in every patient.
  - target: Withdrawal-Associated Reward Deficit
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Withdrawal from chronic exposure lowers dopamine activity in reviewed rodent experiments; the transition to a human subjective reward deficit requires additional interpretation.
    evidence:
    - reference: PMID:25307573
      reference_title: Neurochemical mechanisms of alcohol withdrawal.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      quote_role: REVIEW_SYNTHESIS
      directness: INDIRECT
      snippet: By contrast, withdrawal from chronic alcohol exposure has been reported to result in decreased VTA dopamine neuronal activity (Diana et al., 1996; Bailey et al., 2001), and reduced basal levels of dopamine in ventral and dorsal subregions of the striatum, possibly due to enhanced dopamine uptake (Weiss et al., 1996; Budygin et al., 2007; Barak et al., 2011).
      explanation: The reviewed rodent measurements link withdrawal to reduced VTA firing and striatal dopamine, supporting a reward-deficit model with incompletely resolved behavioral mediation.
  - target: Habitual Alcohol Seeking
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Repeated seeking and reinforcement permit habitual control to develop in the rat paradigm; the predictor relationship does not prove that exposure alone determines later compulsivity.
    evidence:
    - reference: PMID:33955649
      reference_title: Individual differences in the engagement of habitual control over alcohol seeking predict the development of compulsive alcohol seeking and drinking.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      quote_role: PRIMARY_RESULT
      directness: INDIRECT
      snippet: After seeking behaviour was well established, subjects that had developed greater resistance to outcome devaluation (were more habitual) were more likely to show punishment-resistant (compulsive) alcohol seeking.
      explanation: Outcome-devaluation resistance predicted punishment-resistant seeking in selected rats; the association does not prove that habitual control alone causes human compulsive drinking.
  - target: Thiamine Deficiency
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: Heavy drinking can reduce nutritional intake and impair thiamine availability. These known nutritional intermediates are not expanded into separate nodes here.
    evidence:
    - reference: url:https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf
      reference_title: https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      directness: INDIRECT
      snippet: Patients consuming large volumes of alcohol are at an increased risk of developing Wernicke encephalopathy due to inadequate nutrition as well as biological interactions between cellular functioning and alcohol.
      explanation: The guideline connects heavy drinking with nutritional and biological risks for thiamine-related disease, supporting a conditional deficiency pathway.
  - target: TLR4-Dependent Inflammatory Signaling
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Chronic ethanol exposure produces TLR4-dependent inflammatory responses in mouse and astrocyte models; the experiments do not establish ethanol as a direct TLR4 ligand.
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6634595/
      reference_title: Pivotal Role of TLR4 Receptors in Alcohol-Induced Neuroinflammation and Brain Damage - PMC
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      quote_role: PRIMARY_RESULT
      directness: INDIRECT
      snippet: Our findings support the critical role of the TLR4 response in the neuroinflammation, brain injury, and possibly in the neurodegeneration induced by chronic ethanol intake.
      explanation: The mouse study supports receptor dependence of measured inflammatory and injury markers; neurodegeneration was proposed rather than a measured clinical outcome.
  - target: Alcohol Cue Responsivity
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Repeated pairing and learning offer an interpretation of cue-associated responses; the imaging synthesis alone does not prove longitudinal sensitization.
    evidence:
    - reference: PMID:22574861
      reference_title: 'Functional neuroimaging studies of alcohol cue reactivity: a quantitative meta-analysis and systematic review.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: PRIMARY_RESULT
      directness: INDIRECT
      snippet: Among cases, alcohol cues elicited robust activation of limbic and prefrontal regions, including ventral striatum, anterior cingulate and ventromedial prefrontal cortex.
      explanation: The human imaging meta-analysis localizes within-case cue responses to ventral striatal and prefrontal circuitry, without equating activation with a causal deficit.
    - reference: PMID:22574861
      reference_title: 'Functional neuroimaging studies of alcohol cue reactivity: a quantitative meta-analysis and systematic review.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: PRIMARY_RESULT
      directness: INDIRECT
      snippet: Cue-elicited activation of ventral striatum was most frequently correlated with behavioral measures and most frequently reduced by treatment, but these results were often derived from region-of-interest analyses that interrogated only limbic regions.
      explanation: Behavioral correlations and treatment-related changes support cue responsivity as an associative mechanism candidate, while region-of-interest selection limits generalization.
  - target: Impaired Executive Control
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: The framework describes an exposure-associated contribution to executive dysfunction; pre-existing liability and other factors cannot be excluded by cross-sectional imaging.
    evidence:
    - reference: PMID:27475769
      reference_title: 'Neurobiology of addiction: a neurocircuitry analysis.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      directness: INDIRECT
      snippet: The craving and deficits in executive function in the so-called preoccupation/anticipation stage involve the dysregulation of key afferent projections from the prefrontal cortex and insula, including glutamate, to the basal ganglia and extended amygdala.
      explanation: The synthesis links executive-control problems to prefrontal projections, providing circuit context without proving a single lesion causes impaired control.
  - target: Withdrawal-Associated Autonomic Activation
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Withdrawal after sustained heavy exposure can activate autonomic responses in physiologically dependent individuals.
    evidence:
    - reference: PMID:25307573
      reference_title: Neurochemical mechanisms of alcohol withdrawal.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      directness: INDIRECT
      snippet: Clinical features of alcohol withdrawal include signs of central nervous system hyperexcitability, heightened autonomic nervous system activation, and a constellation of symptoms contributing to psychologic discomfort and negative affect.
      explanation: The human withdrawal syndrome includes both central hyperexcitability and autonomic activation; this clinical description alone does not identify a particular receptor mediator.
  - target: Hepatic Steatosis
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: Alcohol metabolism and disturbed lipid handling connect sustained exposure to hepatic fat accumulation; those known liver-specific intermediates are curated in Alcoholic_Liver_Disease.
    evidence:
    - reference: PMID:31536239
      reference_title: Alcohol-Associated Liver Disease.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      directness: INDIRECT
      snippet: Alcoholic Fatty Liver or Steatosis - At this stage, fat accumulates in the liver parenchyma.
      explanation: The clinical review describes hepatic fat accumulation as alcohol-associated steatosis; the detailed metabolic pathway is curated separately.
  - target: Cirrhosis
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: Alcohol-associated liver disease can progress from steatosis through hepatitis to cirrhosis in a subset of patients; the liver-specific intermediate processes are not expanded in this AUD graph.
    evidence:
    - reference: PMID:31536239
      reference_title: Alcohol-Associated Liver Disease.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      directness: DIRECT
      snippet: The alcoholic liver disease covers a spectrum of disorders beginning from the fatty liver, progressing at times to alcoholic hepatitis and culminating in alcoholic cirrhosis
      explanation: The clinical synthesis describes progression to cirrhosis within alcohol-associated liver disease; progression is conditional, not inevitable.
  - target: Dilated Cardiomyopathy
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: Chronic alcohol toxicity can produce myocardial injury and adverse remodeling before ventricular dilation; the organ-specific intermediates are not expanded here.
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK436003/
      reference_title: 'Alcohol Use Disorder: Screening, Evaluation, and Management - StatPearls - NCBI Bookshelf'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      directness: INDIRECT
      snippet: Chronic alcohol use can accelerate coronary artery disease and cause dilated cardiomyopathy.
      explanation: The source recognizes dilated cardiomyopathy as a possible consequence of chronic alcohol use, rather than a defining AUD phenotype.
  - target: Pancreatitis
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: Alcohol-related pancreatic injury and inflammation can lead to acute or chronic pancreatitis through organ-specific pathways omitted from this graph.
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK436003/
      reference_title: 'Alcohol Use Disorder: Screening, Evaluation, and Management - StatPearls - NCBI Bookshelf'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      directness: INDIRECT
      snippet: In addition to liver disease, alcohol can cause both acute and chronic pancreatitis as well as exocrine insufficiency.
      explanation: The clinical synthesis supports both acute and chronic pancreatitis as alcohol-related complications; it does not assign a population frequency.
  - target: Peripheral Neuropathy
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: Direct neurotoxicity and nutritional injury are recognized routes from chronic alcohol use to peripheral neuropathy; the nerve-specific intermediates are not expanded here.
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK436003/
      reference_title: 'Alcohol Use Disorder: Screening, Evaluation, and Management - StatPearls - NCBI Bookshelf'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      directness: INDIRECT
      snippet: Alcohol can also cause peripheral neuropathy of small fibers
      explanation: The quoted clinical observation supports alcohol-associated small-fiber neuropathy, without implying every neuropathy in an AUD patient has that cause.
  - target: Acetaldehyde Accumulation
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: Ethanol is converted by ADH enzymes to acetaldehyde; accumulation depends on the balance between this known formation step and ALDH-mediated clearance.
    evidence:
    - reference: PMID:17718394
      reference_title: 'The genetics of alcohol metabolism: role of alcohol dehydrogenase and aldehyde dehydrogenase variants.'
      supports: SUPPORT
      evidence_source: IN_VITRO
      quote_role: REVIEW_SYNTHESIS
      directness: INDIRECT
      snippet: A variant of the ALDH2 gene encodes an essentially inactive ALDH enzyme, resulting in acetaldehyde accumulation
      explanation: Reduced ALDH2 function decreases aldehyde clearance and favors acetaldehyde accumulation during drinking; its association with lower dependence risk is protective.
- name: Increased ADH1B-Mediated Ethanol Oxidation
  biological_scale: MOLECULAR
  description: In carriers of protective high-activity ADH1B alleles, faster enzyme-catalyzed conversion of ethanol to acetaldehyde is proposed to contribute to aversive effects and reduced dependence risk. Purified-enzyme kinetics do not imply the same fold change in whole-body clearance or a universal flushing response.
  evidence:
  - reference: PMID:17718394
    reference_title: 'The genetics of alcohol metabolism: role of alcohol dehydrogenase and aldehyde dehydrogenase variants.'
    supports: SUPPORT
    evidence_source: IN_VITRO
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: certain ADH1B and ADH1C alleles encode particularly active ADH enzymes, resulting in more rapid conversion of alcohol (i.e., ethanol) to acetaldehyde
    explanation: High-activity ADH alleles accelerate the enzymatic ethanol-to-acetaldehyde step; net systemic accumulation still depends on concurrent aldehyde clearance.
  genes:
  - preferred_term: ADH1B
    term:
      id: hgnc:250
      label: ADH1B
  molecular_functions:
  - preferred_term: alcohol dehydrogenase (NAD+) activity
    term:
      id: GO:0004022
      label: alcohol dehydrogenase (NAD+) activity
    modifier: INCREASED
  downstream:
  - target: Acetaldehyde Accumulation
    causal_link_type: DIRECT
    description: Faster formation may increase local or transient acetaldehyde exposure; systemic accumulation and symptom severity also depend on clearance.
    evidence:
    - reference: PMID:17718394
      reference_title: 'The genetics of alcohol metabolism: role of alcohol dehydrogenase and aldehyde dehydrogenase variants.'
      supports: SUPPORT
      evidence_source: IN_VITRO
      quote_role: REVIEW_SYNTHESIS
      directness: DIRECT
      snippet: certain ADH1B and ADH1C alleles encode particularly active ADH enzymes, resulting in more rapid conversion of alcohol (i.e., ethanol) to acetaldehyde
      explanation: High-activity ADH alleles accelerate the enzymatic ethanol-to-acetaldehyde step; net systemic accumulation still depends on concurrent aldehyde clearance.
  locations:
  - preferred_term: liver
    term:
      id: UBERON:0002107
      label: liver
  biological_processes:
  - preferred_term: alcohol metabolic process
    term:
      id: GO:0006066
      label: alcohol metabolic process
- name: Reduced ALDH2-Mediated Acetaldehyde Clearance
  biological_scale: MOLECULAR
  description: The ALDH2*2 variant markedly reduces conversion of acetaldehyde to acetate. Under alcohol exposure this favors acetaldehyde accumulation; the allele is protective against dependence rather than a monogenic cause of AUD.
  evidence:
  - reference: PMID:17718394
    reference_title: 'The genetics of alcohol metabolism: role of alcohol dehydrogenase and aldehyde dehydrogenase variants.'
    supports: SUPPORT
    evidence_source: IN_VITRO
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: A variant of the ALDH2 gene encodes an essentially inactive ALDH enzyme, resulting in acetaldehyde accumulation
    explanation: Reduced ALDH2 function decreases aldehyde clearance and favors acetaldehyde accumulation during drinking; its association with lower dependence risk is protective.
  genes:
  - preferred_term: ALDH2
    term:
      id: hgnc:404
      label: ALDH2
  molecular_functions:
  - preferred_term: aldehyde dehydrogenase (NAD+) activity
    term:
      id: GO:0004029
      label: aldehyde dehydrogenase (NAD+) activity
    modifier: DECREASED
  downstream:
  - target: Acetaldehyde Accumulation
    causal_link_type: DIRECT
    description: Reduced aldehyde oxidation impairs acetaldehyde clearance during alcohol exposure.
    evidence:
    - reference: PMID:17718394
      reference_title: 'The genetics of alcohol metabolism: role of alcohol dehydrogenase and aldehyde dehydrogenase variants.'
      supports: SUPPORT
      evidence_source: IN_VITRO
      quote_role: REVIEW_SYNTHESIS
      directness: DIRECT
      snippet: A variant of the ALDH2 gene encodes an essentially inactive ALDH enzyme, resulting in acetaldehyde accumulation
      explanation: Reduced ALDH2 function decreases aldehyde clearance and favors acetaldehyde accumulation during drinking; its association with lower dependence risk is protective.
  locations:
  - preferred_term: liver
    term:
      id: UBERON:0002107
      label: liver
- name: Acetaldehyde Accumulation
  biological_scale: MOLECULAR
  description: Reduced clearance, or an imbalance between formation and clearance, increases exposure to the toxic ethanol metabolite acetaldehyde. This conditional metabolic branch is especially well supported for reduced ALDH2 activity.
  evidence:
  - reference: PMID:17718394
    reference_title: 'The genetics of alcohol metabolism: role of alcohol dehydrogenase and aldehyde dehydrogenase variants.'
    supports: SUPPORT
    evidence_source: IN_VITRO
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: A variant of the ALDH2 gene encodes an essentially inactive ALDH enzyme, resulting in acetaldehyde accumulation
    explanation: Reduced ALDH2 function decreases aldehyde clearance and favors acetaldehyde accumulation during drinking; its association with lower dependence risk is protective.
  chemical_entities:
  - preferred_term: acetaldehyde
    term:
      id: CHEBI:15343
      label: acetaldehyde
  downstream:
  - target: Acetaldehyde-Associated Aversion
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: Acetaldehyde accumulation elicits downstream vasoactive and autonomic responses that contribute to aversion; these physiological intermediates are not expanded in this graph.
    evidence:
    - reference: PMID:17718394
      reference_title: 'The genetics of alcohol metabolism: role of alcohol dehydrogenase and aldehyde dehydrogenase variants.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      directness: INDIRECT
      snippet: Acetaldehyde is a toxic substance whose accumulation leads to a highly aversive reaction that includes facial flushing, nausea, and rapid heart beat (i.e., tachycardia).
      explanation: The review explicitly connects accumulated acetaldehyde with flushing, nausea and tachycardia, supporting an aversive modifier rather than a required AUD pathway.
- name: Acetaldehyde-Associated Aversion
  biological_scale: ORGANISM
  description: Flushing, nausea and tachycardia after acetaldehyde accumulation can discourage drinking. This is a protective modifier pathway, not an obligatory step in the progression of AUD. Disulfiram deliberately engages an aversive response by inhibiting aldehyde clearance.
  evidence:
  - reference: PMID:17718394
    reference_title: 'The genetics of alcohol metabolism: role of alcohol dehydrogenase and aldehyde dehydrogenase variants.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Acetaldehyde is a toxic substance whose accumulation leads to a highly aversive reaction that includes facial flushing, nausea, and rapid heart beat (i.e., tachycardia).
    explanation: The review explicitly connects accumulated acetaldehyde with flushing, nausea and tachycardia, supporting an aversive modifier rather than a required AUD pathway.
  downstream:
  - target: Facial Flushing After Alcohol Intake
    causal_link_type: DIRECT
    description: Flushing is one component of the exposure-dependent aversive reaction.
    evidence:
    - reference: PMID:17718394
      reference_title: 'The genetics of alcohol metabolism: role of alcohol dehydrogenase and aldehyde dehydrogenase variants.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      directness: DIRECT
      snippet: Acetaldehyde is a toxic substance whose accumulation leads to a highly aversive reaction that includes facial flushing, nausea, and rapid heart beat (i.e., tachycardia).
      explanation: The review explicitly connects accumulated acetaldehyde with flushing, nausea and tachycardia, supporting an aversive modifier rather than a required AUD pathway.
- name: Acute GABA-A Signaling Modulation
  biological_scale: MOLECULAR
  description: Acute ethanol can enhance GABAergic inhibition through effects that depend on receptor composition, synaptic compartment, dose and brain region. The review evidence includes rodent and cellular work; it does not establish uniform potentiation at every receptor or a single necessary route to human intoxication. GABAergic neurons supply the inhibitory transmitter; receptor-bearing target neurons need not themselves be GABAergic.
  evidence:
  - reference: PMID:25954150
    reference_title: Targeting glutamate uptake to treat alcohol use disorders.
    supports: SUPPORT
    evidence_source: IN_VITRO
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: the acute actions of ethanol are to inhibit glutamatergic activity and potentiate GABAergic activity.
    explanation: The review describes acute enhancement of inhibitory GABA signaling; receptor subtype, cellular compartment and experimental preparation determine the response.
  molecular_functions:
  - preferred_term: GABA-A receptor activity
    term:
      id: GO:0004890
      label: GABA-A receptor activity
  cell_types:
  - preferred_term: GABAergic neuron
    term:
      id: CL:0000617
      label: GABAergic neuron
  biological_processes:
  - preferred_term: synaptic transmission, GABAergic
    term:
      id: GO:0051932
      label: synaptic transmission, GABAergic
    modifier: INCREASED
- name: Acute NMDA Receptor Inhibition
  biological_scale: MOLECULAR
  description: Experimental literature describes inhibition of NMDA-receptor-mediated calcium influx by ethanol. This acute receptor effect is distinct from chronic changes in receptor trafficking, glutamate release and uptake.
  evidence:
  - reference: PMID:25954150
    reference_title: Targeting glutamate uptake to treat alcohol use disorders.
    supports: SUPPORT
    evidence_source: IN_VITRO
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Intracellularly, ethanol inhibits, non-competitively, the NMDAR-mediated calcium influx in the cortex, Acb, amygdala, hippocampus, and VTA (Nie et al., 1994; Wirkner et al., 2000; Roberto et al., 2004; Stobbs et al., 2004; Zhu et al., 2007).
    explanation: The reviewed neuronal experiments identify inhibition of NMDA-mediated calcium influx, supporting the acute receptor effect rather than chronic glutamate depletion.
  molecular_functions:
  - preferred_term: NMDA glutamate receptor activity
    term:
      id: GO:0004972
      label: NMDA glutamate receptor activity
    modifier: DECREASED
  locations:
  - preferred_term: nucleus accumbens
    term:
      id: UBERON:0001882
      label: nucleus accumbens
  - preferred_term: ventral tegmental area
    term:
      id: UBERON:0002691
      label: ventral tegmental area
  - preferred_term: cerebral cortex
    term:
      id: UBERON:0000956
      label: cerebral cortex
  - preferred_term: hippocampal formation
    term:
      id: UBERON:0002421
      label: hippocampal formation
  biological_processes:
  - preferred_term: synaptic transmission, glutamatergic
    term:
      id: GO:0035249
      label: synaptic transmission, glutamatergic
    modifier: DECREASED
- name: Alcohol-Evoked Endogenous Opioid Signaling
  biological_scale: CELLULAR
  description: Human positron-emission tomography after drinking showed displacement of a mu-opioid radioligand in nucleus accumbens and orbitofrontal cortex, interpreted as endogenous opioid release. This is an indirect release measure; the study did not identify the peptide, resolve a dopamine relay, or test naltrexone efficacy.
  evidence:
  - reference: PMID:22238334
    reference_title: Alcohol consumption induces endogenous opioid release in the human orbitofrontal cortex and nucleus accumbens.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: Drinking alcohol induced opioid release in the nucleus accumbens and orbitofrontal cortex, areas of the brain implicated in reward valuation.
    explanation: Human ligand-displacement PET supports alcohol-evoked endogenous opioid release in accumbens and orbitofrontal cortex, without resolving a peptide or downstream dopamine relay.
  downstream:
  - target: Impaired Control over Alcohol Use
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Alcohol-evoked opioid signaling provides a reward-related input that may promote continued use; this PET experiment does not demonstrate the intervening steps to loss of control.
    evidence:
    - reference: PMID:22238334
      reference_title: Alcohol consumption induces endogenous opioid release in the human orbitofrontal cortex and nucleus accumbens.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: PRIMARY_RESULT
      directness: INDIRECT
      snippet: Drinking alcohol induced opioid release in the nucleus accumbens and orbitofrontal cortex, areas of the brain implicated in reward valuation.
      explanation: Human ligand-displacement PET supports alcohol-evoked endogenous opioid release in accumbens and orbitofrontal cortex, without resolving a peptide or downstream dopamine relay.
  locations:
  - preferred_term: nucleus accumbens
    term:
      id: UBERON:0001882
      label: nucleus accumbens
  - preferred_term: orbitofrontal cortex
    term:
      id: UBERON:0004167
      label: orbitofrontal cortex
  biological_processes:
  - preferred_term: G protein-coupled opioid receptor signaling pathway
    term:
      id: GO:0038003
      label: G protein-coupled opioid receptor signaling pathway
- name: Mesolimbic Dopamine Reinforcement
  conforms_to: "addiction_cycle#Acute Mesolimbic Dopamine Reinforcement"
  biological_scale: CELLULAR
  description: Mesolimbic dopamine signaling contributes to alcohol reinforcement in the reviewed experimental framework. Dopamine is one contributor among several; the cited human opioid PET result alone does not prove an opioid-to-dopamine causal sequence.
  evidence:
  - reference: PMID:25307573
    reference_title: Neurochemical mechanisms of alcohol withdrawal.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Dopamine, through its actions via mesolimbic and mesocortical pathways, has long been viewed as playing a central role in mediating alcohol reward (Gonzales et al., 2004; Spanagel, 2009).
    explanation: The experimental synthesis assigns mesolimbic and mesocortical dopamine a reinforcement role; extension to loss of control requires additional circuit and behavioral steps.
  cell_types:
  - preferred_term: dopaminergic neuron
    term:
      id: CL:0000700
      label: dopaminergic neuron
  downstream:
  - target: Impaired Control over Alcohol Use
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Dopamine-dependent reinforcement can strengthen alcohol-directed behavior, while the transition to impaired control involves additional learning and executive processes.
    evidence:
    - reference: PMID:25307573
      reference_title: Neurochemical mechanisms of alcohol withdrawal.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      quote_role: REVIEW_SYNTHESIS
      directness: INDIRECT
      snippet: Dopamine, through its actions via mesolimbic and mesocortical pathways, has long been viewed as playing a central role in mediating alcohol reward (Gonzales et al., 2004; Spanagel, 2009).
      explanation: The experimental synthesis assigns mesolimbic and mesocortical dopamine a reinforcement role; extension to loss of control requires additional circuit and behavioral steps.
  locations:
  - preferred_term: ventral tegmental area
    term:
      id: UBERON:0002691
      label: ventral tegmental area
  - preferred_term: nucleus accumbens
    term:
      id: UBERON:0001882
      label: nucleus accumbens
- name: Alcohol Cue Responsivity
  conforms_to: "addiction_cycle#Incentive Salience and Habit Formation"
  biological_scale: TISSUE
  description: Alcohol-associated cues evoke brain responses that can correlate with craving. The meta-analysis included 28 studies of heavy-drinking/AUD samples; within-case ventral-striatal activation was not equivalent to a significant case-versus-control difference. Region-of-interest selection, heterogeneous ascertainment and mainly male samples limit generalization. This is an associative circuit finding, not a validated clinical biomarker.
  evidence:
  - reference: PMID:22574861
    reference_title: 'Functional neuroimaging studies of alcohol cue reactivity: a quantitative meta-analysis and systematic review.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: Among cases, alcohol cues elicited robust activation of limbic and prefrontal regions, including ventral striatum, anterior cingulate and ventromedial prefrontal cortex.
    explanation: The human imaging meta-analysis localizes within-case cue responses to ventral striatal and prefrontal circuitry, without equating activation with a causal deficit.
  - reference: PMID:22574861
    reference_title: 'Functional neuroimaging studies of alcohol cue reactivity: a quantitative meta-analysis and systematic review.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: Cue-elicited activation of ventral striatum was most frequently correlated with behavioral measures and most frequently reduced by treatment, but these results were often derived from region-of-interest analyses that interrogated only limbic regions.
    explanation: Behavioral correlations and treatment-related changes support cue responsivity as an associative mechanism candidate, while region-of-interest selection limits generalization.
  downstream:
  - target: Impaired Control over Alcohol Use
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Cue-related circuit responses correlate with behavior, but the imaging synthesis does not prove that those responses cause later loss of control.
    evidence:
    - reference: PMID:22574861
      reference_title: 'Functional neuroimaging studies of alcohol cue reactivity: a quantitative meta-analysis and systematic review.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: PRIMARY_RESULT
      directness: INDIRECT
      snippet: Among cases, alcohol cues elicited robust activation of limbic and prefrontal regions, including ventral striatum, anterior cingulate and ventromedial prefrontal cortex.
      explanation: The human imaging meta-analysis localizes within-case cue responses to ventral striatal and prefrontal circuitry, without equating activation with a causal deficit.
    - reference: PMID:22574861
      reference_title: 'Functional neuroimaging studies of alcohol cue reactivity: a quantitative meta-analysis and systematic review.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: PRIMARY_RESULT
      directness: INDIRECT
      snippet: Cue-elicited activation of ventral striatum was most frequently correlated with behavioral measures and most frequently reduced by treatment, but these results were often derived from region-of-interest analyses that interrogated only limbic regions.
      explanation: Behavioral correlations and treatment-related changes support cue responsivity as an associative mechanism candidate, while region-of-interest selection limits generalization.
  - target: Craving
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Brain cue responses can correlate with reported craving, but association does not establish a necessary causal circuit.
    evidence:
    - reference: PMID:22574861
      reference_title: 'Functional neuroimaging studies of alcohol cue reactivity: a quantitative meta-analysis and systematic review.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: PRIMARY_RESULT
      directness: INDIRECT
      snippet: Among cases, alcohol cues elicited robust activation of limbic and prefrontal regions, including ventral striatum, anterior cingulate and ventromedial prefrontal cortex.
      explanation: The human imaging meta-analysis localizes within-case cue responses to ventral striatal and prefrontal circuitry, without equating activation with a causal deficit.
    - reference: PMID:22574861
      reference_title: 'Functional neuroimaging studies of alcohol cue reactivity: a quantitative meta-analysis and systematic review.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: PRIMARY_RESULT
      directness: INDIRECT
      snippet: Cue-elicited activation of ventral striatum was most frequently correlated with behavioral measures and most frequently reduced by treatment, but these results were often derived from region-of-interest analyses that interrogated only limbic regions.
      explanation: Behavioral correlations and treatment-related changes support cue responsivity as an associative mechanism candidate, while region-of-interest selection limits generalization.
  locations:
  - preferred_term: ventral striatum
    term:
      id: UBERON:0005403
      label: ventral striatum
  - preferred_term: prefrontal cortex
    term:
      id: UBERON:0000451
      label: prefrontal cortex
- name: GABA-A Receptor Redistribution
  biological_scale: MOLECULAR
  description: Rodent chronic-intermittent-ethanol studies and cell/slice assays describe time- and compartment-dependent changes in GABA-A receptor surface composition. Reduced tonic ethanol sensitivity can coexist with increased sensitivity of some synaptic currents. Single-dose changes can reverse, while repeated regimens produce longer persistence; endpoint-specific tolerance is not universal receptor loss or proven lifelong human dysfunction. Hippocampal and cortical pyramidal-neuron recordings are among the preparations supporting these changes.
  evidence:
  - reference: PMID:28931433
    reference_title: Role of GABA(A) receptors in alcohol use disorders suggested by chronic intermittent ethanol (CIE) rodent model.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: One-dose ethanol exposure induces transient plastic changes in GABAA receptor subunit levels, composition, and regional and subcellular localization.
    explanation: Rodent exposure experiments summarized here show receptor redistribution after one dose, supporting plasticity without implying permanent or uniform receptor loss.
  - reference: PMID:25307573
    reference_title: Neurochemical mechanisms of alcohol withdrawal.
    supports: SUPPORT
    evidence_source: IN_VITRO
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: For example, studies in hippocampal and cortical pyramidal neurons have shown that chronic alcohol exposure reduces the frequency, amplitude, and decay time of mini inhibitory postsynaptic currents, effects that all contribute to increased neural excitability during withdrawal (Fleming et al., 2009).  # codespell:ignore-line
    explanation: The review explicitly identifies hippocampal and cortical pyramidal-neuron recordings as evidence for altered inhibitory currents after chronic exposure.
  - reference: PMID:28931433
    reference_title: Role of GABA(A) receptors in alcohol use disorders suggested by chronic intermittent ethanol (CIE) rodent model.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    quote_role: REVIEW_SYNTHESIS
    directness: INDIRECT
    snippet: One-dose ethanol exposure induces transient plastic changes in GABA A receptor subunit levels, composition, and regional and subcellular localization. ... After chronic intermittent ethanol (CIE) treatment the same changes are observed but they become persistent after 30 or more doses, lasting for at least 120 days in the rat
    explanation: The review distinguishes persistent receptor remodeling after repeated exposure from the reversible single-dose changes; this is a rat result, not a human threshold.
  molecular_functions:
  - preferred_term: GABA-A receptor activity
    term:
      id: GO:0004890
      label: GABA-A receptor activity
  downstream:
  - target: Withdrawal-Associated CNS Hyperexcitability
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: Changes in inhibitory or excitatory synaptic signaling alter neuronal excitability when ethanol is reduced. These known physiological intermediates are summarized here; their relative contribution differs across models and patients.
    evidence:
    - reference: PMID:28931433
      reference_title: Role of GABA(A) receptors in alcohol use disorders suggested by chronic intermittent ethanol (CIE) rodent model.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      quote_role: REVIEW_SYNTHESIS
      directness: INDIRECT
      snippet: Compensatory up-regulation of synaptically localized α4 and α2 subunit-containing GABAA receptor subtypes, mediating ethanol-sensitive synaptic inhibitory currents follow, but exhibit altered physio-pharmacology, seizure susceptibility, hyperexcitability, anxiety, and tolerance to GABAergic positive allosteric modulators, corresponding to heightened alcohol withdrawal syndrome.
      explanation: The review relates rodent receptor remodeling to altered physiology and withdrawal-related endpoints; this does not establish a uniform human receptor mechanism.
    - reference: PMID:25307573
      reference_title: Neurochemical mechanisms of alcohol withdrawal.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      directness: INDIRECT
      snippet: Clinical features of alcohol withdrawal include signs of central nervous system hyperexcitability, heightened autonomic nervous system activation, and a constellation of symptoms contributing to psychologic discomfort and negative affect.
      explanation: The human withdrawal syndrome includes both central hyperexcitability and autonomic activation; this clinical description alone does not identify a particular receptor mediator.
  locations:
  - preferred_term: hippocampal formation
    term:
      id: UBERON:0002421
      label: hippocampal formation
  - preferred_term: cerebral cortex
    term:
      id: UBERON:0000956
      label: cerebral cortex
  cell_types:
  - preferred_term: pyramidal neuron
    term:
      id: CL:0000598
      label: pyramidal neuron
- name: Altered Glutamate Homeostasis
  biological_scale: CELLULAR
  description: Repeated ethanol exposure and withdrawal can alter glutamate release, uptake and receptor regulation. Elevated extracellular glutamate is supported in particular rodent dependence models, while human spectroscopy results vary by region and timing and do not all show elevation. The whole process should not be reduced to universal NMDA-receptor upregulation.
  evidence:
  - reference: PMID:25307573
    reference_title: Neurochemical mechanisms of alcohol withdrawal.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Some studies have reported reduced cortical glutamate levels associated with dependence and acute withdrawal (Mon et al., 2012; Ende et al., 2013), while other studies have shown elevated glutamate activity in anterior cingulate and striatum in alcohol-dependent subjects (Hermann et al., 2012; Bauer et al., 2013).  # codespell:ignore-line
    explanation: Human measurements differ by brain region and withdrawal timing, supporting altered glutamate regulation rather than a universal increase or decrease.
  - reference: PMID:25307573
    reference_title: Neurochemical mechanisms of alcohol withdrawal.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Repeated cycles of chronic intermittent exposure to alcohol vapor were shown to increase basal levels of glutamate in the nucleus accumbens (NAc) at time points beyond acute withdrawal.
    explanation: Repeated vapor exposure increases accumbal glutamate in the reviewed rodent experiments beyond the acute withdrawal period.
  biological_processes:
  - preferred_term: synaptic transmission, glutamatergic
    term:
      id: GO:0035249
      label: synaptic transmission, glutamatergic
    modifier: ABNORMAL
  downstream:
  - target: Withdrawal-Associated CNS Hyperexcitability
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: Changes in inhibitory or excitatory synaptic signaling alter neuronal excitability when ethanol is reduced. These known physiological intermediates are summarized here; their relative contribution differs across models and patients.
    evidence:
    - reference: PMID:25307573
      reference_title: Neurochemical mechanisms of alcohol withdrawal.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      quote_role: REVIEW_SYNTHESIS
      directness: INDIRECT
      snippet: These adaptive changes in NMDA expression and function are suggested to contribute to withdrawal-related CNS hyperexcitability and escalation of drinking and cognitive impairments associated with dependence (Wang et al., 2010; Kroener et al., 2012; Ben Hamida et al., 2013).
      explanation: The review explicitly proposes a contribution of experimentally observed NMDA adaptations to withdrawal hyperexcitability; it does not establish uniform receptor mediation in human AUD.
    - reference: PMID:25307573
      reference_title: Neurochemical mechanisms of alcohol withdrawal.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      directness: INDIRECT
      snippet: Clinical features of alcohol withdrawal include signs of central nervous system hyperexcitability, heightened autonomic nervous system activation, and a constellation of symptoms contributing to psychologic discomfort and negative affect.
      explanation: The human withdrawal syndrome includes both central hyperexcitability and autonomic activation; this clinical description alone does not identify a particular receptor mediator.
  locations:
  - preferred_term: nucleus accumbens
    term:
      id: UBERON:0001882
      label: nucleus accumbens
  - preferred_term: cerebral cortex
    term:
      id: UBERON:0000956
      label: cerebral cortex
- name: Withdrawal-Associated CNS Hyperexcitability
  biological_scale: CELLULAR
  description: Reduction or cessation after sustained heavy exposure in a physiologically dependent person can uncover altered inhibitory/excitatory regulation. This contributes to tremor, insomnia, hallucinations and, in severe cases, seizures or delirium. Withdrawal is neither universal in AUD nor a requirement for diagnosis.
  evidence:
  - reference: PMID:25307573
    reference_title: Neurochemical mechanisms of alcohol withdrawal.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Clinical features of alcohol withdrawal include signs of central nervous system hyperexcitability, heightened autonomic nervous system activation, and a constellation of symptoms contributing to psychologic discomfort and negative affect.
    explanation: The human withdrawal syndrome includes both central hyperexcitability and autonomic activation; this clinical description alone does not identify a particular receptor mediator.
  downstream:
  - target: Tremor
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: Withdrawal-related neural hyperexcitability can manifest as tremor through motor-system output.
    evidence:
    - reference: url:https://www.aafp.org/pubs/afp/issues/2021/0900/p253.pdf
      reference_title: https://www.aafp.org/pubs/afp/issues/2021/0900/p253.pdf
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: leading to tremors, insomnia, nausea and vomiting, hallucinations, anxiety, and agitation.
      explanation: Lists tremor as a core alcohol withdrawal sign.
      directness: INDIRECT
      quote_role: REVIEW_SYNTHESIS
  - target: Alcohol Withdrawal Seizures
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: Excessive synchronized neuronal activity can produce a generalized withdrawal seizure in susceptible patients.
    evidence:
    - reference: url:https://www.aafp.org/pubs/afp/issues/2021/0900/p253.pdf
      reference_title: https://www.aafp.org/pubs/afp/issues/2021/0900/p253.pdf
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: If untreated or inadequately treated, withdrawal can progress to generalized tonic-clonic seizures, delirium tremens, and death.
      explanation: Identifies withdrawal seizures as a complication of untreated withdrawal.
      directness: INDIRECT
      quote_role: REVIEW_SYNTHESIS
  - target: Alcohol Withdrawal Delirium
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Severe withdrawal can impair attention and awareness through distributed brain dysfunction; hyperexcitability is contributory rather than a complete explanation of delirium.
    evidence:
    - reference: url:https://www.aafp.org/pubs/afp/issues/2021/0900/p253.pdf
      reference_title: https://www.aafp.org/pubs/afp/issues/2021/0900/p253.pdf
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: If untreated or inadequately treated, withdrawal can progress to generalized tonic-clonic seizures, delirium tremens, and death.
      explanation: Establishes delirium tremens as the severe end of the withdrawal spectrum.
      directness: INDIRECT
      quote_role: REVIEW_SYNTHESIS
  - target: Withdrawal Hallucinations
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Withdrawal-associated circuit dysfunction can produce hallucinations; the precise sensory-network mediation is incompletely resolved.
    evidence:
    - reference: url:https://www.aafp.org/pubs/afp/issues/2021/0900/p253.pdf
      reference_title: https://www.aafp.org/pubs/afp/issues/2021/0900/p253.pdf
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: leading to tremors, insomnia, nausea and vomiting, hallucinations, anxiety, and agitation.
      explanation: Lists hallucinations among the withdrawal manifestations.
      directness: INDIRECT
      quote_role: REVIEW_SYNTHESIS
  - target: Insomnia
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: Withdrawal-related arousal can disrupt sleep through central sleep-wake regulation.
    evidence:
    - reference: url:https://www.aafp.org/pubs/afp/issues/2021/0900/p253.pdf
      reference_title: https://www.aafp.org/pubs/afp/issues/2021/0900/p253.pdf
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: leading to tremors, insomnia, nausea and vomiting, hallucinations, anxiety, and agitation.
      explanation: Lists insomnia among the withdrawal manifestations.
      directness: INDIRECT
      quote_role: REVIEW_SYNTHESIS
    - reference: PMID:25307573
      reference_title: Neurochemical mechanisms of alcohol withdrawal.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      directness: INDIRECT
      snippet: A common complaint among alcoholics is disruption in sleep, which typically emerges during early periods of abstinence and often extends to the more protracted phase of abstinence
      explanation: The clinical review describes sleep disruption during both early and protracted abstinence, supporting the timing of the insomnia claim.
  - target: Nausea and Vomiting
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Withdrawal can produce nausea and vomiting through central and autonomic responses; the cited clinical account does not resolve their exact mediation.
    evidence:
    - reference: url:https://www.aafp.org/pubs/afp/issues/2021/0900/p253.pdf
      reference_title: https://www.aafp.org/pubs/afp/issues/2021/0900/p253.pdf
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: leading to tremors, insomnia, nausea and vomiting, hallucinations, anxiety, and agitation.
      explanation: Lists nausea and vomiting among withdrawal manifestations.
      directness: INDIRECT
      quote_role: REVIEW_SYNTHESIS
- name: Withdrawal-Associated Autonomic Activation
  biological_scale: ORGANISM
  description: Autonomic activation during withdrawal can produce tachycardia, sweating and elevated blood pressure. This component is separated from cortical excitability because controlling heart rate or blood pressure does not prevent withdrawal seizures or delirium.
  evidence:
  - reference: url:https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf
    reference_title: https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Clinical signs include sweating, elevated blood pressure, tachycardia, hyperthermia, and hyperactive reflexes.
    explanation: The guideline explicitly lists sweating, tachycardia and elevated blood pressure among withdrawal signs, supporting the autonomic branch.
  downstream:
  - target: Withdrawal Tachycardia
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: Sympathetic efferent signaling increases cardiac rate during withdrawal.
    evidence:
    - reference: url:https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf
      reference_title: https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      directness: INDIRECT
      snippet: Clinical signs include sweating, elevated blood pressure, tachycardia, hyperthermia, and hyperactive reflexes.
      explanation: The guideline explicitly lists sweating, tachycardia and elevated blood pressure among withdrawal signs, supporting the autonomic branch.
  - target: Withdrawal Hyperhidrosis
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: Autonomic sudomotor output increases sweating during withdrawal.
    evidence:
    - reference: url:https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf
      reference_title: https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      directness: INDIRECT
      snippet: Clinical signs include sweating, elevated blood pressure, tachycardia, hyperthermia, and hyperactive reflexes.
      explanation: The guideline explicitly lists sweating, tachycardia and elevated blood pressure among withdrawal signs, supporting the autonomic branch.
  - target: Withdrawal Hypertension
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: Autonomic cardiovascular output can raise blood pressure during withdrawal.
    evidence:
    - reference: url:https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf
      reference_title: https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      directness: INDIRECT
      snippet: Clinical signs include sweating, elevated blood pressure, tachycardia, hyperthermia, and hyperactive reflexes.
      explanation: The guideline explicitly lists sweating, tachycardia and elevated blood pressure among withdrawal signs, supporting the autonomic branch.
- name: CRF-Associated Stress Signaling
  conforms_to: "addiction_cycle#Reward Deficit and Stress-System Recruitment"
  biological_scale: MOLECULAR
  description: The addiction framework implicates CRF signaling in dependence-related stress and negative affect, with much of the causal evidence from rodent regional pharmacology. This is distinct from the nondependent VTA CRF-binding-protein/CRF2 drinking-in-the-dark experiment; that result is not evidence of central-amygdala CRF1 mediation.
  evidence:
  - reference: PMID:27475769
    reference_title: 'Neurobiology of addiction: a neurocircuitry analysis.'
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: The increases in negative emotional states and dysphoric and stress-like responses in the withdrawal/negative affect stage involve decreases in the function of the dopamine component of the reward system and recruitment of brain stress neurotransmitters, such as corticotropin-releasing factor and dynorphin, in the neurocircuitry of the extended amygdala.
    explanation: The review places CRF, dynorphin and reduced reward signaling within the extended-amygdala withdrawal framework; their contributions are not an obligatory sequence in every patient.
  downstream:
  - target: Withdrawal-Associated Negative Affect
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: The review framework proposes a contribution to aversive withdrawal states; human mediation and treatment response are not established by the cited model evidence.
    evidence:
    - reference: PMID:27475769
      reference_title: 'Neurobiology of addiction: a neurocircuitry analysis.'
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      quote_role: REVIEW_SYNTHESIS
      directness: INDIRECT
      snippet: The increases in negative emotional states and dysphoric and stress-like responses in the withdrawal/negative affect stage involve decreases in the function of the dopamine component of the reward system and recruitment of brain stress neurotransmitters, such as corticotropin-releasing factor and dynorphin, in the neurocircuitry of the extended amygdala.
      explanation: The review places CRF, dynorphin and reduced reward signaling within the extended-amygdala withdrawal framework; their contributions are not an obligatory sequence in every patient.
  locations:
  - preferred_term: central amygdaloid nucleus
    term:
      id: UBERON:0002883
      label: central amygdaloid nucleus
  - preferred_term: bed nucleus of stria terminalis
    term:
      id: UBERON:0001880
      label: bed nucleus of stria terminalis
  biological_processes:
  - preferred_term: response to stress
    term:
      id: GO:0006950
      label: response to stress
    modifier: INCREASED
- name: Dynorphin–Kappa-Opioid Signaling
  conforms_to: "addiction_cycle#Reward Deficit and Stress-System Recruitment"
  biological_scale: MOLECULAR
  description: Dynorphin and kappa-opioid signaling are implicated in aversion and dependence-related drinking in experimental literature. Effects depend on timing, region, sex and model; knockout findings are not uniform. The conference review contains preliminary reports, and human postmortem expression associations do not prove that blocking this pathway treats AUD.
  evidence:
  - reference: PMID:22459870
    reference_title: Targeting dynorphin/kappa opioid receptor systems to treat alcohol abuse and dependence.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Dr. Brendan Walker presented data characterizing the effects of KOR antagonism within the extended amygdala on withdrawal-induced escalation of alcohol self-administration in dependent animals.
    explanation: Kappa-opioid antagonist effects in dependent animals support an extended-amygdala dynorphin hypothesis, not established efficacy of such treatment in humans.
  downstream:
  - target: Withdrawal-Associated Negative Affect
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: The review framework proposes a contribution to aversive withdrawal states; human mediation and treatment response are not established by the cited model evidence.
    evidence:
    - reference: PMID:27475769
      reference_title: 'Neurobiology of addiction: a neurocircuitry analysis.'
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      quote_role: REVIEW_SYNTHESIS
      directness: INDIRECT
      snippet: The increases in negative emotional states and dysphoric and stress-like responses in the withdrawal/negative affect stage involve decreases in the function of the dopamine component of the reward system and recruitment of brain stress neurotransmitters, such as corticotropin-releasing factor and dynorphin, in the neurocircuitry of the extended amygdala.
      explanation: The review places CRF, dynorphin and reduced reward signaling within the extended-amygdala withdrawal framework; their contributions are not an obligatory sequence in every patient.
  locations:
  - preferred_term: central amygdaloid nucleus
    term:
      id: UBERON:0002883
      label: central amygdaloid nucleus
  - preferred_term: bed nucleus of stria terminalis
    term:
      id: UBERON:0001880
      label: bed nucleus of stria terminalis
- name: Withdrawal-Associated Reward Deficit
  conforms_to: "addiction_cycle#Reward Deficit and Stress-System Recruitment"
  biological_scale: TISSUE
  description: Reviewed dependence models show reduced dopamine neuronal activity or basal striatal dopamine during withdrawal. These observations support a reward-deficit hypothesis but should not be generalized to every brain region, exposure phase or individual with AUD.
  evidence:
  - reference: PMID:25307573
    reference_title: Neurochemical mechanisms of alcohol withdrawal.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: By contrast, withdrawal from chronic alcohol exposure has been reported to result in decreased VTA dopamine neuronal activity (Diana et al., 1996; Bailey et al., 2001), and reduced basal levels of dopamine in ventral and dorsal subregions of the striatum, possibly due to enhanced dopamine uptake (Weiss et al., 1996; Budygin et al., 2007; Barak et al., 2011).
    explanation: The reviewed rodent measurements link withdrawal to reduced VTA firing and striatal dopamine, supporting a reward-deficit model with incompletely resolved behavioral mediation.
  downstream:
  - target: Withdrawal-Associated Negative Affect
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: The review framework proposes a contribution to aversive withdrawal states; human mediation and treatment response are not established by the cited model evidence.
    evidence:
    - reference: PMID:27475769
      reference_title: 'Neurobiology of addiction: a neurocircuitry analysis.'
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      quote_role: REVIEW_SYNTHESIS
      directness: INDIRECT
      snippet: The increases in negative emotional states and dysphoric and stress-like responses in the withdrawal/negative affect stage involve decreases in the function of the dopamine component of the reward system and recruitment of brain stress neurotransmitters, such as corticotropin-releasing factor and dynorphin, in the neurocircuitry of the extended amygdala.
      explanation: The review places CRF, dynorphin and reduced reward signaling within the extended-amygdala withdrawal framework; their contributions are not an obligatory sequence in every patient.
  locations:
  - preferred_term: ventral tegmental area
    term:
      id: UBERON:0002691
      label: ventral tegmental area
  - preferred_term: ventral striatum
    term:
      id: UBERON:0005403
      label: ventral striatum
  - preferred_term: dorsal striatum
    term:
      id: UBERON:0005382
      label: dorsal striatum
  biological_processes:
  - preferred_term: dopamine secretion
    term:
      id: GO:0014046
      label: dopamine secretion
    modifier: DECREASED
- name: Withdrawal-Associated Negative Affect
  biological_scale: ORGANISM
  description: Anxiety, dysphoria and other aversive states can motivate renewed drinking for relief. Hyperkatifeia is a cross-drug heuristic framework integrating reward deficits and stress signaling, not a biomarker or a required stage in every patient. Persistent symptoms also require assessment for independent psychiatric illness.
  evidence:
  - reference: PMID:33318153
    reference_title: 'Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development.'
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: This review focuses on neurochemical/neurocircuitry dysregulations that contribute to hyperkatifeia, defined as a greater intensity of negative emotional/motivational signs and symptoms during withdrawal from drugs of abuse in the withdrawal/negative affect stage of the addiction cycle.
    explanation: The review defines heightened negative affect during withdrawal and proposes its motivational role; it does not establish a single causal neurochemical route.
  downstream:
  - target: Impaired Control over Alcohol Use
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Relief of aversive withdrawal states can motivate renewed use through negative reinforcement; this does not account for all patterns of impaired control.
    evidence:
    - reference: PMID:33318153
      reference_title: 'Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development.'
      supports: SUPPORT
      evidence_source: OTHER
      quote_role: REVIEW_SYNTHESIS
      snippet: Hyperkatifeia provides an additional source of motivation for compulsive drug seeking via negative reinforcement.
      explanation: The review explicitly proposes negative reinforcement as a route from aversive withdrawal states to compulsive seeking; its cross-drug framework remains indirect for AUD.
      directness: INDIRECT
  - target: Anxiety
    causal_link_type: DIRECT
    description: Anxiety can be part of an aversive withdrawal state, without implying all independent anxiety disorders arise through this route.
    evidence:
    - reference: PMID:33318153
      reference_title: 'Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development.'
      supports: SUPPORT
      evidence_source: OTHER
      quote_role: REVIEW_SYNTHESIS
      snippet: This review focuses on neurochemical/neurocircuitry dysregulations that contribute to hyperkatifeia, defined as a greater intensity of negative emotional/motivational signs and symptoms during withdrawal from drugs of abuse in the withdrawal/negative affect stage of the addiction cycle.
      explanation: The review defines heightened negative affect during withdrawal and proposes its motivational role; it does not establish a single causal neurochemical route.
      directness: DIRECT
- name: Habitual Alcohol Seeking
  conforms_to: "addiction_cycle#Incentive Salience and Habit Formation"
  biological_scale: ORGANISM
  description: In alcohol-preferring male rats, devaluation-insensitive seeking predicted subsequent punishment-resistant seeking and quinine-resistant drinking. The cited abstract supplies behavioral evidence; its background anatomical account is not a new direct assay of dorsal-striatal dopamine or proof of the same causal sequence in humans.
  evidence:
  - reference: PMID:33955649
    reference_title: Individual differences in the engagement of habitual control over alcohol seeking predict the development of compulsive alcohol seeking and drinking.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: After seeking behaviour was well established, subjects that had developed greater resistance to outcome devaluation (were more habitual) were more likely to show punishment-resistant (compulsive) alcohol seeking.
    explanation: Outcome-devaluation resistance predicted punishment-resistant seeking in selected rats; the association does not prove that habitual control alone causes human compulsive drinking.
  downstream:
  - target: Impaired Control over Alcohol Use
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: In the rat paradigm, stronger habitual control predicted punishment-resistant seeking; extrapolation to human impaired control remains indirect.
    evidence:
    - reference: PMID:33955649
      reference_title: Individual differences in the engagement of habitual control over alcohol seeking predict the development of compulsive alcohol seeking and drinking.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      quote_role: PRIMARY_RESULT
      directness: INDIRECT
      snippet: After seeking behaviour was well established, subjects that had developed greater resistance to outcome devaluation (were more habitual) were more likely to show punishment-resistant (compulsive) alcohol seeking.
      explanation: Outcome-devaluation resistance predicted punishment-resistant seeking in selected rats; the association does not prove that habitual control alone causes human compulsive drinking.
- name: Impaired Executive Control
  conforms_to: "addiction_cycle#Prefrontal Executive Control Deficit"
  biological_scale: TISSUE
  description: Reduced inhibitory control and altered decision-making can contribute to difficulty limiting alcohol use in the addiction framework. Cross-sectional MRI differences in AUD provide anatomical associations, not proof that alcohol caused progressive atrophy or that a measured structural difference mediated an executive deficit.
  evidence:
  - reference: PMID:27475769
    reference_title: 'Neurobiology of addiction: a neurocircuitry analysis.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: The craving and deficits in executive function in the so-called preoccupation/anticipation stage involve the dysregulation of key afferent projections from the prefrontal cortex and insula, including glutamate, to the basal ganglia and extended amygdala.
    explanation: The synthesis links executive-control problems to prefrontal projections, providing circuit context without proving a single lesion causes impaired control.
  - reference: PMID:32643841
    reference_title: How do substance use disorders compare to other psychiatric conditions on structural brain abnormalities? A cross-disorder meta-analytic comparison using the ENIGMA consortium findings.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: INDIRECT
    snippet: On measures of cortical thickness, AUD was associated with significant differences bilaterally in the fusiform gyrus, inferior temporal gyrus, temporal pole, superior frontal gyrus, and rostral and caudal anterior cingulate gyri.
    explanation: Cross-sectional anatomical associations support context for the framework, without directly measuring a causal effect on executive performance.
  downstream:
  - target: Impaired Control over Alcohol Use
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Reduced executive regulation can make limiting use more difficult, but imaging and review evidence do not establish one necessary causal pathway.
    evidence:
    - reference: PMID:27475769
      reference_title: 'Neurobiology of addiction: a neurocircuitry analysis.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      directness: INDIRECT
      snippet: The craving and deficits in executive function in the so-called preoccupation/anticipation stage involve the dysregulation of key afferent projections from the prefrontal cortex and insula, including glutamate, to the basal ganglia and extended amygdala.
      explanation: The synthesis links executive-control problems to prefrontal projections, providing circuit context without proving a single lesion causes impaired control.
  - target: Impaired Executive Functioning
    causal_link_type: DIRECT
    description: This clinical domain is represented in the review framework; severity and cause vary among individuals.
    evidence:
    - reference: PMID:27475769
      reference_title: 'Neurobiology of addiction: a neurocircuitry analysis.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      directness: DIRECT
      snippet: The craving and deficits in executive function in the so-called preoccupation/anticipation stage involve the dysregulation of key afferent projections from the prefrontal cortex and insula, including glutamate, to the basal ganglia and extended amygdala.
      explanation: The synthesis links executive-control problems to prefrontal projections, providing circuit context without proving a single lesion causes impaired control.
  locations:
  - preferred_term: prefrontal cortex
    term:
      id: UBERON:0000451
      label: prefrontal cortex
- name: Impaired Control over Alcohol Use
  conforms_to: "addiction_cycle#Compulsive Seeking and Loss of Control"
  biological_scale: ORGANISM
  description: Impaired control and persistent use despite harm are clinical manifestations to which reinforcement, learned cue responses, aversive-state relief and executive-control problems may contribute. These routes can coexist but are not a mandatory ordered sequence, and DSM criteria allow heterogeneous presentations.
  evidence:
  - reference: PMID:37844924
    reference_title: Canadian guideline for the clinical management of high-risk drinking and alcohol use disorder.
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: The diagnosis of AUD can be made when a patient has a problematic pattern of alcohol use over a year that leads to clinically significant impairment or distress, involving at least 2 of the 11 DSM-5-TR criteria.
    explanation: The guideline states the DSM-5-TR clinical threshold, supporting the diagnostic construct rather than a molecular cause of addiction.
  downstream:
  - target: Addictive Alcohol Use
    causal_link_type: DIRECT
    description: The node describes the impaired-control component of the clinical phenotype, while individual DSM criterion combinations vary.
    evidence:
    - reference: PMID:37844924
      reference_title: Canadian guideline for the clinical management of high-risk drinking and alcohol use disorder.
      supports: SUPPORT
      evidence_source: OTHER
      quote_role: REVIEW_SYNTHESIS
      snippet: The diagnosis of AUD can be made when a patient has a problematic pattern of alcohol use over a year that leads to clinically significant impairment or distress, involving at least 2 of the 11 DSM-5-TR criteria.
      explanation: The guideline states the DSM-5-TR clinical threshold, supporting the diagnostic construct rather than a molecular cause of addiction.
      directness: DIRECT
  - target: Problematic Alcohol Consumption
    causal_link_type: DIRECT
    description: Persistent impaired control can produce problematic consumption and related impairment.
    evidence:
    - reference: PMID:37844924
      reference_title: Canadian guideline for the clinical management of high-risk drinking and alcohol use disorder.
      supports: SUPPORT
      evidence_source: OTHER
      quote_role: REVIEW_SYNTHESIS
      snippet: The diagnosis of AUD can be made when a patient has a problematic pattern of alcohol use over a year that leads to clinically significant impairment or distress, involving at least 2 of the 11 DSM-5-TR criteria.
      explanation: The guideline states the DSM-5-TR clinical threshold, supporting the diagnostic construct rather than a molecular cause of addiction.
      directness: DIRECT
  - target: Repeated Ethanol Exposure
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Difficulty limiting use can perpetuate exposure, creating a feedback relationship rather than a necessary one-way progression.
    evidence:
    - reference: PMID:37844924
      reference_title: Canadian guideline for the clinical management of high-risk drinking and alcohol use disorder.
      supports: SUPPORT
      evidence_source: OTHER
      quote_role: REVIEW_SYNTHESIS
      snippet: the patient often takes alcohol in larger amounts or over a longer period than they had intended (1); the patient has a persistent desire or has been unsuccessful in their efforts to cut down or control their use of alcohol (2)
      explanation: The criteria describe excess duration or amount and failed control of drinking, supporting a clinical feedback interpretation rather than an experimentally established causal loop.
      directness: INDIRECT
- name: Thiamine Deficiency
  biological_scale: MOLECULAR
  description: Poor intake and alcohol-related interference with thiamine handling can produce deficiency and neurologic complications. Nutritional deficiency is an exposure-associated pathway distinct from reinforcement and receptor adaptation; not everyone with AUD develops it.
  evidence:
  - reference: url:https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf
    reference_title: https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Patients consuming large volumes of alcohol are at an increased risk of developing Wernicke encephalopathy due to inadequate nutrition as well as biological interactions between cellular functioning and alcohol.
    explanation: The guideline connects heavy drinking with nutritional and biological risks for thiamine-related disease, supporting a conditional deficiency pathway.
  downstream:
  - target: Memory Impairment
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: Thiamine deficiency can cause metabolic brain injury and region-specific neurologic dysfunction, leading to this manifestation in affected patients.
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK436003/
      reference_title: 'Alcohol Use Disorder: Screening, Evaluation, and Management - StatPearls - NCBI Bookshelf'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      directness: INDIRECT
      snippet: Chronic alcohol use leading to thiamine deficiency can result in Korsakoff syndrome marked by antero- and retrograde amnesia.
      explanation: The clinical synthesis links thiamine-related Korsakoff syndrome to anterograde and retrograde memory impairment; this is a complication in a subset of patients.
  - target: Ataxia
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: Thiamine deficiency can cause metabolic brain injury and region-specific neurologic dysfunction, leading to this manifestation in affected patients.
    evidence:
    - reference: url:https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf
      reference_title: https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      directness: INDIRECT
      snippet: Patients with thiamine deficiency often present with signs and symptoms such as confusion, abnormal gaze patterns or nystagmus, ataxia, and possibly delirium.
      explanation: The guideline lists ataxia among manifestations of thiamine deficiency, supporting the nutritional complication without making it a general AUD finding.
- name: TLR4-Dependent Inflammatory Signaling
  biological_scale: MOLECULAR
  description: In female mice exposed to ethanol for five months and in neonatal rodent astrocyte preparations, Tlr4 deletion or knockdown attenuated inflammatory responses. Direct ethanol binding to TLR4 was not established. The constitutive whole-body knockout does not isolate an astrocyte- or microglia-autonomous mechanism in vivo or prove this pathway causes human AUD.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6634595/
    reference_title: Pivotal Role of TLR4 Receptors in Alcohol-Induced Neuroinflammation and Brain Damage - PMC
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: Our findings support the critical role of the TLR4 response in the neuroinflammation, brain injury, and possibly in the neurodegeneration induced by chronic ethanol intake.
    explanation: The mouse study supports receptor dependence of measured inflammatory and injury markers; neurodegeneration was proposed rather than a measured clinical outcome.
  genes:
  - preferred_term: TLR4
    term:
      id: hgnc:11850
      label: TLR4
  downstream:
  - target: Astrocytic NF-kappa-B Activation
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: TLR4 signals through intracellular adaptor and kinase pathways to NF-kappa-B. Astrocyte knockdown supports this route, while the intervening canonical signaling steps are not separate graph nodes.
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6634595/
      reference_title: Pivotal Role of TLR4 Receptors in Alcohol-Induced Neuroinflammation and Brain Damage - PMC
      supports: SUPPORT
      evidence_source: IN_VITRO
      quote_role: PRIMARY_RESULT
      directness: INDIRECT
      snippet: Gene silencing of TLR4 downregulates the TLR4 expression and reduces NFκB activation induced by ethanol in astrocytes in culture.
      explanation: TLR4 knockdown reduces ethanol-induced NF-kappa-B activation in cultured astrocytes, establishing a perturbation result within that cell preparation.
  - target: Cortical Inflammatory Mediator Induction
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Constitutive Tlr4 deletion prevents the measured cortical cytokine induction in this mouse regimen; cell-specific production and all intervening routes remain unresolved.
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6634595/
      reference_title: Pivotal Role of TLR4 Receptors in Alcohol-Induced Neuroinflammation and Brain Damage - PMC
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      quote_role: PRIMARY_RESULT
      directness: INDIRECT
      snippet: chronic ethanol treatment upregulated the levels of TNF-α, IL-1β, and mRNA IL-6 in the cortex homogenates of the WT mice, whereas no changes were observed in the levels of these cytokines in the cerebral cortices of the TLR4-KO mice.
      explanation: The wild-type versus knockout comparison shows TLR4-dependent cortical cytokine changes in mice; homogenate measurements do not identify every producing cell.
  - target: Cortical Glial Reactivity
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Tlr4 deletion attenuates cortical GFAP reactivity but leaves a residual response; the experiment does not isolate every intervening glial signal.
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6634595/
      reference_title: Pivotal Role of TLR4 Receptors in Alcohol-Induced Neuroinflammation and Brain Damage - PMC
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      quote_role: PRIMARY_RESULT
      directness: INDIRECT
      snippet: although GFAP immunoreactivity markedly increased (∼16-fold) in the medial frontal cortex of the WT ethanol-treated mice, the levels of this protein only increased ∼3-fold in the TLR4-KO ethanol-treated animals
      explanation: The GFAP increase is attenuated but persists in knockout mice, supporting a partial TLR4 contribution rather than complete prevention of glial reactivity.
  - target: Cortical Caspase-3 Activation
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: The mouse comparison associates TLR4 function with ethanol-induced cortical caspase-3 cleavage; the responsible cell type and intervening death pathway remain unresolved.
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6634595/
      reference_title: Pivotal Role of TLR4 Receptors in Alcohol-Induced Neuroinflammation and Brain Damage - PMC
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      quote_role: PRIMARY_RESULT
      directness: INDIRECT
      snippet: the Western blot analysis shows caspase-3 activation as the appearance of the ∼17 kDa caspase-3 cleavage fragment in cerebral cortices of the ethanol-treated WT animals. Conversely, chronic ethanol treatment did not induce caspase-3 activation in the TLR4-KO animals
      explanation: The passage compares ethanol-exposed wild-type and Tlr4-knockout cortices, supporting genotype-dependent caspase-3 activation without identifying a dying cell type.
- name: Astrocytic NF-kappa-B Activation
  biological_scale: MOLECULAR
  description: In neonatal rodent astrocyte cultures, ethanol increased nuclear NF-kappa-B p65 signaling, and TLR4 knockdown or deficiency attenuated it. These cell-culture findings are separate from whole-cortex measurements and do not establish a universal patient biomarker.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6634595/
    reference_title: Pivotal Role of TLR4 Receptors in Alcohol-Induced Neuroinflammation and Brain Damage - PMC
    supports: SUPPORT
    evidence_source: IN_VITRO
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: Gene silencing of TLR4 downregulates the TLR4 expression and reduces NFκB activation induced by ethanol in astrocytes in culture.
    explanation: TLR4 knockdown reduces ethanol-induced NF-kappa-B activation in cultured astrocytes, establishing a perturbation result within that cell preparation.
  cell_types:
  - preferred_term: astrocyte
    term:
      id: CL:0000127
      label: astrocyte
- name: Cortical Inflammatory Mediator Induction
  biological_scale: CELLULAR
  description: Chronic ethanol-exposed wild-type mouse cortex showed increased TNF-alpha and IL-1beta protein and IL-6 transcript, with attenuated responses in Tlr4-knockout mice. Whole-tissue measurements do not identify the producing cell type, and transcript and protein readouts are not interchangeable.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6634595/
    reference_title: Pivotal Role of TLR4 Receptors in Alcohol-Induced Neuroinflammation and Brain Damage - PMC
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: chronic ethanol treatment upregulated the levels of TNF-α, IL-1β, and mRNA IL-6 in the cortex homogenates of the WT mice, whereas no changes were observed in the levels of these cytokines in the cerebral cortices of the TLR4-KO mice.
    explanation: The wild-type versus knockout comparison shows TLR4-dependent cortical cytokine changes in mice; homogenate measurements do not identify every producing cell.
  locations:
  - preferred_term: cerebral cortex
    term:
      id: UBERON:0000956
      label: cerebral cortex
- name: Cortical Glial Reactivity
  biological_scale: TISSUE
  description: GFAP and CD11b immunoreactivity increased in the cortex of ethanol-exposed wild-type mice. Tlr4 deficiency attenuated these changes, but the residual approximately threefold GFAP increase shows that not all astroglial response was abolished. Immunoreactivity is a marker readout rather than a direct count of newly generated glia.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6634595/
    reference_title: Pivotal Role of TLR4 Receptors in Alcohol-Induced Neuroinflammation and Brain Damage - PMC
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: although GFAP immunoreactivity markedly increased (∼16-fold) in the medial frontal cortex of the WT ethanol-treated mice, the levels of this protein only increased ∼3-fold in the TLR4-KO ethanol-treated animals
    explanation: The GFAP increase is attenuated but persists in knockout mice, supporting a partial TLR4 contribution rather than complete prevention of glial reactivity.
  - reference: url:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6634595/
    reference_title: Pivotal Role of TLR4 Receptors in Alcohol-Induced Neuroinflammation and Brain Damage - PMC
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: A significant upregulation of GFAP ... and CD11b ... immunoreactivity was observed in the ethanol-treated WT mice versus the WT nontreated controls
    explanation: The figure legend reports increases in both glial markers, complementing the separate quantitative GFAP comparison.
  locations:
  - preferred_term: cerebral cortex
    term:
      id: UBERON:0000956
      label: cerebral cortex
- name: Cortical Caspase-3 Activation
  biological_scale: MOLECULAR
  description: Cleaved caspase-3 and immunoreactivity increased in ethanol-exposed wild-type mouse cortex and were attenuated by Tlr4 deficiency. This supports an injury/apoptosis-associated signal, without directly identifying dying neurons, quantifying cognitive impairment, or proving an inflammatory mediator was the necessary intermediate.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6634595/
    reference_title: Pivotal Role of TLR4 Receptors in Alcohol-Induced Neuroinflammation and Brain Damage - PMC
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: the Western blot analysis shows caspase-3 activation as the appearance of the ∼17 kDa caspase-3 cleavage fragment in cerebral cortices of the ethanol-treated WT animals. Conversely, chronic ethanol treatment did not induce caspase-3 activation in the TLR4-KO animals
    explanation: The passage compares ethanol-exposed wild-type and Tlr4-knockout cortices, supporting genotype-dependent caspase-3 activation without identifying a dying cell type.
  locations:
  - preferred_term: cerebral cortex
    term:
      id: UBERON:0000956
      label: cerebral cortex
- name: VTA CRF2-Associated Drinking Modulation
  biological_scale: MOLECULAR
  description: In male mice, local VTA CRF2 antagonism reduced nondependent drinking-in-the-dark intake; CRF-binding-protein interference added to the effect under tested conditions. The study did not assay dopamine, NMDA currents or physical receptor interactions. CRF-binding-protein blockade was ineffective in central amygdala and in the dependent intermittent-access VTA condition.
  evidence:
  - reference: PMID:26247973
    reference_title: 'Corticotropin Releasing Factor Binding Protein and CRF2 Receptors in the Ventral Tegmental Area: Modulation of Ethanol Binge Drinking in C57BL/6J Mice.'
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: These results indicate that VTA CRF2 receptors modulate ethanol binge drinking, and CRFBP may add to the anti-alcohol effect of A2B.
    explanation: Local VTA pharmacology modifies drinking in the nondependent binge paradigm; the result does not establish the same effect in dependence or in all brain regions.
  - reference: PMID:26247973
    reference_title: 'Corticotropin Releasing Factor Binding Protein and CRF2 Receptors in the Ventral Tegmental Area: Modulation of Ethanol Binge Drinking in C57BL/6J Mice.'
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: Intra-CeA CRF6–33 neither affected ethanol binge drinking nor escalated ethanol consumption in mice given IAA.
    explanation: The central-amygdala null result limits regional generalization of the VTA CRF-binding-protein finding.
  downstream:
  - target: Repeated Ethanol Exposure
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Regional pharmacological perturbation altered intake in nondependent DID mice; the intervening neuronal mechanism and human relevance are unresolved.
    evidence:
    - reference: PMID:26247973
      reference_title: 'Corticotropin Releasing Factor Binding Protein and CRF2 Receptors in the Ventral Tegmental Area: Modulation of Ethanol Binge Drinking in C57BL/6J Mice.'
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      quote_role: PRIMARY_RESULT
      directness: INDIRECT
      snippet: These results indicate that VTA CRF2 receptors modulate ethanol binge drinking, and CRFBP may add to the anti-alcohol effect of A2B.
      explanation: Local VTA pharmacology modifies drinking in the nondependent binge paradigm; the result does not establish the same effect in dependence or in all brain regions.
  locations:
  - preferred_term: ventral tegmental area
    term:
      id: UBERON:0002691
      label: ventral tegmental area
phenotypes:
- category: Behavioral
  name: Addictive Alcohol Use
  description: Impaired control, unsuccessful attempts to reduce use and continued use despite harm may characterize AUD. DSM-5-TR requires a combination of criteria, so no single control symptom or withdrawal finding is mandatory in every case.
  phenotype_term:
    preferred_term: Addictive alcohol use
    term:
      id: HP:0030955
      label: Addictive alcohol use
  diagnostic: true
  evidence:
  - reference: PMID:37844924
    reference_title: Canadian guideline for the clinical management of high-risk drinking and alcohol use disorder.
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: The diagnosis of AUD can be made when a patient has a problematic pattern of alcohol use over a year that leads to clinically significant impairment or distress, involving at least 2 of the 11 DSM-5-TR criteria.
    explanation: The guideline states the DSM-5-TR clinical threshold, supporting the diagnostic construct rather than a molecular cause of addiction.
- category: Behavioral
  name: Problematic Alcohol Consumption
  description: A pattern of drinking causing harm to health or social functioning, graded in DSM-5 as mild (2-3 criteria), moderate (4-5), or severe (6 or more) and separated in ICD-11 into harmful pattern of use versus dependence.
  phenotype_term:
    preferred_term: Problematic alcohol consumption
    term:
      id: HP:5200329
      label: Problematic alcohol consumption
  diagnostic: true
  evidence:
  - reference: PMID:31194891
    reference_title: 'Alcohol Use Disorders in ICD-11: Past, Present, and Future.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: This review describes and discusses the alcohol diagnoses within this section of ICD-11, including Alcohol Dependence, Harmful Pattern of Use of Alcohol, and entities such as Alcohol Intoxication, Alcohol Withdrawal, and several alcohol-induced mental disorders, and briefly covers Hazardous Alcohol Use, which is listed separately as a health risk factor.
    explanation: Documents the ICD-11 diagnostic structure that grades problematic drinking into harmful use and dependence.
    quote_role: REVIEW_SYNTHESIS
  - reference: PMID:37844924
    reference_title: Canadian guideline for the clinical management of high-risk drinking and alcohol use disorder.
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: The diagnosis of AUD can be made when a patient has a problematic pattern of alcohol use over a year that leads to clinically significant impairment or distress, involving at least 2 of the 11 DSM-5-TR criteria.
    explanation: The guideline states the DSM-5-TR clinical threshold, supporting the diagnostic construct rather than a molecular cause of addiction.
- category: Behavioral
  name: Craving
  description: A strong desire or urge to use alcohol is one DSM-5-TR criterion and a distinct patient-reported trial outcome. Cue-related imaging is a correlate rather than a diagnostic test or proof of a necessary mechanism.
  notes: 'No `phenotype_term` is bound: HPO has no general craving term (only the food-specific HP:0030083, HP:0030221 and HP:6000785), and using one of those or a generic behavioural parent would misdescribe the claim. Needs term / NTR candidate.'
  diagnostic: true
  evidence:
  - reference: PMID:37844924
    reference_title: Canadian guideline for the clinical management of high-risk drinking and alcohol use disorder.
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: the patient has troublesome craving (desire or urges) to use alcohol (4)
    explanation: Craving is an explicit DSM-5-TR criterion, but it alone is insufficient for the diagnosis.
- category: Behavioral
  name: Hazardous Alcohol Use
  description: Recurrent use in physically hazardous situations is a possible DSM-5-TR criterion. ICD-11 hazardous use is a separate health-risk category and alone does not establish dependence or AUD.
  phenotype_term:
    preferred_term: Hazardous alcohol use
    term:
      id: HP:6000028
      label: Hazardous alcohol use
  evidence:
  - reference: PMID:37844924
    reference_title: Canadian guideline for the clinical management of high-risk drinking and alcohol use disorder.
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: the patient uses alcohol regularly in situations where it is a hazard to them physically (8)
    explanation: Repeated drinking in physically hazardous situations is a diagnostic criterion, distinct from a proven neural mechanism.
- category: Neurologic
  name: Tremor
  description: Tremor can begin within hours after reduction or cessation of sustained heavy drinking in a physiologically dependent person; timing and severity vary.
  phenotype_term:
    preferred_term: Tremor
    term:
      id: HP:0001337
      label: Tremor
    temporality: ACUTE
  evidence:
  - reference: url:https://www.aafp.org/pubs/afp/issues/2021/0900/p253.pdf
    reference_title: https://www.aafp.org/pubs/afp/issues/2021/0900/p253.pdf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: leading to tremors, insomnia, nausea and vomiting, hallucinations, anxiety, and agitation.
    explanation: Lists tremor as a core alcohol withdrawal sign.
    directness: DIRECT
    quote_role: REVIEW_SYNTHESIS
- category: Neurologic
  name: Alcohol Withdrawal Seizures
  description: Generalized tonic-clonic seizures can complicate alcohol withdrawal, typically during the first 12–48 hours after cessation or marked reduction. They can occur despite treatment, and assessment must consider other seizure causes.
  phenotype_term:
    preferred_term: Generalized tonic-clonic seizure
    term:
      id: HP:0002069
      label: Bilateral tonic-clonic seizure
    temporality: ACUTE
  evidence:
  - reference: url:https://www.aafp.org/pubs/afp/issues/2021/0900/p253.pdf
    reference_title: https://www.aafp.org/pubs/afp/issues/2021/0900/p253.pdf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: If untreated or inadequately treated, withdrawal can progress to generalized tonic-clonic seizures, delirium tremens, and death.
    explanation: Identifies withdrawal seizures as a complication of untreated withdrawal.
    directness: DIRECT
    quote_role: REVIEW_SYNTHESIS
- category: Neurologic
  name: Alcohol Withdrawal Delirium
  description: Withdrawal delirium combines disturbed attention and awareness with confusion, often hallucinations and autonomic activation. It is a potentially life-threatening complication requiring close monitoring, and other causes of delirium must also be assessed.
  phenotype_term:
    preferred_term: Delirium
    term:
      id: HP:0031258
      label: Delirium
    temporality: ACUTE
    severity: SEVERE
  evidence:
  - reference: url:https://www.aafp.org/pubs/afp/issues/2021/0900/p253.pdf
    reference_title: https://www.aafp.org/pubs/afp/issues/2021/0900/p253.pdf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: If untreated or inadequately treated, withdrawal can progress to generalized tonic-clonic seizures, delirium tremens, and death.
    explanation: Establishes delirium tremens as the severe end of the withdrawal spectrum.
    directness: DIRECT
    quote_role: REVIEW_SYNTHESIS
- category: Neurologic
  name: Withdrawal Hallucinations
  description: Visual and tactile hallucinations occurring during alcohol withdrawal, with or without accompanying delirium.
  phenotype_term:
    preferred_term: Hallucinations
    term:
      id: HP:0000738
      label: Hallucinations
    temporality: ACUTE
  evidence:
  - reference: url:https://www.aafp.org/pubs/afp/issues/2021/0900/p253.pdf
    reference_title: https://www.aafp.org/pubs/afp/issues/2021/0900/p253.pdf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: leading to tremors, insomnia, nausea and vomiting, hallucinations, anxiety, and agitation.
    explanation: Lists hallucinations among the withdrawal manifestations.
    directness: DIRECT
    quote_role: REVIEW_SYNTHESIS
- category: Neurologic
  name: Insomnia
  description: Insomnia can occur during acute withdrawal and may persist during abstinence; it is not specific to AUD.
  phenotype_term:
    preferred_term: Insomnia
    term:
      id: HP:0100785
      label: Insomnia
  evidence:
  - reference: url:https://www.aafp.org/pubs/afp/issues/2021/0900/p253.pdf
    reference_title: https://www.aafp.org/pubs/afp/issues/2021/0900/p253.pdf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: leading to tremors, insomnia, nausea and vomiting, hallucinations, anxiety, and agitation.
    explanation: Lists insomnia among the withdrawal manifestations.
    directness: DIRECT
    quote_role: REVIEW_SYNTHESIS
  - reference: PMID:25307573
    reference_title: Neurochemical mechanisms of alcohol withdrawal.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: A common complaint among alcoholics is disruption in sleep, which typically emerges during early periods of abstinence and often extends to the more protracted phase of abstinence
    explanation: The clinical review describes sleep disruption during both early and protracted abstinence, supporting the timing of the insomnia claim.
- category: Behavioral
  name: Anxiety
  description: Anxiety can accompany withdrawal or the negative-affect component of dependence; independent anxiety disorders may also coexist. Persistence and mechanisms vary among individuals.
  phenotype_term:
    preferred_term: Anxiety
    term:
      id: HP:0000739
      label: Anxiety
  evidence:
  - reference: url:https://www.aafp.org/pubs/afp/issues/2021/0900/p253.pdf
    reference_title: https://www.aafp.org/pubs/afp/issues/2021/0900/p253.pdf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: leading to tremors, insomnia, nausea and vomiting, hallucinations, anxiety, and agitation.
    explanation: Documents anxiety as an acute withdrawal feature.
    directness: DIRECT
    quote_role: REVIEW_SYNTHESIS
  - reference: PMID:27475769
    reference_title: 'Neurobiology of addiction: a neurocircuitry analysis.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Drug addiction can be defined as a chronically relapsing disorder, characterised by compulsion to seek and take the drug, loss of control in limiting intake, and emergence of a negative emotional state (eg, dysphoria, anxiety, irritability) when access to the drug is prevented.
    explanation: Supports anxiety as part of the negative emotional state beyond acute withdrawal.
    directness: DIRECT
    quote_role: REVIEW_SYNTHESIS
- category: Constitutional
  name: Withdrawal Tachycardia
  description: Increased heart rate can accompany alcohol withdrawal. This finding is separated from hypertension and sweating rather than using a tachycardia term for the whole autonomic syndrome.
  phenotype_term:
    preferred_term: Tachycardia
    term:
      id: HP:0001649
      label: Tachycardia
    temporality: ACUTE
  evidence:
  - reference: url:https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf
    reference_title: https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Clinical signs include sweating, elevated blood pressure, tachycardia, hyperthermia, and hyperactive reflexes.
    explanation: The guideline explicitly lists sweating, tachycardia and elevated blood pressure among withdrawal signs, supporting the autonomic branch.
- category: Gastrointestinal
  name: Nausea and Vomiting
  description: Gastrointestinal upset during alcohol withdrawal.
  phenotype_term:
    preferred_term: Nausea and vomiting
    term:
      id: HP:0002017
      label: Nausea and vomiting
    temporality: ACUTE
  evidence:
  - reference: url:https://www.aafp.org/pubs/afp/issues/2021/0900/p253.pdf
    reference_title: https://www.aafp.org/pubs/afp/issues/2021/0900/p253.pdf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: leading to tremors, insomnia, nausea and vomiting, hallucinations, anxiety, and agitation.
    explanation: Lists nausea and vomiting among withdrawal manifestations.
    directness: DIRECT
    quote_role: REVIEW_SYNTHESIS
- category: Behavioral
  name: Depression
  description: Depressed mood and independent depressive disorders may coexist with AUD. NESARC-III reports cross-sectional psychiatric associations. The five-year study was ascertained for major depressive disorder (269 patients, 66 with AUD), so it does not estimate depression prevalence among all people with AUD or prove alcohol caused depression.
  phenotype_term:
    preferred_term: Depression
    term:
      id: HP:0000716
      label: Depression
  evidence:
  - reference: PMID:32217228
    reference_title: 'Comorbid alcohol use disorder in psychiatric MDD patients: A five-year prospective study.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Patients with AUD spent more time depressed and had more suicide attempts during follow-up.
    explanation: Five-year prospective psychiatric cohort links comorbid AUD to a worse depressive course.
    directness: DIRECT
    quote_role: PRIMARY_RESULT
  - reference: PMID:26039070
    reference_title: 'Epidemiology of DSM-5 Alcohol Use Disorder: Results From the National Epidemiologic Survey on Alcohol and Related Conditions III.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Significant associations were found between 12-month and lifetime AUD and other substance use disorders, major depressive and bipolar I disorders, and antisocial and borderline personality disorders across all levels of AUD severity, with odds ratios ranging from 1.2 (95% CI, 1.08-1.36) to 6.4 (95% CI, 5.76-7.22).
    explanation: Nationally representative data quantify the association between AUD and major depressive disorder.
    directness: DIRECT
    quote_role: PRIMARY_RESULT
- category: Neurologic
  name: Impaired Executive Functioning
  description: Difficulties with inhibitory control and decision-making are described in addiction models and some patients with AUD. Their extent, timing and contribution to drinking vary; cross-sectional brain anatomy alone does not establish cognitive dysfunction or its causal direction.
  phenotype_term:
    preferred_term: Impaired executive functioning
    term:
      id: HP:0033051
      label: Impaired executive functioning
  evidence:
  - reference: PMID:27475769
    reference_title: 'Neurobiology of addiction: a neurocircuitry analysis.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The craving and deficits in executive function in the so-called preoccupation/anticipation stage involve the dysregulation of key afferent projections from the prefrontal cortex and insula, including glutamate, to the basal ganglia and extended amygdala.
    explanation: Identifies executive dysfunction as a defined domain of the addiction cycle.
    directness: DIRECT
    quote_role: REVIEW_SYNTHESIS
- category: Neurologic
  name: Memory Impairment
  description: Memory impairment can be a complication of thiamine deficiency and Korsakoff syndrome in people with sustained heavy alcohol use. It is not a necessary feature of AUD.
  phenotype_term:
    preferred_term: Memory impairment
    term:
      id: HP:0002354
      label: Memory impairment
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK436003/
    reference_title: 'Alcohol Use Disorder: Screening, Evaluation, and Management - StatPearls - NCBI Bookshelf'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Chronic alcohol use leading to thiamine deficiency can result in Korsakoff syndrome marked by antero- and retrograde amnesia.
    explanation: The clinical synthesis links thiamine-related Korsakoff syndrome to anterograde and retrograde memory impairment; this is a complication in a subset of patients.
- category: Neurologic
  name: Ataxia
  description: Ataxia may occur in the setting of alcohol-associated thiamine deficiency and Wernicke encephalopathy; assess nutritional and other neurologic causes rather than attributing every gait problem to AUD.
  phenotype_term:
    preferred_term: Ataxia
    term:
      id: HP:0001251
      label: Ataxia
  evidence:
  - reference: url:https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf
    reference_title: https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Patients with thiamine deficiency often present with signs and symptoms such as confusion, abnormal gaze patterns or nystagmus, ataxia, and possibly delirium.
    explanation: The guideline lists ataxia among manifestations of thiamine deficiency, supporting the nutritional complication without making it a general AUD finding.
- category: Neurologic
  name: Peripheral Neuropathy
  description: Peripheral neuropathy may complicate chronic alcohol exposure, with contributions from direct toxicity and nutritional problems varying by patient. The cited clinical chapter describes small-fiber involvement and a stocking-glove distribution.
  phenotype_term:
    preferred_term: Peripheral neuropathy
    term:
      id: HP:0009830
      label: Peripheral neuropathy
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK436003/
    reference_title: 'Alcohol Use Disorder: Screening, Evaluation, and Management - StatPearls - NCBI Bookshelf'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Alcohol can also cause peripheral neuropathy of small fibers
    explanation: The quoted clinical observation supports alcohol-associated small-fiber neuropathy, without implying every neuropathy in an AUD patient has that cause.
- category: Gastrointestinal
  name: Hepatic Steatosis
  description: Hepatic fat accumulation is an early alcohol-associated liver lesion. Progression to hepatitis or cirrhosis occurs in a subset; this is an exposure complication rather than an AUD diagnostic criterion.
  phenotype_term:
    preferred_term: Hepatic steatosis
    term:
      id: HP:0001397
      label: Hepatic steatosis
  evidence:
  - reference: PMID:31536239
    reference_title: Alcohol-Associated Liver Disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Alcoholic Fatty Liver or Steatosis - At this stage, fat accumulates in the liver parenchyma.
    explanation: The clinical review describes hepatic fat accumulation as alcohol-associated steatosis; the detailed metabolic pathway is curated separately.
- category: Gastrointestinal
  name: Cirrhosis
  description: Cirrhosis can develop as an alcohol-associated liver complication in a subset of people with sustained heavy drinking. Its occurrence depends on exposure and host factors and is not part of the AUD diagnostic criteria.
  phenotype_term:
    preferred_term: Cirrhosis
    term:
      id: HP:0001394
      label: Cirrhosis
  evidence:
  - reference: PMID:31536239
    reference_title: Alcohol-Associated Liver Disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: The alcoholic liver disease covers a spectrum of disorders beginning from the fatty liver, progressing at times to alcoholic hepatitis and culminating in alcoholic cirrhosis
    explanation: The clinical synthesis describes progression to cirrhosis within alcohol-associated liver disease; progression is conditional, not inevitable.
- category: Cardiovascular
  name: Dilated Cardiomyopathy
  description: Alcoholic cardiomyopathy from sustained heavy alcohol exposure.
  phenotype_term:
    preferred_term: Dilated cardiomyopathy
    term:
      id: HP:0001644
      label: Dilated cardiomyopathy
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK436003/
    reference_title: 'Alcohol Use Disorder: Screening, Evaluation, and Management - StatPearls - NCBI Bookshelf'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Chronic alcohol use can accelerate coronary artery disease and cause dilated cardiomyopathy.
    explanation: The source recognizes dilated cardiomyopathy as a possible consequence of chronic alcohol use, rather than a defining AUD phenotype.
- category: Gastrointestinal
  name: Pancreatitis
  description: Acute and chronic pancreatitis precipitated by heavy alcohol use.
  phenotype_term:
    preferred_term: Pancreatitis
    term:
      id: HP:0001733
      label: Pancreatitis
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK436003/
    reference_title: 'Alcohol Use Disorder: Screening, Evaluation, and Management - StatPearls - NCBI Bookshelf'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: In addition to liver disease, alcohol can cause both acute and chronic pancreatitis as well as exocrine insufficiency.
    explanation: The clinical synthesis supports both acute and chronic pancreatitis as alcohol-related complications; it does not assign a population frequency.
- category: Constitutional
  name: Facial Flushing After Alcohol Intake
  description: Acetaldehyde-associated flushing, particularly with reduced ALDH2 activity, is an exposure response associated with lower dependence risk rather than a required or typical feature of established AUD. Protection is probabilistic; ADH1B-associated protection should not be equated with a universal systemic flush reaction.
  phenotype_term:
    preferred_term: Facial flushing after alcohol intake
    term:
      id: HP:0001033
      label: Facial flushing after alcohol intake
  evidence:
  - reference: PMID:17718394
    reference_title: 'The genetics of alcohol metabolism: role of alcohol dehydrogenase and aldehyde dehydrogenase variants.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Acetaldehyde is a toxic substance whose accumulation leads to a highly aversive reaction that includes facial flushing, nausea, and rapid heart beat (i.e., tachycardia).
    explanation: Ties the flushing phenotype to acetaldehyde accumulation.
    directness: DIRECT
    quote_role: REVIEW_SYNTHESIS
- name: Withdrawal Hyperhidrosis
  category: Constitutional
  phenotype_term:
    preferred_term: Hyperhidrosis
    term:
      id: HP:0000975
      label: Hyperhidrosis
  description: Sweating is an autonomic sign of alcohol withdrawal.
  evidence:
  - reference: url:https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf
    reference_title: https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Clinical signs include sweating, elevated blood pressure, tachycardia, hyperthermia, and hyperactive reflexes.
    explanation: The guideline explicitly lists sweating, tachycardia and elevated blood pressure among withdrawal signs, supporting the autonomic branch.
- name: Withdrawal Hypertension
  category: Cardiovascular
  phenotype_term:
    preferred_term: Hypertension
    term:
      id: HP:0000822
      label: Hypertension
  description: Elevated blood pressure may accompany withdrawal; persistent hypertension requires assessment beyond the withdrawal episode.
  evidence:
  - reference: url:https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf
    reference_title: https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Clinical signs include sweating, elevated blood pressure, tachycardia, hyperthermia, and hyperactive reflexes.
    explanation: The guideline explicitly lists sweating, tachycardia and elevated blood pressure among withdrawal signs, supporting the autonomic branch.
genetic:
- name: ADH1B
  gene_term:
    preferred_term: ADH1B
    term:
      id: hgnc:250
      label: ADH1B
  relationship_type: PROTECTIVE
  association: ADH1B*2 (rs1229984, His48) encodes an enzyme with increased ethanol-oxidizing activity and is associated with lower alcohol-dependence risk. Purified-enzyme turnover is not a fixed multiplier of whole-body clearance. The proposed aversive mechanism and magnitude of protection vary with genetic and environmental context.
  evidence:
  - reference: PMID:17718394
    reference_title: 'The genetics of alcohol metabolism: role of alcohol dehydrogenase and aldehyde dehydrogenase variants.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The ADH1B*2 allele, which is associated with particularly rapid ethanol oxidation, has shown protective effects against alcohol dependence in a variety of populations.
    explanation: The review summarizes human protective associations for ADH1B*2, separate from the purified-enzyme kinetics cited in the mechanism branch.
    directness: DIRECT
    quote_role: REVIEW_SYNTHESIS
  - reference: PMID:16822169
    reference_title: Meta-analyses of ALDH2 and ADH1B with alcohol dependence in Asians.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Recruitment strategy and gender moderated the effect of ADH1B*2.
    explanation: Meta-analysis of ADH1B in Asian populations establishes the association and identifies moderators of its magnitude.
    directness: DIRECT
    quote_role: PRIMARY_RESULT
- name: ALDH2
  gene_term:
    preferred_term: ALDH2
    term:
      id: hgnc:404
      label: ALDH2
  relationship_type: PROTECTIVE
  association: ALDH2*2 (rs671, Glu504Lys in the precursor protein) markedly reduces mitochondrial acetaldehyde clearance, promoting acetaldehyde accumulation and aversive symptoms after alcohol. It is strongly associated with lower dependence risk, especially in studied East Asian populations; neither ancestry nor genotype makes AUD impossible.
  evidence:
  - reference: PMID:17718394
    reference_title: 'The genetics of alcohol metabolism: role of alcohol dehydrogenase and aldehyde dehydrogenase variants.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The presence of even a single ALDH2*2 allele is strongly protective against alcohol dependence.
    explanation: The reviewed human genetic observations support a protective ALDH2*2 association; allele-specific enzyme dysfunction is represented separately.
    directness: DIRECT
    quote_role: REVIEW_SYNTHESIS
  - reference: PMID:16822169
    reference_title: Meta-analyses of ALDH2 and ADH1B with alcohol dependence in Asians.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Diagnostic criteria, recruitment strategy, and Japanese ethnicity moderated the effect of ALDH2*2.
    explanation: Meta-analysis quantifying the ALDH2*2 protective effect in Asian populations and its moderators.
    directness: DIRECT
    quote_role: PRIMARY_RESULT
- name: GABRA2
  gene_term:
    preferred_term: GABRA2
    term:
      id: hgnc:4076
      label: GABRA2
  relationship_type: SUSCEPTIBILITY
  association: A study of multiply affected families associated GABRA2 haplotypes with alcohol dependence and beta-frequency EEG oscillations. Lack of coding differences motivated a regulatory hypothesis, but this study did not establish altered receptor expression, currents or causal mediation of dependence.
  evidence:
  - reference: PMID:15024690
    reference_title: Variations in GABRA2, encoding the alpha 2 subunit of the GABA(A) receptor, are associated with alcohol dependence and with brain oscillations.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Thirty-one SNPs in GABRA2, but only 1 of the 20 SNPs in the flanking genes, showed significant association with alcoholism.
    explanation: Family-based association study localizing the signal specifically to GABRA2 within the chromosome 4 p GABA-A receptor gene cluster.
    directness: DIRECT
    quote_role: PRIMARY_RESULT
  - reference: PMID:15024690
    reference_title: Variations in GABRA2, encoding the alpha 2 subunit of the GABA(A) receptor, are associated with alcohol dependence and with brain oscillations.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: No coding differences were found between the high-risk and low-risk haplotypes, suggesting that the effect is mediated through gene regulation.
    explanation: The authors propose regulation from absence of coding differences; this is not a direct expression assay.
    directness: INDIRECT
    quote_role: PRIMARY_RESULT
- name: OPRM1
  gene_term:
    preferred_term: OPRM1
    term:
      id: hgnc:8156
      label: OPRM1
  relationship_type: SUSCEPTIBILITY
  association: The 2023 PAU GWAS confirms association of rs1799971 (A118G), distinct from the question of genotype-guided naltrexone treatment. Earlier pharmacogenetic proposals remain unvalidated for routine selection; the cited 147-person head-to-head trial found no genotype treatment interaction, which does not exclude every possible subgroup effect.
  evidence:
  - reference: PMID:38062264
    reference_title: Multi-ancestry study of the genetics of problematic alcohol use in over 1 million individuals.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: This is the first GWAS to confirm the association of rs1799971 in PAU; the risk allele is the same as for OUD.
    explanation: The PAU GWAS confirms the OPRM1 association, which is distinct from predicting an individual's response to naltrexone.
  - reference: PMID:22909206
    reference_title: Influence of the OPRM1 A118G polymorphism on alcohol-induced euphoria, risk for alcoholism and the clinical efficacy of naltrexone.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Although screening of patients in a clinical setting remains premature, results suggest the A118G substitution may influence one etiological pathway to alcoholism, for which naltrexone pharmacotherapy is more effective.
    explanation: Review supporting a modifier role while explicitly cautioning that clinical screening is premature.
    directness: DIRECT
    quote_role: REVIEW_SYNTHESIS
  - reference: PMID:38706338
    reference_title: 'Topiramate Versus Naltrexone for Alcohol Use Disorder: A Genotype-Stratified Double-Blind Randomized Controlled Trial.'
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: Neither rs2832407 nor rs1799971 had effects on topiramate and naltrexone treatments, respectively.
    explanation: This trial did not detect the proposed pharmacogenetic effects; it does not prove absence of effects in every population or treatment context.
    directness: DIRECT
    quote_role: PRIMARY_RESULT
- name: GCKR
  gene_term:
    preferred_term: GCKR
    term:
      id: hgnc:4196
      label: GCKR
  relationship_type: SUSCEPTIBILITY
  association: Statistical fine mapping in the European-ancestry PAU analysis nominated GCKR rs1260326 in a singleton credible set with posterior inclusion probability of at least 99%. This supports locus association and candidate-variant prioritization, without demonstrating a biochemical causal route to AUD.
  evidence:
  - reference: PMID:38062264
    reference_title: Multi-ancestry study of the genetics of problematic alcohol use in over 1 million individuals.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: 'Among the 85 regions, there were 5 credible sets that include only a single variant with PIP ≥99% (presumably indicating successful identification of specific causal variants): rs1260326 in GCKR, rs472140 and rs1229984 in ADH1B, rs2699453 (intergenic) and rs2098112 (intergenic).'
    explanation: Fine-mapping concentrates posterior probability on a GCKR variant, providing statistical prioritization rather than an experimentally proven brain mechanism.
- name: KLB
  gene_term:
    preferred_term: KLB
    term:
      id: hgnc:15527
      label: KLB
  relationship_type: SUSCEPTIBILITY
  association: KLB was among genes computationally prioritized by PAU association, genetically predicted brain expression and chromatin interaction annotations in the European-ancestry analysis. This study did not experimentally establish a KLB–FGF21 liver–brain pathway or direction of clinical effect.
  evidence:
  - reference: PMID:38062264
    reference_title: Multi-ancestry study of the genetics of problematic alcohol use in over 1 million individuals.
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: Among the 130 genes associated with PAU in EUR, 62 were also implicated by TWAS findings either by single brain tissue (S-PrediXcan) or across brain tissues (S-MultiXcan), 82 have evidence of brain chromatin interaction and 51 have evidence from both TWAS and Hi-C annotations including ADH1B, DRD2, KLB and others (Supplementary Table 9).
    explanation: The KLB nomination combines European-ancestry transcriptome and chromatin annotations; it does not demonstrate endocrine mediation in patients.
environmental:
- name: Alcohol consumption
  description: Alcohol intake supplies the exposure required for alcohol-related reinforcement and complications. Repeated heavy exposure can produce receptor adaptations in experimental paradigms, but exposure does not inevitably lead to AUD. Effects depend on dose, timing and host context.
  effect: Exposure required for alcohol-related effects; insufficient alone to establish AUD
  exposure_term:
    preferred_term: exposure to alcohol consumption
    term:
      id: ECTO:0001082
      label: exposure to alcohol consumption
  chemicals:
  - ethanol
  influences_mechanisms:
  - target: Repeated Ethanol Exposure
    environmental_effect: TRIGGERS
    causal_link_type: DIRECT
    description: Repeated consumption supplies ethanol exposure.
  - target: GABA-A Receptor Redistribution
    environmental_effect: TRIGGERS
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Repeated exposure promotes longer-lasting receptor remodeling in reviewed rodent protocols; the intermediate steps and human time course are unresolved.
    evidence:
    - reference: PMID:28931433
      reference_title: Role of GABA(A) receptors in alcohol use disorders suggested by chronic intermittent ethanol (CIE) rodent model.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      quote_role: REVIEW_SYNTHESIS
      directness: INDIRECT
      snippet: After chronic intermittent ethanol (CIE) treatment the same changes are observed but they become persistent after 30 or more doses, lasting for at least 120 days in the rat
      explanation: The reviewed rat regimen produces persistent receptor changes after repeated doses; the observation should not be generalized to all human drinking histories.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK436003/
    reference_title: 'Alcohol Use Disorder: Screening, Evaluation, and Management - StatPearls - NCBI Bookshelf'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: The fact that not every person who drinks alcohol will necessarily experience a loss of control and progression to addiction indicates that AUD is not solely driven by exposure to alcohol.
    explanation: The clinical synthesis distinguishes alcohol exposure from the additional susceptibility required for impaired control and addiction.
treatments:
- name: Oral Naltrexone
  description: First-line opioid-receptor antagonist for adults with moderate to severe AUD seeking abstinence or reduced drinking. Oral 50 mg/day has the strongest formulation-specific trial evidence for reducing return to heavy drinking; pair with appropriate psychosocial support and patient-defined goals. Current opioid use and acute hepatitis or liver failure are important contraindications; assess future opioid analgesia needs.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: naltrexone
      term:
        id: CHEBI:7465
        label: naltrexone
  notes: Nausea, vomiting and dizziness can occur. Comparative trials did not establish universal superiority over acamprosate. Benefits concern consumption endpoints; evidence for mortality and other long-term health outcomes is limited.
  evidence:
  - reference: PMID:37844924
    reference_title: Canadian guideline for the clinical management of high-risk drinking and alcohol use disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: Adult patients with moderate to severe AUD should be offered naltrexone or acamprosate as a first-line pharmacotherapy to support achievement of patient-identified treatment goals.
    explanation: The guideline recommends naltrexone or acamprosate as first-line options for adults with moderate to severe AUD, selected with the patient's goals.
  - reference: url:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10630900/
    reference_title: 'Pharmacotherapy for Alcohol Use Disorder: A Systematic Review and Meta-Analysis - PMC'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Compared with placebo, oral naltrexone (50 mg/d) was associated with lower rates of return to heavy drinking, with a number needed to treat of 11 (95% CI, 5-41).
    explanation: Pooled placebo-controlled human trials support oral 50-mg naltrexone for reducing return to heavy drinking; the estimate is specific to that outcome and formulation.
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK436003/
    reference_title: 'Alcohol Use Disorder: Screening, Evaluation, and Management - StatPearls - NCBI Bookshelf'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Naltrexone is a mu-opioid receptor antagonist that can be taken daily by mouth or as a monthly intramuscular injection administered in the clinic setting.
    explanation: The clinical pharmacology summary identifies mu-opioid antagonism and the two delivery schedules; efficacy estimates still require formulation-specific trial evidence.
  target_mechanisms:
  - target: Alcohol-Evoked Endogenous Opioid Signaling
    treatment_effect: INHIBITS
    description: Opioid-receptor antagonism blocks signaling rather than proving that suppression of a particular endogenous peptide or dopamine relay mediates clinical response.
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK436003/
      reference_title: 'Alcohol Use Disorder: Screening, Evaluation, and Management - StatPearls - NCBI Bookshelf'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      directness: INDIRECT
      snippet: Naltrexone is a mu-opioid receptor antagonist that can be taken daily by mouth or as a monthly intramuscular injection administered in the clinic setting.
      explanation: The clinical pharmacology summary identifies mu-opioid antagonism and the two delivery schedules; efficacy estimates still require formulation-specific trial evidence.
- name: Extended-Release Injectable Naltrexone
  description: Monthly intramuscular opioid antagonist that reduces the need for daily pill taking but still requires return visits and treatment engagement. Injectable-specific efficacy evidence is smaller and outcome-dependent; it should not be assumed superior to oral medication or to eliminate adherence problems. The same opioid-related precautions apply.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: naltrexone
      term:
        id: CHEBI:7465
        label: naltrexone
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK436003/
    reference_title: 'Alcohol Use Disorder: Screening, Evaluation, and Management - StatPearls - NCBI Bookshelf'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Naltrexone is a mu-opioid receptor antagonist that can be taken daily by mouth or as a monthly intramuscular injection administered in the clinic setting.
    explanation: The clinical pharmacology summary identifies mu-opioid antagonism and the two delivery schedules; efficacy estimates still require formulation-specific trial evidence.
  - reference: url:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10630900/
    reference_title: 'Pharmacotherapy for Alcohol Use Disorder: A Systematic Review and Meta-Analysis - PMC'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Fewer data were available for the 100-mg/d oral and injectable doses.
    explanation: The systematic review reports a smaller evidence base for injectable and higher-dose oral naltrexone, limiting transfer of the 50-mg oral estimate.
  notes: The review describes US approval for patients who have established abstinence. Formulation-specific data are more limited than for oral 50 mg/day; outcome differences and uncertainty should guide interpretation.
  target_mechanisms:
  - target: Alcohol-Evoked Endogenous Opioid Signaling
    treatment_effect: INHIBITS
    description: The formulation delivers sustained opioid-receptor antagonism; the human PET experiment does not itself test this treatment.
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK436003/
      reference_title: 'Alcohol Use Disorder: Screening, Evaluation, and Management - StatPearls - NCBI Bookshelf'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      directness: INDIRECT
      snippet: Naltrexone is a mu-opioid receptor antagonist that can be taken daily by mouth or as a monthly intramuscular injection administered in the clinic setting.
      explanation: The clinical pharmacology summary identifies mu-opioid antagonism and the two delivery schedules; efficacy estimates still require formulation-specific trial evidence.
- name: Acamprosate
  description: First-line medication for an abstinence goal, generally started after withdrawal and abstinence. Trial evidence supports reduced return to any drinking, without a clear benefit for preventing return to heavy drinking. The molecular mechanism remains uncertain; it is not curated as a proven reversal of a particular glutamate abnormality. Severe renal impairment is a contraindication and moderate impairment requires dose adjustment.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: acamprosate
      term:
        id: CHEBI:51041
        label: acamprosate
  evidence:
  - reference: PMID:37844924
    reference_title: Canadian guideline for the clinical management of high-risk drinking and alcohol use disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: Adult patients with moderate to severe AUD should be offered naltrexone or acamprosate as a first-line pharmacotherapy to support achievement of patient-identified treatment goals.
    explanation: The guideline recommends naltrexone or acamprosate as first-line options for adults with moderate to severe AUD, selected with the patient's goals.
  - reference: url:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10630900/
    reference_title: 'Pharmacotherapy for Alcohol Use Disorder: A Systematic Review and Meta-Analysis - PMC'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Acamprosate was not associated with benefit for return to heavy drinking (moderate strength of evidence).
    explanation: The pooled human evidence does not show benefit for return to heavy drinking, distinguishing that endpoint from acamprosate's abstinence-related benefits.
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK436003/
    reference_title: 'Alcohol Use Disorder: Screening, Evaluation, and Management - StatPearls - NCBI Bookshelf'
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: '[Acamprosate:] mechanism of action is unknown but likely modulates the GABAergic system.'
    explanation: The clinical chapter explicitly attributes the uncertain mechanism to acamprosate; it does not establish reversal of a specific glutamate abnormality.
- name: Disulfiram
  description: An aldehyde-dehydrogenase inhibitor used as an aversive deterrent in selected patients pursuing abstinence. Informed agreement and support or observed dosing are important; drinking while taking it can cause a hazardous reaction. Supervised/open-label studies and blinded efficacy studies have different limitations. Avoid overstating comparative benefit from network estimates.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: disulfiram
      term:
        id: CHEBI:4659
        label: disulfiram
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK436003/
    reference_title: 'Alcohol Use Disorder: Screening, Evaluation, and Management - StatPearls - NCBI Bookshelf'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Mechanistically, the medication inhibits the enzyme acetaldehyde dehydrogenase, which causes an accumulation of acetaldehyde.
    explanation: The pharmacology account identifies aldehyde dehydrogenase inhibition as the route by which disulfiram promotes acetaldehyde accumulation.
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK436003/
    reference_title: 'Alcohol Use Disorder: Screening, Evaluation, and Management - StatPearls - NCBI Bookshelf'
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: Treatment with disulfiram is best suited to those with a support person who can help administer or observe the patient taking the medication.
    explanation: The clinical guidance emphasizes observed administration and support, reflecting the importance of adherence for disulfiram use.
  - reference: url:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10630900/
    reference_title: 'Pharmacotherapy for Alcohol Use Disorder: A Systematic Review and Meta-Analysis - PMC'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: relatively limited evidence exists to support the efficacy of disulfiram compared with placebo for preventing return to any drinking or other alcohol consumption outcomes.
    explanation: The review finds limited placebo-controlled evidence for disulfiram consumption outcomes, qualifying its place among available treatments.
  notes: Consider cardiac and hepatic contraindications and liver monitoring. It is not an anti-craving medication and requires informed patient agreement.
  target_mechanisms:
  - target: Acetaldehyde Accumulation
    treatment_effect: ACTIVATES
    description: Inhibiting aldehyde clearance causes acetaldehyde accumulation if alcohol is consumed; this intended deterrent also creates reaction risk.
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK436003/
      reference_title: 'Alcohol Use Disorder: Screening, Evaluation, and Management - StatPearls - NCBI Bookshelf'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      directness: INDIRECT
      snippet: Mechanistically, the medication inhibits the enzyme acetaldehyde dehydrogenase, which causes an accumulation of acetaldehyde.
      explanation: The pharmacology account identifies aldehyde dehydrogenase inhibition as the route by which disulfiram promotes acetaldehyde accumulation.
- name: Topiramate
  description: An off-label alternative when first-line medication is ineffective, contraindicated or not preferred. The Canadian guideline gives a strong recommendation with moderate-certainty evidence; systematic review supports reduced consumption endpoints. Cognitive slowing, language difficulties, paresthesias and other adverse effects require consideration. A 147-person 12-week comparison with naltrexone did not establish formal equivalence or superiority on its primary heavy-drinking outcome.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: topiramate
      term:
        id: CHEBI:63631
        label: topiramate
  evidence:
  - reference: PMID:37844924
    reference_title: Canadian guideline for the clinical management of high-risk drinking and alcohol use disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: Adult patients with moderate to severe AUD who do not benefit from, have contraindications to, or express a preference for an alternate to first-line medications can be offered topiramate or gabapentin.
    explanation: The guideline places topiramate and gabapentin after first-line options are unsuitable or not preferred, rather than making them universal initial treatment.
  - reference: url:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10630900/
    reference_title: 'Pharmacotherapy for Alcohol Use Disorder: A Systematic Review and Meta-Analysis - PMC'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: topiramate was associated with adverse effects that included cognitive dysfunction, dizziness, numbness and/or tingling, and taste abnormalities.
    explanation: Pooled trial adverse-event findings support counseling about topiramate's cognitive, sensory and other tolerability effects.
  - reference: PMID:38706338
    reference_title: 'Topiramate Versus Naltrexone for Alcohol Use Disorder: A Genotype-Stratified Double-Blind Randomized Controlled Trial.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: For the number of heavy drinking days per week, there was a near-significant time-by-treatment interaction. For the number of standard drinks per drinking day per week, there was a significant time-by-treatment interaction, which favored topiramate.
    explanation: The primary heavy-drinking-day comparison did not reach significance; the secondary drinks-per-drinking-day result favored topiramate. Neither result establishes formal equivalence.
- name: Gabapentin
  description: An off-label alternative for ongoing AUD care when first-line agents are unsuitable, with a conditional recommendation and low-certainty evidence in the Canadian guideline. Sedation, dizziness, renal function and concurrent opioids or other depressants matter. Use for ongoing AUD and use in selected mild withdrawal are separate indications; it does not replace monitored treatment for high-risk withdrawal.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: gabapentin
      term:
        id: CHEBI:42797
        label: gabapentin
  target_mechanisms:
  - target: Withdrawal-Associated Negative Affect
    treatment_effect: INHIBITS
    description: >-
      In ethanol-dependent rats, gabapentin acts on central amygdala GABAergic
      transmission and reverses the anxiety-like state of abstinence. Its
      molecular mechanism in AUD is otherwise unsettled.
    evidence:
    - reference: PMID:18509038
      reference_title: Cellular and behavioral interactions of gabapentin with alcohol dependence.
      supports: SUPPORT
      directness: INDIRECT
      quote_role: PRIMARY_RESULT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        Systemic gabapentin reduced ethanol intake in dependent, but not in
        nondependent, rats and reversed the anxiogenic-like effects of ethanol
        abstinence using an acute dependence model.
      explanation: >-
        The effect is selective for the dependent state and reverses the
        abstinence-related negative affect this node describes. Indirect because
        it is a rat model.
  evidence:
  - reference: PMID:37844924
    reference_title: Canadian guideline for the clinical management of high-risk drinking and alcohol use disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: Adult patients with moderate to severe AUD who do not benefit from, have contraindications to, or express a preference for an alternate to first-line medications can be offered topiramate or gabapentin.
    explanation: The guideline places topiramate and gabapentin after first-line options are unsuitable or not preferred, rather than making them universal initial treatment.
  - reference: url:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10630900/
    reference_title: 'Pharmacotherapy for Alcohol Use Disorder: A Systematic Review and Meta-Analysis - PMC'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Studies of baclofen and gabapentin had low strength of evidence for benefit in at least 1 outcome.
    explanation: The review grades gabapentin's outcome evidence as low strength, limiting certainty about its benefits.
- name: Baclofen
  description: A GABA-B agonist studied as an off-label option. The conventional systematic review found low-certainty evidence for preventing return to any drinking because results were inconsistent and imprecise; network ranking alone does not establish first-line status or broad safety. Sedation and tolerability require attention. ASAM finds insufficient evidence for treating alcohol withdrawal with baclofen.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: baclofen
      term:
        id: CHEBI:2972
        label: baclofen
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10630900/
    reference_title: 'Pharmacotherapy for Alcohol Use Disorder: A Systematic Review and Meta-Analysis - PMC'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Because of imprecision of the effect estimate and inconsistency of results, baclofen data were graded as having low strength of evidence.
    explanation: Imprecision and inconsistent human trial results explain the low-strength assessment of baclofen for ongoing AUD care.
  - reference: url:https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf
    reference_title: https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: There is insufficient evidence to support the use of baclofen for the treatment of alcohol withdrawal.
    explanation: The withdrawal guideline finds insufficient supporting evidence for baclofen in acute withdrawal, a different indication from ongoing AUD treatment.
- name: Benzodiazepine Withdrawal Management
  description: First-line medication for moderate to severe alcohol withdrawal and prevention or treatment of withdrawal seizures and delirium, with monitoring for oversedation and respiratory depression. Symptom-triggered protocols require reliable assessment; fixed or front-loading approaches may be appropriate. Agent selection and dosing depend on liver function, comorbidity and setting. This is a short-course withdrawal treatment, not ongoing AUD pharmacotherapy.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: benzodiazepine
      term:
        id: NCIT:C1012
        label: Benzodiazepine
  evidence:
  - reference: url:https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf
    reference_title: https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: Benzodiazepines are first-line treatment because of their well-documented effectiveness in reducing the signs and symptoms of withdrawal including the incidence of seizure and delirium.
    explanation: The guideline's synthesis of clinical treatment evidence supports benzodiazepines for withdrawal symptoms and prevention of seizures and delirium.
  - reference: PMID:37844924
    reference_title: Canadian guideline for the clinical management of high-risk drinking and alcohol use disorder.
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: Benzodiazepines should not be prescribed as ongoing treatment for AUD
    explanation: The guideline separates short withdrawal treatment from ongoing prescribing for AUD and advises against the latter.
  target_mechanisms:
  - target: Withdrawal-Associated CNS Hyperexcitability
    treatment_effect: INHIBITS
    description: Enhancing inhibitory signaling controls withdrawal and reduces severe complications; ongoing relapse prevention requires additional care.
    evidence:
    - reference: url:https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf
      reference_title: https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      directness: INDIRECT
      snippet: Benzodiazepines are first-line treatment because of their well-documented effectiveness in reducing the signs and symptoms of withdrawal including the incidence of seizure and delirium.
      explanation: The guideline's synthesis of clinical treatment evidence supports benzodiazepines for withdrawal symptoms and prevention of seizures and delirium.
- name: Thiamine Repletion
  description: Give thiamine promptly to prevent or treat deficiency-related neurologic injury. ASAM favors parenteral administration for poor nutrition, malabsorption or severe withdrawal complications. Prevention and treatment of suspected Wernicke encephalopathy require appropriate clinical protocols. Glucose can be given before, after or concurrently; urgent glucose should not be delayed while awaiting thiamine.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Supportive Care
    term:
      id: NCIT:C15747
      label: Supportive Care
    therapeutic_agent:
    - preferred_term: thiamine
      term:
        id: CHEBI:18385
        label: thiamine(1+)
  evidence:
  - reference: url:https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf
    reference_title: https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: Thiamine should be provided to prevent Wernicke encephalopathy.
    explanation: The guideline recommends replacement to prevent thiamine-related encephalopathy in the withdrawal-care setting.
  - reference: url:https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf
    reference_title: https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: it is important that glucose delivery not be delayed in patients who are nutritionally compromised.
    explanation: The recommendation explicitly prioritizes timely glucose delivery when needed, correcting a rigid thiamine-before-glucose sequence.
  - reference: url:https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf
    reference_title: https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: these could be provided in any order or concurrently in order to not delay treatment.
    explanation: The guideline permits concurrent administration or either order, supporting prompt treatment of both nutritional risks.
  target_mechanisms:
  - target: Thiamine Deficiency
    treatment_effect: INHIBITS
    description: Replenishes a deficient vitamin to prevent or treat its complications; it does not directly treat reinforcement or craving.
    evidence:
    - reference: url:https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf
      reference_title: https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf
      supports: SUPPORT
      evidence_source: OTHER
      quote_role: REVIEW_SYNTHESIS
      snippet: Thiamine should be provided to prevent Wernicke encephalopathy.
      explanation: The guideline recommends replacement to prevent thiamine-related encephalopathy in the withdrawal-care setting.
- name: Cognitive Behavioral Therapy
  description: Structured therapy addresses coping, drinking-related cognitions and relapse prevention. The cited 30-trial meta-analysis included alcohol and other drug disorders; effects were larger against minimal care than against active treatments, with early benefits against nonspecific controls less clear at later follow-up. Lack of a significant difference from another active therapy is not formal equivalence.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: Cognitive Behavior Therapy
    term:
      id: NCIT:C64345
      label: Cognitive Behavior Therapy
  evidence:
  - reference: PMID:31599606
    reference_title: 'A meta-analysis of cognitive-behavioral therapy for alcohol or other drug use disorders: Treatment efficacy by contrast condition.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: The current meta-analysis shows that CBT is more effective than a no treatment, minimal treatment, or nonspecific control.
    explanation: The human trial meta-analysis favors CBT over minimal or nonspecific care, rather than demonstrating superiority over every active therapy.
  - reference: PMID:31599606
    reference_title: 'A meta-analysis of cognitive-behavioral therapy for alcohol or other drug use disorders: Treatment efficacy by contrast condition.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: CBT effects in contrast to a specific therapy were consistently nonsignificant across outcomes and follow-up time points.
    explanation: The same analysis found no consistent advantage over specific active therapies, qualifying the comparative claim for CBT.
- name: Alcoholics Anonymous and Twelve-Step Facilitation
  description: Offer peer support and, when consistent with patient preferences, structured professional facilitation of AA participation. In the 2020 Cochrane review, manualized TSF improved continuous abstinence at 12 months compared with other clinical approaches (two studies, 1936 participants; RR 1.21, 95% CI 1.03–1.42). Evidence for drinking intensity and consequences was less certain and generally did not show clear differences. These mostly US, noncoerced studies do not establish equal efficacy of every mutual-help format or an obligation to attend AA.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: Behavioral Counseling
    term:
      id: NCIT:C181743
      label: Behavioral Counseling
  evidence:
  - reference: PMID:32159228
    reference_title: Alcoholics Anonymous and other 12-step programs for alcohol use disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: RCTs comparing manualized AA/TSF to other clinical interventions (e.g. CBT), showed AA/TSF improves rates of continuous abstinence at 12 months (risk ratio (RR) 1.21, 95% confidence interval (CI) 1.03 to 1.42; 2 studies, 1936 participants; high-certainty evidence).
    explanation: The pooled randomized trials support manualized AA/TSF for continuous abstinence at 12 months, with an endpoint- and comparator-specific effect.
  - reference: PMID:32159228
    reference_title: Alcoholics Anonymous and other 12-step programs for alcohol use disorder.
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: If people with AUD are opposed to attending AA, despite the strong evidence for its potential to aid recovery, clinicians might consider linkage to alternative mutual‐help organizations as they may confer benefits at similar levels of engagement.
    explanation: The review recommends alternatives when AA is not acceptable; this is a care preference statement rather than a direct equivalence trial of all mutual-help groups.
  notes: The review found no measured quality-of-life or psychological-well-being outcomes. Proposed coping and social-network mechanisms and temporal mediation analyses do not demonstrate normalization of a specific brain circuit.
- name: Semaglutide (investigational)
  description: GLP-1 receptor agonism remains under investigation for AUD. The 2025 phase 2 trial randomized 48 nontreatment-seeking adults with BMI≥23; paired laboratory self-administration analyses involved 25 participants, while weekly drinking models used the randomized sample. Drinks per calendar day and number of drinking days did not significantly improve; craving and drinks per drinking day were exploratory findings. A separate 26-week trial randomized 108 treatment-seeking adults with moderate/severe AUD and obesity to semaglutide or placebo plus CBT, finding a 13.7-percentage-point adjusted between-group reduction in heavy-drinking days.
  therapeutic_modality: PEPTIDE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: semaglutide
      term:
        id: CHEBI:167574
        label: semaglutide
  notes: These selected phase 2 populations and short-term results do not establish general effectiveness, comparative superiority to first-line AUD drugs or a human reward-circuit mechanism. The 2026 result is curated from the available abstract; 88/108 completed and the primary analysis used intention-to-treat with multiple imputation. Gastrointestinal effects and weight loss are relevant.
  target_mechanisms:
  - target: Mesolimbic Dopamine Reinforcement
    treatment_effect: INHIBITS
    description: >-
      In rodents, GLP-1 receptor agonism reduces alcohol-evoked dopamine release
      in the nucleus accumbens. Whether this mediates the reduction in heavy
      drinking seen in human trials has not been tested.
    evidence:
    - reference: PMID:37295046
      reference_title: Semaglutide reduces alcohol intake and relapse-like drinking in male and female rats.
      supports: SUPPORT
      directness: INDIRECT
      quote_role: PRIMARY_RESULT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        semaglutide attenuated the ability of alcohol to cause hyperlocomotion
        and to elevate dopamine in NAc in male mice
      explanation: >-
        Mouse microdialysis shows semaglutide blunts the alcohol-evoked
        accumbens dopamine rise that this node describes. Indirect because the
        measurement is in mice, not in people with AUD.
  evidence:
  - reference: PMID:39937469
    reference_title: 'Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: Semaglutide treatment did not affect average drinks per calendar day or number of drinking days, but significantly reduced drinks per drinking day
    explanation: The small randomized trial found an effect on drinks per drinking day but not all consumption endpoints, limiting a blanket efficacy claim.
  - reference: PMID:42070571
    reference_title: 'Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Semaglutide was associated with a reduction in heavy drinking days (-41·1 percentage points from baseline, 95% CI -48·7 to -33·5) compared with placebo (-26·4, -34·1 to -18·6; estimated treatment difference -13·7 percentage points, -22·0 to -5·4; p=0·0015), and had substantial effects on multiple secondary alcohol-related and somatic outcomes.
    explanation: A 26-week randomized placebo-controlled trial quantifies the reduction in heavy drinking days in patients with AUD and comorbid obesity.
    directness: DIRECT
    quote_role: PRIMARY_RESULT
- name: Shared-Decision Ongoing AUD Care
  description: Develop a plan around patient goals, which may include abstinence or reduced drinking, and integrate medical, psychiatric and social needs. Offer ongoing care after withdrawal and adjust treatment as circumstances change.
  therapeutic_modality: BEHAVIORAL
  evidence:
  - reference: PMID:37844924
    reference_title: Canadian guideline for the clinical management of high-risk drinking and alcohol use disorder.
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: All patients who complete withdrawal management should be offered ongoing AUD care.
    explanation: The guideline distinguishes completing withdrawal from treating AUD and recommends continued care after stabilization.
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK436003/
    reference_title: 'Alcohol Use Disorder: Screening, Evaluation, and Management - StatPearls - NCBI Bookshelf'
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: Goal setting may include abstinence or reduction in drinking.
    explanation: The clinical guidance permits abstinence or reduction goals, supporting individualized shared decisions.
- name: Brief Motivational Intervention
  description: Offer a brief collaborative intervention after high-risk screening or diagnosis to discuss concerns, goals and treatment options. Its evidence in unhealthy drinking should not be mistaken for adequate stand-alone treatment of every severe AUD presentation.
  therapeutic_modality: BEHAVIORAL
  evidence:
  - reference: PMID:37844924
    reference_title: Canadian guideline for the clinical management of high-risk drinking and alcohol use disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: All patients who screen positive for high-risk alcohol use should be offered brief intervention
    explanation: The guideline recommends brief intervention after a positive high-risk screen; screening positivity alone is not a diagnosis of AUD.
- name: Specialist Psychosocial and Family Support
  description: Offer access to structured psychosocial treatment, including family-based approaches where appropriate and acceptable to the patient. Support social needs and referrals alongside medication rather than making medication access depend on participation in a single therapy format.
  therapeutic_modality: BEHAVIORAL
  evidence:
  - reference: PMID:37844924
    reference_title: Canadian guideline for the clinical management of high-risk drinking and alcohol use disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: Adult and youth patients with mild to severe AUD should be offered information about and referrals to specialist-led psychosocial treatment interventions in the community
    explanation: The recommendation supports referral to structured psychosocial care across youth and adult AUD populations.
- name: Monitored Withdrawal and Level-of-Care Selection
  description: Assess prior complicated withdrawal, current symptoms, medical/psychiatric illness and home support. Ambulatory care is for appropriately selected patients with reassessment; severe or complicated withdrawal requires an adequately monitored setting. Withdrawal management should connect directly to ongoing AUD care.
  therapeutic_modality: OTHER
  evidence:
  - reference: url:https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf
    reference_title: https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: Most withdrawal severity scales reflect current signs and symptoms and should not be used alone to determine level of care.
    explanation: A current symptom score is not a complete risk or placement assessment, supporting the additional clinical factors described here.
  - reference: url:https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf
    reference_title: https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: should be provided close nursing observation and supportive care, which often necessitates admission to an intensive or critical care unit.
    explanation: The recommendation links withdrawal delirium to close observation and often critical care, rather than routine unsupervised management.
- name: Selected Nonbenzodiazepine Withdrawal Options
  description: Gabapentin or carbamazepine can be considered for selected mild withdrawal at low risk of complications. Phenobarbital is an alternative or adjunct for experienced clinicians with appropriate monitoring; parenteral use requires highly supervised care because of oversedation and respiratory risk.
  therapeutic_modality: SMALL_MOLECULE
  evidence:
  - reference: url:https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf
    reference_title: https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: Phenobarbital can be used for some patients in inpatient settings; however, it should only be used by clinicians experienced with its use given its narrow therapeutic window and side effects.
    explanation: The guideline restricts phenobarbital use to suitably experienced clinicians and settings because of its therapeutic window and adverse effects.
- name: Adjunct Control of Withdrawal Autonomic Symptoms
  description: Alpha-2 agonists or beta-blockers may be added for persistent autonomic symptoms in selected patients. They do not prevent or treat withdrawal seizures or delirium and must not replace effective withdrawal therapy.
  therapeutic_modality: SMALL_MOLECULE
  evidence:
  - reference: url:https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf
    reference_title: https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: Alpha2-adrenergic agonists (AA2 s) such as clonidine and dexmedetomidine can be used as an adjunct to benzodiazepine therapy to control autonomic hyperactivity and anxiety when these signs are not controlled by benzodiazepines alone. They should not be used alone to prevent or treat withdrawal-related seizures or delirium.
    explanation: ASAM recommends alpha-2 agonists for adjunctive control of autonomic hyperactivity and anxiety, while explicitly excluding their use alone for seizures or delirium.
  - reference: url:https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf
    reference_title: https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: Beta-adrenergic antagonists (beta-blockers) can be used as an adjunct to benzodiazepines in select patients for control of persistent hypertension or tachycardia
    explanation: ASAM supports adjunct beta-blockers for persistent hypertension or tachycardia after benzodiazepines; this symptom control does not treat the underlying withdrawal process.
  target_mechanisms:
  - target: Withdrawal-Associated Autonomic Activation
    treatment_effect: INHIBITS
    description: Adjunctive symptom control does not correct the entire withdrawal process or protect against its severe neurologic complications.
    evidence:
    - reference: url:https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf
      reference_title: https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf
      supports: SUPPORT
      evidence_source: OTHER
      quote_role: REVIEW_SYNTHESIS
      snippet: Alpha2-adrenergic agonists (AA2 s) such as clonidine and dexmedetomidine can be used as an adjunct to benzodiazepine therapy to control autonomic hyperactivity and anxiety when these signs are not controlled by benzodiazepines alone. They should not be used alone to prevent or treat withdrawal-related seizures or delirium.
      explanation: ASAM recommends alpha-2 agonists for adjunctive control of autonomic hyperactivity and anxiety, while explicitly excluding their use alone for seizures or delirium.
    - reference: url:https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf
      reference_title: https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf
      supports: SUPPORT
      evidence_source: OTHER
      quote_role: REVIEW_SYNTHESIS
      snippet: Beta-adrenergic antagonists (beta-blockers) can be used as an adjunct to benzodiazepines in select patients for control of persistent hypertension or tachycardia
      explanation: ASAM supports adjunct beta-blockers for persistent hypertension or tachycardia after benzodiazepines; this symptom control does not treat the underlying withdrawal process.
biochemical:
- name: Phosphatidylethanol (PEth)
  presence: Elevated with recent heavy alcohol consumption
  specificity: Alcohol-exposure biomarker; diagnostic performance varies by threshold, exposure definition and population
  notes: A blood phospholipid formed in the presence of ethanol can support assessment of recent exposure over a period of weeks. The review included 12 heterogeneous studies of unhealthy drinking, not a uniform DSM AUD diagnostic cohort. Formation and elimination vary; concentrations do not uniquely recover a person’s daily intake or establish AUD. Reported study cutoffs ranged from 4.2 to 250 ng/mL.
  evidence:
  - reference: PMID:37569551
    reference_title: 'Phosphatidylethanol (PEth) in Blood as a Marker of Unhealthy Alcohol Use: A Systematic Review with Novel Molecular Insights.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: In recent years, phosphatidylethanol (PEth) in blood has emerged as a marker of unhealthy alcohol use.
    explanation: Systematic review establishes PEth as a biomarker of unhealthy alcohol use.
    directness: DIRECT
    quote_role: REVIEW_SYNTHESIS
  - reference: PMID:37569551
    reference_title: 'Phosphatidylethanol (PEth) in Blood as a Marker of Unhealthy Alcohol Use: A Systematic Review with Novel Molecular Insights.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: PEth interpretative cut-offs varied greatly among the included records, ranging from 4.2 ng/mL to 250 ng/mL, with sensitivity and specificity in the ranges of 58-100% and 64-100%, respectively.
    explanation: Quantifies the wide variation in reported cut-offs and diagnostic accuracy, which limits how prescriptively the marker can be used.
    directness: DIRECT
    quote_role: REVIEW_SYNTHESIS
- name: Gamma-Glutamyltransferase (GGT)
  presence: Elevated with sustained heavy alcohol consumption
  specificity: Low-moderate; individually insensitive and also elevated by non-alcoholic liver disease, obesity, and enzyme-inducing drugs
  notes: Indirect and nonspecific exposure-associated liver marker. In a selected study of 165 heavy drinkers versus moderate-drinker/abstainer references, sensitivity was 58% for GGT and 90% for the combined GGT-CDT index. In a different 1022-men/583-women study, GGT sensitivities were 30% and 23%; these are study-specific performance estimates, not universal accuracy. It does not diagnose AUD.
  evidence:
  - reference: PMID:16799164
    reference_title: Comparison of the combined marker GGT-CDT and the conventional laboratory markers of alcohol abuse in heavy drinkers, moderate drinkers and abstainers.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The sensitivity of GGT-CDT (90%) in correctly classifying heavy drinkers exceeded that of CDT (63%), GGT (58%), mean corpuscular volume (MCV) (45%), aspartate aminotransferase (AST) (47%), and alanine aminotransferase (ALT) (50%), being also essentially similar for alcoholics with (93%) or without (88%) liver disease.
    explanation: Quantifies the sensitivity of each conventional marker and of the combined GGT-CDT index in a cohort of 165 heavy drinkers against moderate-drinker and abstainer references.
    directness: DIRECT
    quote_role: PRIMARY_RESULT
  - reference: PMID:16799164
    reference_title: Comparison of the combined marker GGT-CDT and the conventional laboratory markers of alcohol abuse in heavy drinkers, moderate drinkers and abstainers.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: GGT-CDT improves the sensitivity of detecting excessive ethanol consumption as compared with the traditional markers of ethanol consumption.
    explanation: States the study's conclusion that the combined GGT-CDT index outperforms the individual conventional markers.
    directness: DIRECT
    quote_role: PRIMARY_RESULT
  - reference: PMID:17767129
    reference_title: The Early Detection of Alcohol Consumption (EDAC) test shows better performance than gamma-glutamyltransferase (GGT) to detect heavy drinking in a large population of males and females.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: The results showed that 30% of males reporting heavy drinking tested GGT positive compared to 65% who tested EDAC positive.
    explanation: The male heavy-drinking subgroup had low GGT positivity at the study threshold, demonstrating that a normal result cannot exclude substantial consumption.
  - reference: PMID:17767129
    reference_title: The Early Detection of Alcohol Consumption (EDAC) test shows better performance than gamma-glutamyltransferase (GGT) to detect heavy drinking in a large population of males and females.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: For females, the results showed that 23% of those reporting heavy drinking tested GGT positive compared to 34% who tested EDAC positive.
    explanation: The female heavy-drinking subgroup also had limited GGT positivity, reinforcing the threshold- and population-specific nature of this marker.
  - reference: PMID:36983134
    reference_title: 'Old and New Biomarkers of Alcohol Abuse: Narrative Review.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: "[In the GGT row:] The specificity is reduced by obesity, diabetes, non-alcoholic liver diseases, pancreatitis, hyperlipidemia, heart failure, massive injuries, drugs (barbiturates, antiepileptic drugs, anticoagulants), kidney diseases."
    explanation: The GGT row of the review table names non-alcoholic causes of elevation, supporting limited specificity independently of the sensitivity cohorts.
  reference_ranges:
  - loinc_term:
      id: LOINC:2324-2
      label: Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma
    upper_bound: 85.0
    unit: U/L
    population: males; screening cutoff for heavy drinking
    notes: Study-specific assay decision threshold for classifying alcohol exposure, not a universal clinical reference interval or diagnostic cutoff for AUD.
    evidence:
    - reference: PMID:17767129
      reference_title: The Early Detection of Alcohol Consumption (EDAC) test shows better performance than gamma-glutamyltransferase (GGT) to detect heavy drinking in a large population of males and females.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: The GGT test used a cutoff of 85 U/L for males and 65 U/L for females.
      explanation: Source of the sex-specific GGT cutoffs used to screen for heavy drinking.
      directness: DIRECT
      quote_role: PRIMARY_RESULT
  - loinc_term:
      id: LOINC:2324-2
      label: Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma
    upper_bound: 65.0
    unit: U/L
    population: females; screening cutoff for heavy drinking
    notes: Study-specific assay decision threshold for classifying alcohol exposure, not a universal clinical reference interval or diagnostic cutoff for AUD.
    evidence:
    - reference: PMID:17767129
      reference_title: The Early Detection of Alcohol Consumption (EDAC) test shows better performance than gamma-glutamyltransferase (GGT) to detect heavy drinking in a large population of males and females.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: The GGT test used a cutoff of 85 U/L for males and 65 U/L for females.
      explanation: Source of the sex-specific GGT cutoffs used to screen for heavy drinking.
      directness: DIRECT
      quote_role: PRIMARY_RESULT
- name: Carbohydrate-Deficient Transferrin (CDT)
  presence: Elevated with sustained heavy alcohol consumption
  specificity: Moderate-high; the most specific of the conventional indirect markers, though affected by pregnancy, severe liver disease, and rare transferrin variants
  notes: Indirect marker of sustained alcohol exposure, not a diagnostic test for AUD. The 63% sensitivity and 90% combined GGT-CDT sensitivity came from the selected 165-heavy-drinker study. A separate forensic cohort of 562 people assessed percentage disialotransferrin with a 1.7% HPLC decision cutoff against hair EtG; neither the cutoff nor agreement proves complete abstinence.
  evidence:
  - reference: PMID:16799164
    reference_title: Comparison of the combined marker GGT-CDT and the conventional laboratory markers of alcohol abuse in heavy drinkers, moderate drinkers and abstainers.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The sensitivity of GGT-CDT (90%) in correctly classifying heavy drinkers exceeded that of CDT (63%), GGT (58%), mean corpuscular volume (MCV) (45%), aspartate aminotransferase (AST) (47%), and alanine aminotransferase (ALT) (50%), being also essentially similar for alcoholics with (93%) or without (88%) liver disease.
    explanation: The heavy-drinker cohort supplies the CDT sensitivity and combined GGT-CDT estimate, separate from the HPLC decision threshold below.
    directness: DIRECT
    quote_role: PRIMARY_RESULT
  - reference: PMID:36983134
    reference_title: 'Old and New Biomarkers of Alcohol Abuse: Narrative Review.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: '[In the CDT row:] The most specific marker available today. The specificity is reduced by rare genetic defects in transferrin. ... Certain diseases reduce the specificity of the CDT test. These include non-alcoholic liver diseases (primary biliary cirrhosis, chronic active inflammation, -HCV, hepatocellular carcinoma), senile dementia, depression, pregnancy'
    explanation: The review describes relatively high CDT specificity among conventional markers, while identifying rare transferrin variants and several non-alcoholic conditions that reduce it.
  reference_ranges:
  - loinc_term:
      id: LOINC:48495-6
      label: Transferrin.carbohydrate deficient/Transferrin.total in Serum or Plasma
    upper_bound: 1.7
    unit: '%'
    population: adults; %disialotransferrin by HPLC candidate reference method
    notes: Study-specific assay decision threshold for classifying alcohol exposure, not a universal clinical reference interval or diagnostic cutoff for AUD.
    evidence:
    - reference: PMID:25698630
      reference_title: A comparison between serum carbohydrate-deficient transferrin and hair ethyl glucuronide in detecting chronic alcohol consumption in routine.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: 'Serum CDT was measured by the candidate HPLC reference method and expressed as relative amount of disialotransferrin (%DST: cutoff 1.7%).'
      explanation: Source of the % CDT (disialotransferrin) upper-limit cutoff used clinically.
      directness: DIRECT
      quote_role: PRIMARY_RESULT
- name: Mean Corpuscular Volume (MCV)
  presence: Elevated with sustained heavy alcohol consumption (macrocytosis)
  specificity: Low; also elevated by folate/B12 deficiency, liver disease, hypothyroidism, and reticulocytosis independent of alcohol
  notes: Macrocytosis is nonspecific and can accompany sustained alcohol exposure or nutritional and other disease. The 45% sensitivity belongs to a selected 165-heavy-drinker study. The 96/98 fL upper limits came from 845 reference individuals classified as abstainers/moderate drinkers, not validated AUD diagnostic cutoffs.
  evidence:
  - reference: PMID:16799164
    reference_title: Comparison of the combined marker GGT-CDT and the conventional laboratory markers of alcohol abuse in heavy drinkers, moderate drinkers and abstainers.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The sensitivity of GGT-CDT (90%) in correctly classifying heavy drinkers exceeded that of CDT (63%), GGT (58%), mean corpuscular volume (MCV) (45%), aspartate aminotransferase (AST) (47%), and alanine aminotransferase (ALT) (50%), being also essentially similar for alcoholics with (93%) or without (88%) liver disease.
    explanation: Quantifies MCV's individual sensitivity (45%) for classifying heavy drinkers, well below the combined GGT-CDT index.
    directness: DIRECT
    quote_role: PRIMARY_RESULT
  - reference: PMID:36983134
    reference_title: 'Old and New Biomarkers of Alcohol Abuse: Narrative Review.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: The possible false positive increases in MCV include vitamin B12 and folic acid deficiency, hypothyroidism, hemolytic disease with reticulocytosis, non-alcoholic liver disease
    explanation: The review identifies alternative causes of macrocytosis; the heavy-drinker sensitivity estimate alone does not establish this specificity caveat.
  reference_ranges:
  - loinc_term:
      id: LOINC:30428-7
      label: MCV [Entitic mean volume] in Red Blood Cells
    upper_bound: 96.0
    unit: fL
    population: abstainers (NORIP reference data)
    notes: The LOINC code was verified against the NLM clinical-tables LOINC service; LOINC is not covered by the repository's OAK term validation.
    evidence:
    - reference: PMID:16581347
      reference_title: 'Long-term ethanol consumption and macrocytosis: diagnostic and pathogenic implications.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: the upper normal limit for MCV based on the data from moderate drinkers was 98 fl, as compared with 96 fl from abstainers
      explanation: Source of the abstainer upper normal limit for MCV, derived from NORIP reference data.
      directness: DIRECT
      quote_role: PRIMARY_RESULT
  - loinc_term:
      id: LOINC:30428-7
      label: MCV [Entitic mean volume] in Red Blood Cells
    upper_bound: 98.0
    unit: fL
    population: moderate drinkers (NORIP reference data)
    notes: The higher upper limit in moderate drinkers versus abstainers itself reflects a dose-related response of MCV to ethanol intake. The LOINC code was verified against the NLM clinical-tables LOINC service; LOINC is not covered by the repository's OAK term validation.
    evidence:
    - reference: PMID:16581347
      reference_title: 'Long-term ethanol consumption and macrocytosis: diagnostic and pathogenic implications.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: the upper normal limit for MCV based on the data from moderate drinkers was 98 fl, as compared with 96 fl from abstainers
      explanation: Source of the moderate-drinker upper normal limit for MCV, derived from NORIP reference data.
      directness: DIRECT
      quote_role: PRIMARY_RESULT
diagnosis:
- name: DSM-5-TR clinical diagnosis
  description: A problematic pattern causing clinically significant impairment or distress with any two or more of eleven criteria within a year supports diagnosis. Two or three criteria indicate mild, four or five moderate, and six or more severe AUD. Tolerance and withdrawal are optional criteria. Review history, functional impact, other substance use and psychiatric or medical explanations; exposure biomarkers alone do not diagnose AUD.
  evidence:
  - reference: PMID:37844924
    reference_title: Canadian guideline for the clinical management of high-risk drinking and alcohol use disorder.
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: The diagnosis of AUD can be made when a patient has a problematic pattern of alcohol use over a year that leads to clinically significant impairment or distress, involving at least 2 of the 11 DSM-5-TR criteria.
    explanation: The guideline states the DSM-5-TR clinical threshold, supporting the diagnostic construct rather than a molecular cause of addiction.
  - reference: PMID:37844924
    reference_title: Canadian guideline for the clinical management of high-risk drinking and alcohol use disorder.
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: Patients are diagnosed with mild AUD if they have 2–3 criteria; moderate AUD with 4–5 criteria; and severe AUD with 6 or more criteria.
    explanation: The DSM-5-TR severity bands count diagnostic criteria, rather than biological subtypes or withdrawal severity.
- name: ICD-11 alcohol diagnoses
  description: ICD-11 distinguishes alcohol dependence and harmful pattern of use; hazardous use is a separately listed health-risk factor. These categories should not be treated as exact synonyms for the DSM-5-TR severity spectrum.
  evidence:
  - reference: PMID:31194891
    reference_title: 'Alcohol Use Disorders in ICD-11: Past, Present, and Future.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: This review describes and discusses the alcohol diagnoses within this section of ICD-11, including Alcohol Dependence, Harmful Pattern of Use of Alcohol, and entities such as Alcohol Intoxication, Alcohol Withdrawal, and several alcohol-induced mental disorders, and briefly covers Hazardous Alcohol Use, which is listed separately as a health risk factor.
    explanation: Authoritative description of the ICD-11 alcohol diagnostic structure.
    quote_role: REVIEW_SYNTHESIS
- name: AUDIT, AUDIT-C and brief screening
  description: Validated questionnaires identify unhealthy or high-risk drinking and prompt a diagnostic interview. Thresholds depend on the population and screening purpose. AUDIT-C assesses consumption, whereas the AUDIT problems subscale used in PAU genetics is a different measure. Neither is a stand-alone molecular or clinical confirmation of AUD.
  evidence:
  - reference: PMID:37844924
    reference_title: Canadian guideline for the clinical management of high-risk drinking and alcohol use disorder.
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: The AUDIT and AUDIT-C tools were designed to screen for hazardous or harmful alcohol use, using a cut-off score of 8 (for AUDIT) or 3 and 4 for women and men, respectively (for AUDIT-C).
    explanation: The guideline provides screening thresholds for hazardous or harmful use, which require clinical follow-up rather than automatic AUD diagnosis.
  - reference: PMID:37844924
    reference_title: Canadian guideline for the clinical management of high-risk drinking and alcohol use disorder.
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: Adults and youth who screen positive for high-risk drinking should undergo a diagnostic interview for mild, moderate or severe AUD using the DSM-5-TR criteria
    explanation: A positive screen prompts a diagnostic interview, explicitly separating screening from diagnosis.
- name: Withdrawal risk and severity assessment
  description: History of seizures or delirium, current findings, coexisting disease and available support guide the level of care. PAWSS predicts risk in studied medically ill populations; CIWA-Ar measures current withdrawal symptoms and can be confounded by other illness. CIWA-Ar depends on patient report and should not be used to assess delirium.
  evidence:
  - reference: url:https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf
    reference_title: https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: Most withdrawal severity scales reflect current signs and symptoms and should not be used alone to determine level of care.
    explanation: A current symptom score is not a complete risk or placement assessment, supporting the additional clinical factors described here.
  - reference: url:https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf
    reference_title: https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: It is not recommended to use the CIWA-Ar in patients with delirium because it relies on patient-reported symptoms.
    explanation: The guideline excludes CIWA-Ar in delirium because reliable patient-reported symptoms are required.
- name: AUDIT total-score zones
  description: >-
    The full Alcohol Use Disorders Identification Test. Its total score is used
    as a screen at a cut-off of 8 and is graded into the zones suggested by the
    World Health Organization. In alcohol-dependent outpatients, indicators of
    dependence severity increased across those zones.
  notes: >-
    Copyright © 2001 World Health Organization. Used with permission.
    The instrument is bound at its LOINC panel code and the zones at its
    total-score code. The instrument's items are not reproduced in this entry;
    only published thresholds are recorded. This row and the AUDIT-C row below
    carry one instrument each; the screening-pathway row above names both and
    is unchanged. The diagnosis_term is the NCIT term for the AUDIT itself.
  diagnosis_term:
    preferred_term: AUDIT
    term:
      id: NCIT:C188039
      label: Alcohol Use Disorders Identification Test
  measurements:
  - preferred_term: AUDIT
    term:
      id: LOINC:72110-0
      label: Alcohol Use Disorder Identification Test [AUDIT]
  reference_ranges:
  - loinc_term:
      id: LOINC:75624-7
      label: Total score [AUDIT]
    unit: '{score}'
    population: >-
      WHO AUDIT zones as applied in the COMBINE study: alcohol-dependent
      individuals (n = 1335) entering out-patient treatment at eleven academic
      clinical research centers across the United States
    notes: >-
      The COMBINE abstract states the zones as "AUDIT total score = 8-15,
      16-19, 20-40", and reports that "the highest zone, with scores of 20 and
      above, was markedly different with respect to severity". The AUDIT score
      is an integer, so the half-open bands [8, 16), [16, 20) and [20, ) match
      those zones exactly. The band below 8 is not a zone named in that
      abstract; its boundary is the AUDIT screening cut-off of 8 stated in the
      Canadian guideline (PMID:37844924). Because the COMBINE sample had already
      met dependence criteria, the zones there index severity among dependent
      patients rather than screening yield. The severity values follow the
      zones' order; the abstract does not use the words mild, moderate or
      severe.
    evidence:
    - reference: PMID:17156168
      reference_title: "Concurrent validity of the Alcohol Use Disorders Identification Test (AUDIT) and AUDIT zones in defining levels of severity among out-patients with alcohol dependence in the COMBINE study."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: PRIMARY_RESULT
      snippet: "Participants were classified into AUDIT zones (AUDIT total score = 8-15, 16-19, 20-40)"
      explanation: States the three AUDIT total-score zones used to grade severity.
    - reference: PMID:17156168
      reference_title: "Concurrent validity of the Alcohol Use Disorders Identification Test (AUDIT) and AUDIT zones in defining levels of severity among out-patients with alcohol dependence in the COMBINE study."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: PRIMARY_RESULT
      snippet: "Indicators of severity of dependence and alcohol-related problems increased linearly with total score and differed significantly across AUDIT zones."
      explanation: Shows that the zones are ordered by severity of dependence and alcohol-related problems.
    - reference: PMID:37844924
      reference_title: Canadian guideline for the clinical management of high-risk drinking and alcohol use disorder.
      supports: SUPPORT
      evidence_source: OTHER
      quote_role: REVIEW_SYNTHESIS
      snippet: The AUDIT and AUDIT-C tools were designed to screen for hazardous or harmful alcohol use, using a cut-off score of 8 (for AUDIT) or 3 and 4 for women and men, respectively (for AUDIT-C).
      explanation: Gives the AUDIT screening cut-off of 8 that bounds the lowest band.
    interpretation_bands:
    - name: Below the screening cut-off of 8
      upper_bound: 8
      unit: '{score}'
      abnormal_flag: NORMAL
    - name: AUDIT zone 8-15
      lower_bound: 8
      upper_bound: 16
      unit: '{score}'
      abnormal_flag: HIGH
      severity: MILD
    - name: AUDIT zone 16-19
      lower_bound: 16
      upper_bound: 20
      unit: '{score}'
      abnormal_flag: HIGH
      severity: MODERATE
    - name: AUDIT zone 20-40
      lower_bound: 20
      unit: '{score}'
      abnormal_flag: HIGH
      severity: SEVERE
  evidence:
  - reference: PMID:17156168
    reference_title: "Concurrent validity of the Alcohol Use Disorders Identification Test (AUDIT) and AUDIT zones in defining levels of severity among out-patients with alcohol dependence in the COMBINE study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "The AUDIT total score is a brief measure that appears to provide an index of severity of dependence in a sample of alcohol-dependent individuals seeking out-patient treatment"
    explanation: Supports the AUDIT total score as a severity measure in alcohol dependence, beyond its screening role.
- name: AUDIT-C consumption screen
  description: >-
    The consumption questions of the AUDIT, used as a brief screen for alcohol
    misuse. Its primary-care validation study derived sex-specific screening
    thresholds against an interview reference standard. A positive screen
    prompts a diagnostic interview rather than establishing AUD.
  notes: >-
    The instrument is bound at its LOINC panel code and the thresholds at its
    total-score code. Neither code carries a third-party copyright notice in the
    LOINC 2.83 table (the Tuva Project release pinned in
    data/loinc/MANIFEST.yaml). The instrument's items are not reproduced in this
    entry; only published thresholds are recorded. No diagnosis_term is bound:
    NCIT label searches for "AUDIT-C" return only question-level and CDISC
    codelist terms, not a term for the instrument.
  measurements:
  - preferred_term: AUDIT-C
    term:
      id: LOINC:72109-2
      label: Alcohol Use Disorder Identification Test - Consumption [AUDIT-C]
  reference_ranges:
  - loinc_term:
      id: LOINC:75626-2
      label: Total score [AUDIT-C]
    unit: '{score}'
    population: >-
      Men among adult outpatients at an academic family practice clinic,
      1993 to 1994 (392 men in the validation sample)
    notes: >-
      The abstract states the threshold as "> or =4 in men", so 4 is in the
      positive tier. The reference standard was alcohol misuse, defined as a
      DSM-IV alcohol use disorder and/or drinking above recommended limits in
      the past year, not AUD alone.
    evidence:
    - reference: PMID:17451397
      reference_title: AUDIT-C as a brief screen for alcohol misuse in primary care.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: PRIMARY_RESULT
      snippet: "The AUDIT-C screening thresholds that simultaneously maximized sensitivity and specificity were > or =4 in men (sensitivity 0.86, specificity 0.89)"
      explanation: States the AUDIT-C screening threshold for men.
    interpretation_bands:
    - name: Below the threshold for men
      upper_bound: 4
      unit: '{score}'
      abnormal_flag: NORMAL
    - name: At or above the threshold for men (screen positive)
      lower_bound: 4
      unit: '{score}'
      abnormal_flag: HIGH
  - loinc_term:
      id: LOINC:75626-2
      label: Total score [AUDIT-C]
    unit: '{score}'
    population: >-
      Women among adult outpatients at an academic family practice clinic,
      1993 to 1994 (927 women in the validation sample)
    notes: >-
      The abstract states the threshold as "> or =3 in women", so 3 is in the
      positive tier. The reference standard was alcohol misuse, defined as a
      DSM-IV alcohol use disorder and/or drinking above recommended limits in
      the past year, not AUD alone.
    evidence:
    - reference: PMID:17451397
      reference_title: AUDIT-C as a brief screen for alcohol misuse in primary care.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: PRIMARY_RESULT
      snippet: "> or =3 in women (sensitivity 0.73, specificity 0.91)"
      explanation: States the AUDIT-C screening threshold for women.
    interpretation_bands:
    - name: Below the threshold for women
      upper_bound: 3
      unit: '{score}'
      abnormal_flag: NORMAL
    - name: At or above the threshold for women (screen positive)
      lower_bound: 3
      unit: '{score}'
      abnormal_flag: HIGH
  evidence:
  - reference: PMID:17451397
    reference_title: AUDIT-C as a brief screen for alcohol misuse in primary care.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "The AUDIT-C was an effective screening test for alcohol misuse in this primary care sample."
    explanation: Supports the AUDIT-C as a validated primary-care screen for alcohol misuse.
clinical_trials:
- name: clinicaltrials:NCT05520775
  phase: PHASE_II
  status: COMPLETED
  description: Completed phase 2 trial randomized 48 nontreatment-seeking adults 21–65 with AUD and BMI≥23. Semaglutide 0.25 mg/week for 4 weeks then 0.5 mg/week for 4 weeks preceded the primary laboratory assessment; week 9 dose escalation followed primary collection. Paired laboratory analyses included 25 participants, so this was not a complete-case 48-person primary outcome. Registered calendar-day drinking was null; other weekly quantity/craving outcomes were exploratory.
  target_phenotypes:
  - preferred_term: Addictive alcohol use
    term:
      id: HP:0030955
      label: Addictive alcohol use
  evidence:
  - reference: PMID:39937469
    reference_title: 'Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Low-dose semaglutide reduced the amount of alcohol consumed during a posttreatment laboratory self-administration task, with evidence of medium to large effect sizes for grams of alcohol consumed
    explanation: Reports the primary laboratory self-administration outcome of this trial.
    directness: DIRECT
    quote_role: PRIMARY_RESULT
  - reference: clinicaltrials:NCT05520775
    reference_title: Human Laboratory Screening of Semaglutide for Alcohol Use Disorder
    supports: SUPPORT
    evidence_source: OTHER
    snippet: This is an early-Phase II human laboratory trial using a randomized, placebo-controlled, dose-ranging design to investigate the effects of semaglutide, a GLP-1 receptor agonist, on alcohol-related outcomes in adults with alcohol use disorder (AUD).
    explanation: The registry summary describes study design; current status was separately checked through the live registry API and efficacy comes from the published report.
  notes: 'Live ClinicalTrials.gov API status checked 2026-09-21: COMPLETED, phase 2. Registry brief-summary caches support study identity; live API supplies current administrative status.'
- name: clinicaltrials:NCT05895643
  phase: PHASE_II
  status: COMPLETED
  description: Completed single-center 26-week phase 2 trial randomized 108 treatment-seeking adults with moderate/severe AUD and obesity (54 per group) to weekly semaglutide up to 2.4 mg or placebo, both with CBT. 88 completed; intention-to-treat primary analysis used multiple imputation. Adjusted heavy-drinking-day difference was −13.7 percentage points, not a relative 70% treatment benefit; long-term/general-population effects remain uncertain.
  target_phenotypes:
  - preferred_term: Problematic alcohol consumption
    term:
      id: HP:5200329
      label: Problematic alcohol consumption
  evidence:
  - reference: PMID:42070571
    reference_title: 'Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Semaglutide showed robust therapeutic effects in treatment-seeking participants with obesity and alcohol use disorder and this trial supports previous preclinical and clinical findings suggesting GLP-1 receptor agonists as a potential novel treatment target for alcohol use disorder.
    explanation: States the trial's overall conclusion for its treatment-seeking, comorbid-obesity population.
    directness: DIRECT
    quote_role: PRIMARY_RESULT
  - reference: clinicaltrials:NCT05895643
    reference_title: Does the Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Semaglutide Reduce Alcohol Intake in Patients With Alcohol Use Disorder and Comorbid Obesity?
    supports: SUPPORT
    evidence_source: OTHER
    snippet: The medication will be provided as a supplement to standardised cognitive behavioural therapy.
    explanation: The registry summary describes study design; current status was separately checked through the live registry API and efficacy comes from the published report.
  notes: 'Live ClinicalTrials.gov API status checked 2026-09-21: COMPLETED, phase 2. Registry brief-summary caches support study identity; live API supplies current administrative status.'
animal_models:
- name: Alcohol-preferring P rats
  species: Rattus norvegicus
  genotype: Selectively bred P line
  description: Review of selected rats with voluntary ethanol intake, reinforcement and protocol-dependent binge/deprivation responses. The historical animal criteria are not DSM-5-TR criteria, and neither human age at onset nor all AUD domains are reproduced. Intoxicating concentrations depend on the access paradigm.
  evidence:
  - reference: PMID:24268381
    reference_title: The alcohol-preferring (P) and high-alcohol-drinking (HAD) rats--animal models of alcoholism.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: The P line of rats meets all of the originally proposed criteria for a suitable animal model of alcoholism.
    explanation: The review characterizes the selectively bred P rat as an experimental alcoholism model; model criteria are not equivalent to a human diagnosis.
  - reference: PMID:24268381
    reference_title: The alcohol-preferring (P) and high-alcohol-drinking (HAD) rats--animal models of alcoholism.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: The P line also exhibits excessive binge-like alcohol drinking, attaining blood alcohol concentrations (BACs) of 200 mg% on a daily basis.
    explanation: Reported high blood alcohol levels support the line's binge-like exposure phenotype under the reviewed experimental conditions.
  modeled_mechanisms:
  - target: Repeated Ethanol Exposure
    relationship: MEASURES
    fidelity: MODERATE
    description: Voluntary intake and binge-access endpoints model high alcohol exposure.
    limitations: Selection for intake is not a model of every clinical criterion or an established human causal allele.
    evidence:
    - reference: PMID:24268381
      reference_title: The alcohol-preferring (P) and high-alcohol-drinking (HAD) rats--animal models of alcoholism.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      quote_role: REVIEW_SYNTHESIS
      directness: DIRECT
      snippet: Under 24-h free-choice conditions, the P rat will voluntarily consume 5–8 g/kg/day and produce BACs in the range of 50–200 mg%
      explanation: The review reports voluntary ethanol intake and attained blood alcohol concentrations under a specified free-choice protocol.
    readouts:
    - name: Voluntary ethanol intake
      target: Repeated Ethanol Exposure
      direction: INCREASED
      interpretation: Voluntary intake and binge-access endpoints model high alcohol exposure.
      evidence:
      - reference: PMID:24268381
        reference_title: The alcohol-preferring (P) and high-alcohol-drinking (HAD) rats--animal models of alcoholism.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        quote_role: REVIEW_SYNTHESIS
        directness: DIRECT
        snippet: Under 24-h free-choice conditions, the P rat will voluntarily consume 5–8 g/kg/day and produce BACs in the range of 50–200 mg%
        explanation: The review reports voluntary ethanol intake and attained blood alcohol concentrations under a specified free-choice protocol.
- name: High-alcohol-drinking HAD rat lines
  species: Rattus norvegicus
  genotype: Selectively bred HAD1 and HAD2 lines
  description: The reviewed HAD lines show high intake and deprivation-related responses under specific protocols. The review reports four of six historical animal criteria, with tolerance and withdrawal not examined; the P-line completeness statement must not be transferred to HAD.
  evidence:
  - reference: PMID:24268381
    reference_title: The alcohol-preferring (P) and high-alcohol-drinking (HAD) rats--animal models of alcoholism.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: The HAD1,2 rats satisfy several of the criteria for an animal model of alcoholism, e.g., these rats will voluntarily consume ethanol in a free-choice situation to produce BACs between 50 and 200 mg%.
    explanation: Voluntary drinking in HAD lines produces substantial blood alcohol concentrations, supporting an exposure model without implying all human AUD features.
  modeled_mechanisms:
  - target: Repeated Ethanol Exposure
    relationship: MEASURES
    fidelity: MODERATE
    description: Selected high-drinking lines model voluntary exposure.
    limitations: Unexamined tolerance and withdrawal domains limit correspondence to physiological dependence.
    evidence:
    - reference: PMID:24268381
      reference_title: The alcohol-preferring (P) and high-alcohol-drinking (HAD) rats--animal models of alcoholism.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      quote_role: REVIEW_SYNTHESIS
      directness: DIRECT
      snippet: The HAD1,2 rats satisfy several of the criteria for an animal model of alcoholism, e.g., these rats will voluntarily consume ethanol in a free-choice situation to produce BACs between 50 and 200 mg%.
      explanation: Voluntary drinking in HAD lines produces substantial blood alcohol concentrations, supporting an exposure model without implying all human AUD features.
    readouts:
    - name: Voluntary ethanol intake
      target: Repeated Ethanol Exposure
      direction: INCREASED
      interpretation: Selected high-drinking lines model voluntary exposure.
      evidence:
      - reference: PMID:24268381
        reference_title: The alcohol-preferring (P) and high-alcohol-drinking (HAD) rats--animal models of alcoholism.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        quote_role: REVIEW_SYNTHESIS
        directness: DIRECT
        snippet: The HAD1,2 rats satisfy several of the criteria for an animal model of alcoholism, e.g., these rats will voluntarily consume ethanol in a free-choice situation to produce BACs between 50 and 200 mg%.
        explanation: Voluntary drinking in HAD lines produces substantial blood alcohol concentrations, supporting an exposure model without implying all human AUD features.
- name: HAP/LAP preference QTL mouse cross
  species: Mus musculus
  genotype: High Alcohol Preferring (HAP1, HAP2) and Low Alcohol Preferring (LAP1, LAP2) lines
  description: The 2006 study used a 432-animal F2 cross derived from selectively bred, outbred high- and low-preference lines. A chromosome 9 QTL had stronger support in females. Historical wording about the only extant lines is not a current inventory claim, and mouse preference mapping does not identify a human causal AUD gene.
  evidence:
  - reference: PMID:16482403
    reference_title: Identification of QTLs influencing alcohol preference in the High Alcohol Preferring (HAP) and Low Alcohol Preferring (LAP) mouse lines.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: The High- and Low-Alcohol Preferring (HAP1/LAP1 and HAP2/LAP2) mouse lines were developed by selective breeding for differences in alcohol preference.
    explanation: Selective breeding establishes genetically divergent preference lines for QTL analysis, rather than a single-gene model of human addiction.
  modeled_mechanisms:
  - target: Repeated Ethanol Exposure
    relationship: MEASURES
    fidelity: MODERATE
    description: Alcohol preference varied in a segregating HAP1 × LAP1 F2 cross and was linked to a chromosome 9 QTL; no single increase relative to a control is asserted.
    limitations: Preference is not equivalent to clinical compulsivity, withdrawal or DSM diagnosis.
    evidence:
    - reference: PMID:16482403
      reference_title: Identification of QTLs influencing alcohol preference in the High Alcohol Preferring (HAP) and Low Alcohol Preferring (LAP) mouse lines.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      quote_role: PRIMARY_RESULT
      directness: DIRECT
      snippet: In Study 2, a genome-wide screen was performed in a sample of 432 HAP1xLAP1 F2 animals and a QTL on chromosome 9 (LOD=5.04) was found which met criteria for genome wide significance (p<0.001). ... This study provides additional evidence and confirmation that specific regions on chromosomes 9 and perhaps 2 are important for alcohol preference.
      explanation: The study maps alcohol-preference variation in the F2 cross; it does not report a uniformly increased phenotype in that cross.
    readouts:
    - name: Alcohol preference
      target: Repeated Ethanol Exposure
      interpretation: Alcohol preference varied in a segregating HAP1 × LAP1 F2 cross and was linked to a chromosome 9 QTL; no single increase relative to a control is asserted.
      evidence:
      - reference: PMID:16482403
        reference_title: Identification of QTLs influencing alcohol preference in the High Alcohol Preferring (HAP) and Low Alcohol Preferring (LAP) mouse lines.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        quote_role: PRIMARY_RESULT
        directness: DIRECT
        snippet: In Study 2, a genome-wide screen was performed in a sample of 432 HAP1xLAP1 F2 animals and a QTL on chromosome 9 (LOD=5.04) was found which met criteria for genome wide significance (p<0.001). ... This study provides additional evidence and confirmation that specific regions on chromosomes 9 and perhaps 2 are important for alcohol preference.
        explanation: The study maps alcohol-preference variation in the F2 cross; it does not report a uniformly increased phenotype in that cross.
- name: HDID selected-line aversion and reward assays
  species: Mus musculus
  genotype: High Drinking in the Dark (HDID-1, HDID-2) selected lines, from an HS/Npt heterogeneous stock
  description: Two selected replicates were compared with concurrent heterogeneous-stock controls. Conditioned taste aversion was attenuated at a moderate 2 g/kg ethanol dose but not at 4 g/kg; details varied by replicate and analysis. Conditioned place preference at the tested 2 g/kg dose did not differ. This genetic co-occurrence does not prove reduced aversion mediates every animal’s intake or absence of all reward differences.
  evidence:
  - reference: PMID:23910826
    reference_title: Rewarding and aversive effects of ethanol in High Drinking in the Dark selectively bred mice.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: These results indicate that high blood alcohol levels after drinking in the HDID mice is genetically related to attenuated aversion to alcohol, while sensitivity to alcohol reward is not altered in these mice.
    explanation: Selected HDID mice show reduced conditioned aversion without increased reward sensitivity, separating those candidate contributors to high blood alcohol levels.
  - reference: PMID:23910826
    reference_title: Rewarding and aversive effects of ethanol in High Drinking in the Dark selectively bred mice.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: HDID and HS mice showed comparable development of alcohol-induced conditioned place preference.
    explanation: Comparable conditioned place preference constrains the interpretation that HDID selection simply increased alcohol reward.
  modeled_mechanisms:
  - target: Repeated Ethanol Exposure
    relationship: MEASURES
    fidelity: MODERATE
    description: Blood ethanol concentrations after a four-hour drinking-in-the-dark test increased in both selected replicate lines relative to the founding generation; aversion and reward were assessed in separate experiments.
    limitations: Separate animals and dose-specific conditioning endpoints do not resolve a universal reward mechanism.
    evidence:
    - reference: PMID:24219304
      reference_title: Progress in a replicated selection for elevated blood ethanol concentrations in HDID mice.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      quote_role: PRIMARY_RESULT
      directness: DIRECT
      snippet: High Drinking in the Dark (HDID-1) mice have been bred for 27 selected generations (S27) for elevated blood ethanol concentrations (BECs) after a 4-h period of access to 20% ethanol. A second replicate line (HDID-2) was started later from the same founder population and is currently in S20. ... the lines have shown 4-5 fold increases in BEC since S0
      explanation: Both HDID replicate lines showed increased blood ethanol concentrations across selection generations; this is a drinking measurement, separate from the conditioning assays.
    readouts:
    - name: Blood alcohol after limited-access drinking
      target: Repeated Ethanol Exposure
      direction: INCREASED
      interpretation: Blood ethanol concentrations after a four-hour drinking-in-the-dark test increased in both selected replicate lines relative to the founding generation; aversion and reward were assessed in separate experiments.
      evidence:
      - reference: PMID:24219304
        reference_title: Progress in a replicated selection for elevated blood ethanol concentrations in HDID mice.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        quote_role: PRIMARY_RESULT
        directness: DIRECT
        snippet: High Drinking in the Dark (HDID-1) mice have been bred for 27 selected generations (S27) for elevated blood ethanol concentrations (BECs) after a 4-h period of access to 20% ethanol. A second replicate line (HDID-2) was started later from the same founder population and is currently in S20. ... the lines have shown 4-5 fold increases in BEC since S0
        explanation: Both HDID replicate lines showed increased blood ethanol concentrations across selection generations; this is a drinking measurement, separate from the conditioning assays.
- name: P-rat seeking-taking and outcome-devaluation paradigm
  species: Rattus norvegicus
  genotype: Male alcohol-preferring rats
  description: After intermittent two-bottle pre-exposure and seeking-taking training, devaluation-resistant seeking predicted punishment resistance and quinine-adulterated drinking. Similar earlier preference/intake did not account for all later differences. Available evidence here is the abstract; the study does not directly demonstrate a dorsal-striatal dopamine measurement in its reported experiments.
  evidence:
  - reference: PMID:33955649
    reference_title: Individual differences in the engagement of habitual control over alcohol seeking predict the development of compulsive alcohol seeking and drinking.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: After seeking behaviour was well established, subjects that had developed greater resistance to outcome devaluation (were more habitual) were more likely to show punishment-resistant (compulsive) alcohol seeking.
    explanation: Outcome-devaluation resistance predicted punishment-resistant seeking in selected rats; the association does not prove that habitual control alone causes human compulsive drinking.
  modeled_mechanisms:
  - target: Habitual Alcohol Seeking
    relationship: MEASURES
    fidelity: MODERATE
    description: Behavioral devaluation sensitivity and punishment resistance are related.
    limitations: Predictive association does not by itself prove a particular circuit mediator or a human clinical route.
    evidence:
    - reference: PMID:33955649
      reference_title: Individual differences in the engagement of habitual control over alcohol seeking predict the development of compulsive alcohol seeking and drinking.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      quote_role: PRIMARY_RESULT
      directness: DIRECT
      snippet: After seeking behaviour was well established, subjects that had developed greater resistance to outcome devaluation (were more habitual) were more likely to show punishment-resistant (compulsive) alcohol seeking.
      explanation: Outcome-devaluation resistance predicted punishment-resistant seeking in selected rats; the association does not prove that habitual control alone causes human compulsive drinking.
    readouts:
    - name: Punishment-resistant alcohol seeking
      target: Habitual Alcohol Seeking
      direction: INCREASED
      interpretation: Behavioral devaluation sensitivity and punishment resistance are related.
      evidence:
      - reference: PMID:33955649
        reference_title: Individual differences in the engagement of habitual control over alcohol seeking predict the development of compulsive alcohol seeking and drinking.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        quote_role: PRIMARY_RESULT
        directness: DIRECT
        snippet: After seeking behaviour was well established, subjects that had developed greater resistance to outcome devaluation (were more habitual) were more likely to show punishment-resistant (compulsive) alcohol seeking.
        explanation: Outcome-devaluation resistance predicted punishment-resistant seeking in selected rats; the association does not prove that habitual control alone causes human compulsive drinking.
- name: Chronic intermittent ethanol rodent paradigms
  species: Rattus norvegicus
  genotype: Repeated high-dose intermittent ethanol and withdrawal
  description: The review synthesizes hippocampal receptor redistribution and endpoint-dependent behavioral adaptation. Persistence was measured for 40–120 days in cited rat protocols; the quotation’s lifelong extension is speculation. Sedative and tonic-current tolerance does not imply tolerance to every anxiolytic or anticonvulsant effect. PTZ susceptibility is not a demonstrated spontaneous withdrawal seizure phenotype.
  evidence:
  - reference: PMID:28931433
    reference_title: Role of GABA(A) receptors in alcohol use disorders suggested by chronic intermittent ethanol (CIE) rodent model.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: After chronic intermittent ethanol (CIE) treatment the same changes are observed but they become persistent after 30 or more doses, lasting for at least 120 days in the rat, and probably for life.
    explanation: The reviewed rat regimen documents persistence for at least 120 days; the source's additional lifetime speculation is not treated as an observed endpoint.
  modeled_mechanisms:
  - target: GABA-A Receptor Redistribution
    relationship: MEASURES
    fidelity: MODERATE
    description: Repeated exposure changes receptor composition and localization over measured follow-up.
    limitations: Region-, compartment- and time-specific rodent changes are not a validated irreversible human threshold.
    evidence:
    - reference: PMID:28931433
      reference_title: Role of GABA(A) receptors in alcohol use disorders suggested by chronic intermittent ethanol (CIE) rodent model.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      quote_role: REVIEW_SYNTHESIS
      directness: DIRECT
      snippet: After chronic intermittent ethanol (CIE) treatment the same changes are observed but they become persistent after 30 or more doses, lasting for at least 120 days in the rat, and probably for life.
      explanation: The reviewed rat regimen documents persistence for at least 120 days; the source's additional lifetime speculation is not treated as an observed endpoint.
    readouts:
    - name: GABA-A receptor surface composition
      target: GABA-A Receptor Redistribution
      direction: ALTERED
      interpretation: Repeated exposure changes receptor composition and localization over measured follow-up.
      evidence:
      - reference: PMID:28931433
        reference_title: Role of GABA(A) receptors in alcohol use disorders suggested by chronic intermittent ethanol (CIE) rodent model.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        quote_role: REVIEW_SYNTHESIS
        directness: DIRECT
        snippet: After chronic intermittent ethanol (CIE) treatment the same changes are observed but they become persistent after 30 or more doses, lasting for at least 120 days in the rat, and probably for life.
        explanation: The reviewed rat regimen documents persistence for at least 120 days; the source's additional lifetime speculation is not treated as an observed endpoint.
- name: Regional CRF pharmacology in DID and intermittent-access mice
  species: Mus musculus
  genotype: Male C57BL/6J mice; separate nondependent DID and four-week IAA cohorts
  description: VTA CRF6–33 and astressin 2-B reduced DID intake under selected doses; co-infusion supported additive modulation. CRF6–33 had no significant VTA effect in IAA and no CeA effect in either paradigm. Only IAA increased withdrawal handling-induced convulsions. Water intake and weight were assessed, but comprehensive locomotor or alternative-reward specificity was not established.
  evidence:
  - reference: PMID:26247973
    reference_title: 'Corticotropin Releasing Factor Binding Protein and CRF2 Receptors in the Ventral Tegmental Area: Modulation of Ethanol Binge Drinking in C57BL/6J Mice.'
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: These results indicate that VTA CRF2 receptors modulate ethanol binge drinking, and CRFBP may add to the anti-alcohol effect of A2B.
    explanation: Local VTA pharmacology modifies drinking in the nondependent binge paradigm; the result does not establish the same effect in dependence or in all brain regions.
  - reference: PMID:26247973
    reference_title: 'Corticotropin Releasing Factor Binding Protein and CRF2 Receptors in the Ventral Tegmental Area: Modulation of Ethanol Binge Drinking in C57BL/6J Mice.'
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: Intra-CeA CRF6–33 neither affected ethanol binge drinking nor escalated ethanol consumption in mice given IAA.
    explanation: The central-amygdala null result limits regional generalization of the VTA CRF-binding-protein finding.
  modeled_mechanisms:
  - target: VTA CRF2-Associated Drinking Modulation
    relationship: MEASURES
    fidelity: MODERATE
    description: VTA antagonism reduces intake in the tested DID context.
    limitations: Does not establish dependent negative-reinforcement signaling, central-amygdala benefit, a dopamine intermediary or clinical efficacy.
    evidence:
    - reference: PMID:26247973
      reference_title: 'Corticotropin Releasing Factor Binding Protein and CRF2 Receptors in the Ventral Tegmental Area: Modulation of Ethanol Binge Drinking in C57BL/6J Mice.'
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      quote_role: PRIMARY_RESULT
      directness: DIRECT
      snippet: Here, we present the first evidence that the CRFBP antagonist CRF6–33 and the CRF2 antagonist A2B microinjected into the VTA dose-dependently attenuated alcohol consumption in mice exposed to a binge drinking procedure (DID).
      explanation: Intra-VTA CRF2 antagonism reduced intake in the DID experiment; the separate CeA null result supports the regional limitation only.
    readouts:
    - name: DID ethanol intake
      target: VTA CRF2-Associated Drinking Modulation
      direction: DECREASED
      interpretation: VTA antagonism reduces intake in the tested DID context.
      evidence:
      - reference: PMID:26247973
        reference_title: 'Corticotropin Releasing Factor Binding Protein and CRF2 Receptors in the Ventral Tegmental Area: Modulation of Ethanol Binge Drinking in C57BL/6J Mice.'
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        quote_role: PRIMARY_RESULT
        directness: DIRECT
        snippet: Here, we present the first evidence that the CRFBP antagonist CRF6–33 and the CRF2 antagonist A2B microinjected into the VTA dose-dependently attenuated alcohol consumption in mice exposed to a binge drinking procedure (DID).
        explanation: Intra-VTA CRF2 antagonism reduced intake in the DID experiment; the separate CeA null result supports the regional limitation only.
- name: Chronic ethanol exposure in constitutive Tlr4-knockout mice
  species: Mus musculus
  genotype: Female C57BL/6 wild-type versus constitutive Tlr4-knockout
  description: Starting at 7 weeks, mice received 10% ethanol in drinking water for 5 months; reported intake and blood alcohol concentrations were similar between genotypes. Cortical inflammatory proteins/transcripts, glial immunoreactivity and cleaved caspase-3 were measured. Knockout attenuated outcomes, with residual GFAP response. Neither alcohol seeking, cognition nor neuron-specific death was directly tested.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6634595/
    reference_title: Pivotal Role of TLR4 Receptors in Alcohol-Induced Neuroinflammation and Brain Damage - PMC
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: Our findings support the critical role of the TLR4 response in the neuroinflammation, brain injury, and possibly in the neurodegeneration induced by chronic ethanol intake.
    explanation: The mouse study supports receptor dependence of measured inflammatory and injury markers; neurodegeneration was proposed rather than a measured clinical outcome.
  modeled_mechanisms:
  - target: Cortical Inflammatory Mediator Induction
    relationship: MEASURES
    fidelity: MODERATE
    description: Chronic ethanol increases the measured endpoint in wild-type mice, with attenuation in Tlr4-deficient mice.
    limitations: Whole-body deletion and whole-tissue measurements do not establish cell autonomy or a human AUD phenotype.
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6634595/
      reference_title: Pivotal Role of TLR4 Receptors in Alcohol-Induced Neuroinflammation and Brain Damage - PMC
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      quote_role: PRIMARY_RESULT
      directness: DIRECT
      snippet: chronic ethanol treatment upregulated the levels of TNF-α, IL-1β, and mRNA IL-6 in the cortex homogenates of the WT mice, whereas no changes were observed in the levels of these cytokines in the cerebral cortices of the TLR4-KO mice.
      explanation: The wild-type versus knockout comparison shows TLR4-dependent cortical cytokine changes in mice; homogenate measurements do not identify every producing cell.
    readouts:
    - name: Cortical cytokine protein or transcript abundance
      target: Cortical Inflammatory Mediator Induction
      direction: INCREASED
      interpretation: Chronic ethanol increases the measured endpoint in wild-type mice, with attenuation in Tlr4-deficient mice.
      evidence:
      - reference: url:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6634595/
        reference_title: Pivotal Role of TLR4 Receptors in Alcohol-Induced Neuroinflammation and Brain Damage - PMC
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        quote_role: PRIMARY_RESULT
        directness: DIRECT
        snippet: chronic ethanol treatment upregulated the levels of TNF-α, IL-1β, and mRNA IL-6 in the cortex homogenates of the WT mice, whereas no changes were observed in the levels of these cytokines in the cerebral cortices of the TLR4-KO mice.
        explanation: The wild-type versus knockout comparison shows TLR4-dependent cortical cytokine changes in mice; homogenate measurements do not identify every producing cell.
  - target: Cortical Glial Reactivity
    relationship: MEASURES
    fidelity: MODERATE
    description: Chronic ethanol increases the measured endpoint in wild-type mice, with attenuation in Tlr4-deficient mice.
    limitations: Whole-body deletion and whole-tissue measurements do not establish cell autonomy or a human AUD phenotype.
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6634595/
      reference_title: Pivotal Role of TLR4 Receptors in Alcohol-Induced Neuroinflammation and Brain Damage - PMC
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      quote_role: PRIMARY_RESULT
      directness: DIRECT
      snippet: although GFAP immunoreactivity markedly increased (∼16-fold) in the medial frontal cortex of the WT ethanol-treated mice, the levels of this protein only increased ∼3-fold in the TLR4-KO ethanol-treated animals
      explanation: The GFAP increase is attenuated but persists in knockout mice, supporting a partial TLR4 contribution rather than complete prevention of glial reactivity.
    - reference: url:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6634595/
      reference_title: Pivotal Role of TLR4 Receptors in Alcohol-Induced Neuroinflammation and Brain Damage - PMC
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      quote_role: PRIMARY_RESULT
      directness: DIRECT
      snippet: A significant upregulation of GFAP ... and CD11b ... immunoreactivity was observed in the ethanol-treated WT mice versus the WT nontreated controls
      explanation: The figure legend reports increases in both glial markers, complementing the separate quantitative GFAP comparison.
    readouts:
    - name: Cortical GFAP and CD11b immunoreactivity
      target: Cortical Glial Reactivity
      direction: INCREASED
      interpretation: Chronic ethanol increases the measured endpoint in wild-type mice, with attenuation in Tlr4-deficient mice.
      evidence:
      - reference: url:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6634595/
        reference_title: Pivotal Role of TLR4 Receptors in Alcohol-Induced Neuroinflammation and Brain Damage - PMC
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        quote_role: PRIMARY_RESULT
        directness: DIRECT
        snippet: although GFAP immunoreactivity markedly increased (∼16-fold) in the medial frontal cortex of the WT ethanol-treated mice, the levels of this protein only increased ∼3-fold in the TLR4-KO ethanol-treated animals
        explanation: The GFAP increase is attenuated but persists in knockout mice, supporting a partial TLR4 contribution rather than complete prevention of glial reactivity.
      - reference: url:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6634595/
        reference_title: Pivotal Role of TLR4 Receptors in Alcohol-Induced Neuroinflammation and Brain Damage - PMC
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        quote_role: PRIMARY_RESULT
        directness: DIRECT
        snippet: A significant upregulation of GFAP ... and CD11b ... immunoreactivity was observed in the ethanol-treated WT mice versus the WT nontreated controls
        explanation: The figure legend reports increases in both glial markers, complementing the separate quantitative GFAP comparison.
  - target: Cortical Caspase-3 Activation
    relationship: MEASURES
    fidelity: MODERATE
    description: Chronic ethanol increases the measured endpoint in wild-type mice, with attenuation in Tlr4-deficient mice.
    limitations: Whole-body deletion and whole-tissue measurements do not establish cell autonomy or a human AUD phenotype.
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6634595/
      reference_title: Pivotal Role of TLR4 Receptors in Alcohol-Induced Neuroinflammation and Brain Damage - PMC
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      quote_role: PRIMARY_RESULT
      directness: DIRECT
      snippet: the Western blot analysis shows caspase-3 activation as the appearance of the ∼17 kDa caspase-3 cleavage fragment in cerebral cortices of the ethanol-treated WT animals. Conversely, chronic ethanol treatment did not induce caspase-3 activation in the TLR4-KO animals
      explanation: The passage compares ethanol-exposed wild-type and Tlr4-knockout cortices, supporting genotype-dependent caspase-3 activation without identifying a dying cell type.
    readouts:
    - name: Cortical cleaved caspase-3
      target: Cortical Caspase-3 Activation
      direction: INCREASED
      interpretation: Chronic ethanol increases the measured endpoint in wild-type mice, with attenuation in Tlr4-deficient mice.
      evidence:
      - reference: url:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6634595/
        reference_title: Pivotal Role of TLR4 Receptors in Alcohol-Induced Neuroinflammation and Brain Damage - PMC
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        quote_role: PRIMARY_RESULT
        directness: DIRECT
        snippet: the Western blot analysis shows caspase-3 activation as the appearance of the ∼17 kDa caspase-3 cleavage fragment in cerebral cortices of the ethanol-treated WT animals. Conversely, chronic ethanol treatment did not induce caspase-3 activation in the TLR4-KO animals
        explanation: The passage compares ethanol-exposed wild-type and Tlr4-knockout cortices, supporting genotype-dependent caspase-3 activation without identifying a dying cell type.
discussions:
- discussion_id: aud_model_translation
  kind: HUMAN_MODEL_MISMATCH
  prompt: Which experimental receptor and stress-system adaptations causally contribute to clinically defined AUD in humans?
  attaches_to:
  - pathophysiology#GABA-A Receptor Redistribution
  - pathophysiology#CRF-Associated Stress Signaling
  - pathophysiology#Dynorphin–Kappa-Opioid Signaling
  - pathophysiology#TLR4-Dependent Inflammatory Signaling
  rationale: Rodent exposure, preference and drinking-in-the-dark paradigms interrogate distinct endpoints. They do not reproduce every diagnostic feature, and region-, time- and genotype-dependent effects limit a universal mechanistic chain. Human imaging, genetic associations and treatment efficacy cannot by themselves prove mediation through these specific experimental processes.
- discussion_id: aud_habit_system_human_fidelity
  kind: HUMAN_MODEL_MISMATCH
  prompt: Does devaluation-insensitive alcohol seeking causally mediate persistent harmful drinking in humans?
  attaches_to:
  - pathophysiology#Habitual Alcohol Seeking
  rationale: The curated rat study relates behavioral habit measures to later punishment resistance. Its abstract does not itself measure the proposed dorsal-striatal dopamine mechanism, and the correspondence to human diagnostic loss of control requires direct testing.
- discussion_id: aud_heterogeneity_and_comorbidity
  kind: KNOWLEDGE_GAP
  prompt: Which clinical trajectories reflect exposure effects, pre-existing liability or bidirectional comorbidity?
  attaches_to:
  - phenotypes#Depression
  - pathophysiology#Impaired Executive Control
  - pathophysiology#Polygenic Liability
  rationale: Cross-sectional psychiatric associations and MRI differences do not isolate causal direction. The depression study selected people with major depressive disorder, not an unselected AUD population. Genetic PAU combines heterogeneous diagnoses and questionnaire measures; current polygenic scores are not sufficient for individual clinical risk prediction.
  evidence:
  - reference: PMID:38062264
    reference_title: Multi-ancestry study of the genetics of problematic alcohol use in over 1 million individuals.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: We note that the current findings are not sufficient for clinical risk prediction at the individual level, given the limited SNP-based heritability and small proportion of variance explained by PRS.
    explanation: The authors explicitly reject individual clinical risk prediction from the current results, limiting use of the PAU polygenic score.
references:
- reference: PMID:15024690
  title: Variations in GABRA2, encoding the alpha 2 subunit of the GABA(A) receptor, are associated with alcohol dependence and with brain oscillations.
- reference: PMID:16482403
  title: Identification of QTLs influencing alcohol preference in the High Alcohol Preferring (HAP) and Low Alcohol Preferring (LAP) mouse lines.
- reference: PMID:16581347
  title: 'Long-term ethanol consumption and macrocytosis: diagnostic and pathogenic implications.'
- reference: PMID:16799164
  title: Comparison of the combined marker GGT-CDT and the conventional laboratory markers of alcohol abuse in heavy drinkers, moderate drinkers and abstainers.
- reference: PMID:16822169
  title: Meta-analyses of ALDH2 and ADH1B with alcohol dependence in Asians.
- reference: PMID:17718394
  title: 'The genetics of alcohol metabolism: role of alcohol dehydrogenase and aldehyde dehydrogenase variants.'
- reference: PMID:17767129
  title: The Early Detection of Alcohol Consumption (EDAC) test shows better performance than gamma-glutamyltransferase (GGT) to detect heavy drinking in a large population of males and females.
- reference: PMID:22238334
  title: Alcohol consumption induces endogenous opioid release in the human orbitofrontal cortex and nucleus accumbens.
- reference: PMID:22459870
  title: Targeting dynorphin/kappa opioid receptor systems to treat alcohol abuse and dependence.
- reference: PMID:22574861
  title: 'Functional neuroimaging studies of alcohol cue reactivity: a quantitative meta-analysis and systematic review.'
- reference: PMID:22909206
  title: Influence of the OPRM1 A118G polymorphism on alcohol-induced euphoria, risk for alcoholism and the clinical efficacy of naltrexone.
- reference: PMID:23910826
  title: Rewarding and aversive effects of ethanol in High Drinking in the Dark selectively bred mice.
- reference: PMID:24268381
  title: The alcohol-preferring (P) and high-alcohol-drinking (HAD) rats--animal models of alcoholism.
- reference: PMID:25171596
  title: 'The heritability of alcohol use disorders: a meta-analysis of twin and adoption studies.'
- reference: PMID:25307573
  title: Neurochemical mechanisms of alcohol withdrawal.
- reference: PMID:25698630
  title: A comparison between serum carbohydrate-deficient transferrin and hair ethyl glucuronide in detecting chronic alcohol consumption in routine.
- reference: PMID:25954150
  title: Targeting glutamate uptake to treat alcohol use disorders.
- reference: PMID:26039070
  title: 'Epidemiology of DSM-5 Alcohol Use Disorder: Results From the National Epidemiologic Survey on Alcohol and Related Conditions III.'
- reference: PMID:26247973
  title: 'Corticotropin Releasing Factor Binding Protein and CRF2 Receptors in the Ventral Tegmental Area: Modulation of Ethanol Binge Drinking in C57BL/6J Mice.'
- reference: PMID:27475769
  title: 'Neurobiology of addiction: a neurocircuitry analysis.'
- reference: PMID:28931433
  title: Role of GABA(A) receptors in alcohol use disorders suggested by chronic intermittent ethanol (CIE) rodent model.
- reference: PMID:30146330
  title: 'Alcohol use and burden for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.'
- reference: PMID:31194891
  title: 'Alcohol Use Disorders in ICD-11: Past, Present, and Future.'
- reference: PMID:31536239
  title: Alcohol-Associated Liver Disease.
- reference: PMID:31599606
  title: 'A meta-analysis of cognitive-behavioral therapy for alcohol or other drug use disorders: Treatment efficacy by contrast condition.'
- reference: PMID:32159228
  title: Alcoholics Anonymous and other 12-step programs for alcohol use disorder.
- reference: PMID:32217228
  title: 'Comorbid alcohol use disorder in psychiatric MDD patients: A five-year prospective study.'
- reference: PMID:32643841
  title: How do substance use disorders compare to other psychiatric conditions on structural brain abnormalities? A cross-disorder meta-analytic comparison using the ENIGMA consortium findings.
- reference: PMID:33318153
  title: 'Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development.'
- reference: PMID:33955649
  title: Individual differences in the engagement of habitual control over alcohol seeking predict the development of compulsive alcohol seeking and drinking.
- reference: PMID:37569551
  title: 'Phosphatidylethanol (PEth) in Blood as a Marker of Unhealthy Alcohol Use: A Systematic Review with Novel Molecular Insights.'
- reference: PMID:37844924
  title: Canadian guideline for the clinical management of high-risk drinking and alcohol use disorder.
- reference: PMID:38062264
  title: Multi-ancestry study of the genetics of problematic alcohol use in over 1 million individuals.
- reference: PMID:38706338
  title: 'Topiramate Versus Naltrexone for Alcohol Use Disorder: A Genotype-Stratified Double-Blind Randomized Controlled Trial.'
- reference: PMID:39937469
  title: 'Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial.'
- reference: PMID:42070571
  title: 'Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial.'
- reference: clinicaltrials:NCT05520775
  title: Human Laboratory Screening of Semaglutide for Alcohol Use Disorder
- reference: clinicaltrials:NCT05895643
  title: Does the Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Semaglutide Reduce Alcohol Intake in Patients With Alcohol Use Disorder and Comorbid Obesity?
- reference: url:https://www.aafp.org/pubs/afp/issues/2021/0900/p253.pdf
  title: https://www.aafp.org/pubs/afp/issues/2021/0900/p253.pdf
- reference: url:https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf
  title: https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf
- reference: url:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10630900/
  title: 'Pharmacotherapy for Alcohol Use Disorder: A Systematic Review and Meta-Analysis - PMC'
- reference: url:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6634595/
  title: Pivotal Role of TLR4 Receptors in Alcohol-Induced Neuroinflammation and Brain Damage - PMC
- reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK436003/
  title: 'Alcohol Use Disorder: Screening, Evaluation, and Management - StatPearls - NCBI Bookshelf'
experimental_models:
- name: Neonatal rodent astrocyte TLR4 perturbations
  experimental_model_type: PRIMARY_CELL_CULTURE
  cell_source: Neonatal rat astrocytes with TLR4, CD14 or MD-2 siRNA; separate wild-type and Tlr4-knockout mouse astrocytes
  publication: url:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6634595/
  description: Highly enriched astrocyte cultures were exposed to ethanol with non-targeting siRNA and LPS-related controls. Rat knockdown experiments used 50 mM ethanol, whereas mouse knockout cultures used 10 mM. Nuclear p65, pERK and inflammatory readouts support TLR4 dependence. Lipopolysaccharide contamination controls were performed, but direct ethanol–TLR4 binding was not resolved.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6634595/
    reference_title: Pivotal Role of TLR4 Receptors in Alcohol-Induced Neuroinflammation and Brain Damage - PMC
    supports: SUPPORT
    evidence_source: IN_VITRO
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: Gene silencing of TLR4 downregulates the TLR4 expression and reduces NFκB activation induced by ethanol in astrocytes in culture.
    explanation: TLR4 knockdown reduces ethanol-induced NF-kappa-B activation in cultured astrocytes, establishing a perturbation result within that cell preparation.
  modeled_mechanisms:
  - target: Astrocytic NF-kappa-B Activation
    relationship: MEASURES
    fidelity: MODERATE
    description: TLR4 knockdown attenuates ethanol-associated nuclear p65 signaling.
    limitations: Neonatal cell culture is distinct from intact adult human cortex and clinical addiction.
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6634595/
      reference_title: Pivotal Role of TLR4 Receptors in Alcohol-Induced Neuroinflammation and Brain Damage - PMC
      supports: SUPPORT
      evidence_source: IN_VITRO
      quote_role: PRIMARY_RESULT
      directness: DIRECT
      snippet: Gene silencing of TLR4 downregulates the TLR4 expression and reduces NFκB activation induced by ethanol in astrocytes in culture.
      explanation: TLR4 knockdown reduces ethanol-induced NF-kappa-B activation in cultured astrocytes, establishing a perturbation result within that cell preparation.
    readouts:
    - name: Nuclear NF-kappa-B p65 after TLR4 knockdown
      target: Astrocytic NF-kappa-B Activation
      direction: DECREASED
      interpretation: TLR4 knockdown attenuates ethanol-associated nuclear p65 signaling.
      evidence:
      - reference: url:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6634595/
        reference_title: Pivotal Role of TLR4 Receptors in Alcohol-Induced Neuroinflammation and Brain Damage - PMC
        supports: SUPPORT
        evidence_source: IN_VITRO
        quote_role: PRIMARY_RESULT
        directness: DIRECT
        snippet: Gene silencing of TLR4 downregulates the TLR4 expression and reduces NFκB activation induced by ethanol in astrocytes in culture.
        explanation: TLR4 knockdown reduces ethanol-induced NF-kappa-B activation in cultured astrocytes, establishing a perturbation result within that cell preparation.

📚

References & Deep Research

References

PMID:15024690

Variations in GABRA2, encoding the alpha 2 subunit of the GABA(A) receptor, are associated with alcohol dependence and with brain oscillations.